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Adult HIV prevalence in Zambia is approximately 12%, and an estimated 28% of people 
living with HIV remain undiagnosed. In 2016 Zambia adopted HIV self-testing (HIVST) as 
an additional approach to expand coverage and access to those in need of testing and who 
may not otherwise test. To inform HIV testing scale-up, this thesis aims to: 
1. Assess state of the art in cost and cost-effectiveness analyses on HIV testing services 
in sub-Saharan Africa through a systematic review; 
2. Estimate the costs of HIV self-testing in voluntary medical male circumcision 
(VMMC) and health facilities in Zambia; and 
3. Evaluate the incremental cost-effectiveness ratio (ICER) of adding community-based 
(door-to-door) HIVST kit distribution to conventional facility-based HIV testing 
services (HTS) to reach people who otherwise will not access HTS while visiting 
health facilities in Zambia.  
A systematic literature review summarized the literature on costs and cost-effectiveness 
analyses of HTS in sub-Saharan Africa over the past decade. The costs to test individuals 
through health facility, home-based, and mobile services are comparable; however, the costs 
are higher for campaign-style and stand-alone HTS. Moreover, the review shows that few 
studies have undertaken cost-effectiveness analyses of HTS. Different HIV testing models 
are potentially cost-effective but will increase HIV testing budgets. Thus, it is essential to do 
more cost-effectiveness and budget analyses of different combinations of HIV testing 
modalities to inform HIV testing policy and budgets.  
 
A cost analysis of HIV testing (HTS and HIVST) across Malawi, Zambia, and Zimbabwe 
generated a detailed summary of observed resources used for HIV testing and how these 
vary across settings. The corresponding unit cost per community-based distribution by 
VMMC mobilizers are US$24.83 for Malawi and US$7.71 for Zimbabwe. The corresponding 
unit cost per HIVST kits distributed at the VMMC clinic are US$9.65, US$13.01, and 
US$7.71 for Malawi, Zambia, and Zimbabwe, respectively. For Zambia and Zimbabwe, the 
outpatient department (OPD) and integrated models distribution unit cost per kit distributed 
are US$15.81 and US$9.85. 
 
Lastly, the age- and sex-specific Markov microsimulation model evaluated the costs and 
impact of a one-year HIVST program in Zambia. The model simulated 100,000 individuals 
over a 20-year time horizon. Using HIV Self-Testing Africa (STAR) consortium’s endline 
survey data, the model inputs reflected observed uptake of HTS and assumed that only those 
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who had not tested within the last 12 months were eligible for home-based HIVST; these 
people could then accept or reject HIVST with its associated costs and consequences. ICERs 
were calculated for the intervention relative to the HTS status quo. Effects were presented 
building on the HIV prevention and treatment cascade framework, ultimately estimating 
disability-adjusted life years (DALY) averted. The age and sex-stratified Markov 
microsimulation model predicted that the implementation of community-based (door-to-
door) HIVST distribution would avert more DALYs relative to the standard facility-based 
HTS. The ICERs for adolescent men and women ages 15-24 were $101.81 and $154.73 per 
DALY averted. The ICERs for men and women were $35.26 and $25.18 for ages 25-34 and 
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This is a paper style thesis with five chapters with appendices. This thesis presents three 
result papers, hereafter referred to as papers 1, 2, and 3 in chapters 2, 3, and 4 respectively. 
These three papers are linked by an overall introduction and description of the aims (chapter 
1) and conclusion (chapter 5). The appendices include supplementary documents for paper 
1 and paper 3 and the additional three supporting papers I co-authored as part of the HIV 
self-test in Africa (STAR) project.  
 
Overall, this thesis aims to examine the cost-effectiveness of HIVST compared to the 
existing standard HIV testing services in Zambia. The outcomes from the systematic 
literature review on costs and cost-effectiveness of HTS in sub-Saharan Africa (Paper 1 – 
chapter 2), cost analysis (Paper 2 – chapter 3), and the Markov microsimulation model for 
cost-effectiveness analysis (Paper 3 – chapter 4) are investigated.  
 
The introduction chapter (chapter 1) provides an overview of the HIV epidemic, national 
response to the epidemic, alternative HIV test services in Zambia, and discusses the research 
aim, objectives, and methodological approaches for the result papers. Chapter 2 reviews the 
theory and practice of economic evaluation in health care and systematic literature review 
findings on previous costing and cost-effectiveness studies of HTS in sub-Saharan Africa 
(Paper 1).   
 
Chapter 3 presents the cost analyses of three models of HIVST distribution across Malawi, 
Zambia, and Zimbabwe (Paper 2). Chapter 4 examines a cost-effectiveness analysis of 
community-based (door-to-door) HIVST kits distribution (Paper 3). Chapter 5 brings 
together the key findings from the previous chapters and constructs emerging knowledge 
and empirical evidence from this thesis. It also highlights key policy recommendations and 
future research priorities.   
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CHAPTER 1 INTRODUCTION 
1.1. Overview of HIV epidemics  
 
Globally, approximately 37.9 million (32.7-44.0 million) people are living with HIV/AIDS 
in 2019. Eastern and Southern Africa account for 20.6 million adults and children living with 
HIV globally (1). In Eastern and Southern Africa, between 2000 and 2018, the number of 
new HIV infections decreased by 28%, the number of AIDS-related deaths by 44% and the 
incidence prevalence ratio by 3.9% (Figure 1.1) (1, p.22). In the previous decade, sub-Saharan 
Africa has scaled-up biomedical HIV prevention strategies (5, 6). These include HIV testing 
services (HTS), early HIV diagnosis, and early initiation of antiretroviral therapy (ART) (7, 
8). Despite the findings from qualitative studies and population surveys demonstrating a high 
willingness for HIV testing, uptake of free facility-based HTS remains low (9-11). To increase 
linkage to ART and to maximize the public health impact of HTS, sub-Saharan Africa has 





Figure 1.1 Number of new HIV infections, number of AIDS-related deaths, and incidence-
prevalence ratio in Eastern and Southern Africa between 2000 and 2018 UNAIDS 2019 (1 p.22) 
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1.2. Zambian HIV epidemic and response  
 
Zambia’s total population is estimated at 17 million (17), and around 1.1 million people are 
living with HIV. There are 48,000 new HIV infections every year and a national HIV 
prevalence of 12% (14.6% among females and 9.3% among males) among adults ages 15-59 
years (4). HIV prevalence rates among the female population ages 40-44 and 45-49 years are 
the highest: 29.6% and 23.0%, respectively (4). The HIV prevalence is four times higher 
among females ages 20-24 years (8.3%) compared to males (2.0%) (Figure 2) (4, p.48). Key 
drivers of the Zambian HIV epidemic include low rates of HIV testing, multiple concurrent 
sexual partners, low rates of male circumcision, mother to child transmission, commercial 








Figure 1.2 HIV prevalence among persons ages 0-59 by sex and age Ministry of 
Health Zambia 2019 (4, p.48)  
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Between 2000 and 2015 in Zambia, the number of new HIV infection and AIDS-related 
deaths decreased by 13% and 37%, respectively. However, the incidence prevalence ratio 
was 0.04, where the expected target was 0.03 (Figure 3) (1, p.71). 
 
In 2014, United Nations Programme on HIV/AIDS (UNAIDS) launched the 90-90-90 
targets for 2020: 90% of all HIV-positive persons know their status, 90% of those diagnosed 
are provided with ART, and 90% of those treated achieve viral load suppression. The latest 
report on the progress toward this aim among the population ages between 15-59 years 
showed that 71% of the population are aware of their HIV status, out of the 71%, 87% are 
on treatment, and out of the 87%, 89% are virally suppressed (Figure 4) (4, p.74). However, 
among young adults ages 15-24 years, only 41% (males) and 40% (females) are aware of their 
HIV positive status (4). For those ages between 15 and 49 years, only 59% (males) and 67% 
(females) self-reported knowing their HIV positive status (4). These findings showed that 
there are HIV testing gaps when the Zambian population is stratified by age and gender that 
fail to achieve reaching the UNAIDS 90-90-90 and the fast-track UNAIDS 95-95-95 targets 












Figure 1.3 Zambian HIV epidemic estimates UNAIDS 2019 (1, p.71)  
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Many reasons have been mentioned for the gaps in HIV testing, including fear of 
abandonment by a sexual partner, fear of taking ART, and continued stigma around HIV in 
Zambia (19). The Zambian government continues its effort to increase HTS using alternative 
HIV testing modalities, including community-based testing, mobile outreach, and door-to-
door testings (20). Yet, the most considerable gaps in meeting the 90-90-90 targets are among 
young people and men who do not know their HIV status. Therefore, the Zambian Ministry 
of Health (MoH) has recognized that HTS coverage remains below the UNAIDS targets, 
and it has supported research studies to investigate the addition of HIV self-testing (HIVST) 
to conventional HIV testing approaches to increase uptake of HIV testing among new and 
repeat testers (21).  
 
Since 2015, the Zambian MoH has been working to introduce HIVST as an additional testing 
modality to meet its HIV testing targets. Evidence from other African countries has 
demonstrated the accuracy, acceptability, and performance of HIVST in general and key 
populations (22-28). However, more studies are needed to generate evidence on the costs 
and cost-effectiveness to have the HIV testing service distribute HIV self-test kits in Zambia. 
This is needed to inform programming decisions regarding a scale-up of HIVST in Zambia. 
Because the same budget will fund both HIVST provision and other MoH activities, it is 
essential to show comparative cost and effectiveness of HIVST to ensure optimal allocation 
of resources. These could potentially influence programming decisions about which HIV 
UNAIDS 90-90-90 
UNAIDS 95-95-95 
Figure 1.4 Zambia adult 90-90-90 and the gaps to reach 95-95-95 among adults ages 
15-59 years (1, p.71), Ministry of Health Zambia 2019 (4, p74) 
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testing service to include in the national HIVST scale-up plan (29). This thesis ultimately 
seeks to examine the impact of different HTS, the cost of distributing HIVST using different 
distributing modalities, and the cost-effectiveness of HIVST provision for one year 
compared to the existing standard HIV testing services in Zambia. 
 
1.3. Different HIV testing services  
 
The most recent published report, Differentiated service delivery for HIV: A decision framework for 
HIV testing services, categorizes HIV testing models into health facility, community-based, and 
self-testing (29). Health facility HIV testing services included the provision of HIV testing 
within the department of voluntary counseling and testing (VCT), antenatal clinic (ANC), 
and provider-initiated HIV counseling and testing (PITC) or outpatient department (OPD), 
and within voluntary medical male circumcision (VMMC) centres. Community-based HTS 
includes home-based, mobile, and campaign style HIV testing. Home-based HTS includes 
the provision of pre-test counseling, HIV rapid tests, and post-test counseling by a trained 
HTS provider in the client’s home. Mobile HTS uses tents and mobile vans to provide HIV 
testing in different community locations, such as near markets, transport hubs, and open 
fields. The trained HTS provider selects the specific location on an ad hoc basis. Stand-alone 
HTS is immobile HTS located near transport hubs and markets where it serves community 
members. Self-testing is where a person performs and interprets his or her own HIV test, 
often in private. Self-testing can be done within health facilities or the community. 
 
Delivering HIV testing services alongside other health interventions was more cost-effective 
than delivering either HIV testing or the other intervention alone (30, 31). Studies have found 
that the provision of either home-based HIV testing (32), mobile testing services (33), or 
HIV self-testing (34-37) in addition to routine facility-based HIV testing were potentially 
cost-effective at cost-effectiveness thresholds equivalent to one to three times the gross 
domestic product per disability-adjusted life year (DALY) averted, quality-adjusted-life-year 
(QALY) gained, or life year gained in the respective studies (38). 
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1.4. HIV self-testing 
“HIV self-testing (HIVST) is a process whereby a person who wants to know his or hers 
HIV status collects a specimen, performs a test, and interprets the test result in private” (39, 
p.2). The specimen can be taken from a person in two different ways: the first one is a 
fingerstick test to extract a whole blood sample from a finger to detect evidence of antibody. 
The second technique is a mouth swab of oral mucosal transudate specimen; again, it is used 
to detect evidence of antibodies. HIVST is not considered a diagnostic HIV test, meaning it 
does not provide a definitive HIV positive diagnosis. A negative HIVST test result or non-
reactive self-test results are considered negative; however, a positive or a reactive self-test 
results require a confirmatory HIV test according to the country’s national HIV testing 
algorithms. WHO does not recommend HIVST for people with HIV who are on ART, as a 
false-negative HIVST result can occur. Retesting is highly encouraged for those at ongoing 
risk as a key population and those who reported HIV exposure in the preceding 12 weeks 
(40).  
 
OraQuick® HIV Self-Test, which uses an oral mucosal transudate specimen, is 
manufactured by OraSure Technologies Inc. In 2012, the Food and Drug Administration 
(FDA) approved OraQuick as a rapid home-use HIV test kit (41). In 2016, the WHO issued 
new guidelines on HIV self-testing and partner notification, and in 2017 OraQuick was pre-
qualified to increase HIV diagnosis and treatment (42, 43). 
 
In line with 2016 WHO recommendation of HIVST, many countries developed their own 
HIVST guidelines to optimise HIVST implementation, including consideration of different 
service delivery models followed by effective linkage to care services. Key findings from 
HIVST systematic review showed that compared with standard facility-based HIV testing, 
the provision of HIVST increased the uptake of HIV testing, and the proportion of people 
diagnosed and referred to linkage to care services with HIVST are comparable to those with 
facility-based testing (40). The same WHO systematic review reported on the acceptability 
and feasibility of HIVST in a range of population and settings, the effectiveness of a range 
of HIVST service delivery models and the rarity of misuse and social harms associated with 
HIVST (40). The different HIVST service delivery models include: community-based, health 
facility-based, ordering online an receive via mail, secondary distribution (to partner or peers), 
retail outlets, pharmacies and vending machines, faith-based settings and workplace (40). 
Multiple studies also demonstrated the acceptability and accuracy of self-testing (22-24, 27, 
44, 45). Lay users can perform confidential HIVST and interpret results effectively 
comparable to that of a trained healthcare provider. At present, the only HIV self-test kit 
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available in Zambia is the OraQuick ADVANCE rapid HIV I/II Antibody test (OraSure 
Technologies), which uses an oral mucosal transudate specimen. HIV self-testing has the 
potential to increase the proportion of the population who know their HIV status and 
ultimately lead to linkage to care for ART initiation.  
 
1.5. HIV self-testing in Africa and the (STAR) project background  
The Population Service International (PSI), in collaboration with the WHO, LSHTM, 
Liverpool School of Tropical Medicine, and University College London are implementing 
the self-testing in Africa (STAR) project with support from UNITAID. The STAR project 
has strategised its implementation work in two phases. Phase one was a two-year project 
from 2015-2017 in Zambia, Malawi, and Zimbabwe, and in-country institutes led the 
research activities: Zambart in Zambia, Malawi-Liverpool Wellcome Trust Clinical Research 
Programme in Malawi, and Centre for Sexual Health and HIV/AIDS Research in Zimbabwe.  
 
In phase one, four different models for distributing HIVST were evaluated in Zambia, 
Malawi, and Zimbabwe. These four models were community-based door-to-door 
distributing agents (CBDA), voluntary medical male circumcision (VMMC), health facility 
(HF), workplace distribution models. In phase one, Zambia and Malawi conducted cluster-
randomised trials and all three countries conducted robust economic evaluations, including 
54 health facility costings. 
 
In phase one, the overall evaluation of the STAR project showed that over one million 
HIVST kits were distributed: 628,705 in Malawi, 190,787 in Zambia and 265,091 in 
Zimbabwe. The community-based door-to-door distribution model distributed 519,658 
HIVST kits compared with VMMC (23,561), health facility (21,183), and workplace (9,850). 
These different HIVST kits distribution models reached a higher proportion of men, young 
people, and first time testers in Zambia, Malawi, and Zimbabwe. Men constituted a higher 
proportion of first-time testers than women, (25.4% vs 17.7%) in Zambia, (27.9% vs 25.9%) 
in Malawi, and (16.2% vs 11.4%) in Zimbabwe. The young (16 to 24 years) and older men 
(>50 years) were the highest proportion of first-time testers (46).  
 
The effectiveness of the community-based door-to-door distribution model was assessed 
using cluster-randomised trials in Zambia and Malawi. In Zambia, six matched-pairs 
catchment areas of clusters from four districts were selected. The clusters were randomised 
to receive HIVST in the intervention arm and the national standard HIV testing service in 
the control arm. The primary outcome was self-reported HIV testing within the previous 12 
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months and after 12 months of the intervention (HIVST). A total of 65,585 HIVST kits were 
distributed and HIV testing data were collected using a cross-sectional survey among 
individuals aged ≥16 years, living in households in randomly selected blocks in each cluster. 
 
Despite the higher number of HIVST kits distributed, the results from the cluster-
randomised trial on a community-based distribution of HIVST kits at population level 
among those who HIV tested in the last 12 months did not identify a significant impact on 
recent (last 12 months) or lifetime testing (RR 1.08, Adj 95% CI 0.94-1.24; p=0.15) (47). This 
study also showed that a higher proportion of surveyed adults in the intervention arm 
(HIVST) vs the standard of care arm (88.9% vs 31.5%) had heard of HIVST and ever self-
tested (42.5% vs 8.3%). Before embarking on a cost-effectiveness analysis of HIVST 
compared with standard HIV testing, further investigation went into why the intervention 
(HIVST) did not significantly increase HIV testing at the community-level, considering novel 
HIV testing strategies had shown promise to expand access to HIV testing services (46). The 
investigation identified that the lack significant impact was attributable to poor targeting of 
the intervention population, with high rates of migration between the time that the baseline 
and end line survey were conducted. The fact that ineffective result was attributed to 
incorrect target coverage not to the intervention (HIVST) itself validated the importance of 
conducting cost-effectiveness analysis HIVST. In this thesis, chapter 4 explored the cost-
effectiveness of HIVST in Zambia  
 
was because of incorrect targeted coverage where the population migrated between the time 
when baseline and endline surveys were conducted. The fact that an ineffective result was 
attributed to incorrect target coverage and not to the intervention (HIVST) itself validated 
the importance of conducting cost-effectiveness analysis HIVST. In this thesis, chapter 4 
explored the cost-effectiveness of HIVST in Zambia.  
  
In Malawi, in contrast, the cluster-randomised trials in Malawi stratified 11 health facilities in 
the intervention arm and 11 health facilities in the control arm. The study found that the 
community-based door-to-door HIVST kits distribution model among those who self-
reported HIV testing in the last 12 months significantly increases recent or lifetime testing 
(RR 1.33, Adj 95% CI 1.12-1.59; p=0.003) among populations in a rural setting, including 
men and adolescents (48). This study, however, did not identify a measurable impact on 
population-level ART initiation (RR 1.14, Adj 95% CI 0.75-1.75; p=0.52).  
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STAR’s economic team conducted an economic cost analysis of community-based door-to-
door HIV self-test kits distribution in Malawi, Zambia, and Zimbabwe and reported the unit 
cost per HIVST kit distributed. HIVST kits were distributed across 71 sites: 152,671 in 
Malawi, 103,589 in Zambia, and 93,459 in Zimbabwe, and reported an average cost per 
HIVST kits distributed of US$8.15, US$16.42, and US$13.84 in Malawi, Zambia, and 
Zimbabwe, respectively (49). In this thesis, the cost analysis (Paper 2) presents the cost of 
delivering HIVST kits within 13 VMMC services and 21 health facilities in Malawi, Zambia, 
and Zimbabwe. The cost-effectiveness analyses of HIVST in these three countries are 
underway.  
 
Phase two of the STAR project (2017-2019) has adapted lessons from phase 1 to scaleup 
successful distribution models and evaluate the health impact of HIVST in South Africa, 
Swaziland, and Lesotho. The overall evaluation of the project is underway, including the 
multidisciplinary studies’ findings.  The evaluation is expected to inform policymakers, 
implementers, external donors, and new manufacturers about how to introduce HIV self-
testing as part of a comprehensive HIV testing service in sub-Saharan Africa.  
 
This thesis is embedded in the STAR phase one project in Zambia. The STAR project in 
Zambia has been assessing CBDA, VMMC, and HF models for HIVST distribution. This 
thesis will focus on the cost-effectiveness of CBDA (door-to-door) distribution of HIVST 
kits in Zambia. 
 
1.6. Aim, research questions, and methodology 
In this section, I present the: (I) aim and research questions, (II) conceptual framework and 
relevance to my hypotheses and methodology, (III) intellectual ownership, (IV) ethical 
considerations, and (V) conclusion. 
 
Aim and research questions 
 
The overarching aim of this thesis was to estimate the incremental cost and cost-effectiveness 
of community-based HIV self-test kit distribution compared to the standard of care HIV 
testing services in Zambia. The main research questions were as follows:  
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1. What is the cost of providing HIV testing in sub-Saharan Africa through different 
HIV testing models, and how does the scale of the service impact the costs (Paper 
1)?  
2. How much does self-test kit distribution cost within health facilities and within the 
community in Zambia (Paper 2)? 
3. What is the incremental cost-effectiveness of community-based (mainly door-to-
door) self-test kit distribution compared with the standard of care HTS in Zambia 
(Paper 3)?  
 
Figure 5 presents how the three papers together provide key policy insight into evidence-
based HIV testing programmes in Zambia.
 26 
 
Paper 1: Systematic literature review 
To assess the costs and the cost-effectiveness of HIV testing services in sub-Saharan Africa  
3B) Cost effectiveness analysis using a 
Markov microsimulation Cost per 
DALY averted 
1 Heterogeneity (three age sub-
groups for both men and women)   
i. Adolescent male 15-24 years 
of age  
ii. Adolescent female 15-24 years 
of age  
iii. Male 25-34 years of age 
iv. Female 25-34 years of age 
v. Male 35-49 years of age 
vi. Female 35-49 years of age 
 
3A) Quantitative analysis of Zambian 
DHS data (2013-14) 
1 Descriptive analysis  
a) HIV testing and refusal 
behaviour by age and gender  
2 STAR Endline survey data 
analysis  
a) Uptake of community-based 
HIV self-testing distribution 
modalities by age and gender  
b) Uptake of alternative HIV 
testing services by age and 
gender  
Collect costs and utility parameters for Markov microsimulation  
A) Cost analysis of STAR 
project’s expenditure  




2 Unit cost per HIVST kit 
distributed at OPD 
services in health facilities 
3 Unit cost per HIVST kit 
distributed using VMMC 
model  
 
3C) Sensitivity analysis of the 
Markov microsimulation  
1 Cost allocation factors 
a) Deterministic 
sensitivity analysis 
b) Scenario analysis 
2 Parameter uncertainties  
a) Deterministic and 
probabilistic sensitivity 
analysis  
b) Scenario analysis  
Paper 3: Assess the cost-effectiveness of community-based self-test kit distribution model in Zambia 
 
Paper 2: Cost analysis 
 
Figure 1.5 Framework of the study and linkage between chapters 




1.7. Conceptual framework and relevance to hypothesis  
The objectives of the three papers were developed based on the following hypothesis. First, 
the costs and cost-effectiveness studies are influenced by several factors, namely, study 
perspective, comparators, time horizon, discount rate, choice of health outcomes, 
measurement of effectiveness, choice of model, assumptions, and characterisation of 
uncertainty. These points are captured in Paper 1. The results from Objective Paper 1 are 
used to parametrise the Markov microsimulation model in Paper 3 and will identify the 
critical gaps in costs and cost-effectiveness studies of different HIV testing services in sub-
Saharan Africa.  
 
The STAR economic team led the cost analyses of three HIVST distribution models: (1) 
community-based distribution; (2) VMMC; and (3) outpatient department (OPD) services in 
health facilities. A colleague from Zimbabwe led the writing of a cost analysis of community-
based HIVST distribution model for Malawi, Zambia, and Zimbabwe (50). In the cost 
analysis, I led the Zambian portion of data collection and analysis while also leading the cross 
country write up (Appendix II). The unit cost of community-based HIVST distribution 
helped to parametrise the Markov microsimulation model in Paper 3. I, as part of the STAR 
economic team, led the cost analyses of HIVST kit distribution through existing VMMC and 
outpatient department services for Malawi, Zambia, and Zimbabwe (Paper 2). Paper 2 also 
contributed methods identifying appropriate allocation factors for attributing shared HIVST 
programme costs to specific HIVST models and sites. These allocation factors are the 
methodological contribution to guide future cost analysis, particular in similar settings, using 
different cost inputs.  
 
Second, concerning the “optimal investment in HIV prevention programmes,” governments 
and donors place a strong emphasis on efficiency in HIV testing services, i.e., producing 
testing at the lowest possible cost. Thus, it is imperative to explore how the costs and cost-
effectiveness of new health interventions, including HIVST, could be optimised with the 
lowest possible cost and/or highest impact in Zambia. Findings from Paper 3, which uses a 
Markov microsimulation model, are valuable for exploring the cost-effectiveness of HIVST 
because HIVST is an emerging technology in Zambia that may be added as an alternative 
HIV testing option to those who do not access facility-based HIV testing. Also, there is 
currently insufficient understanding of the use of different HIV testing approaches for 
HIVST distribution and of the costs and effectiveness of HIVST. It is possible that, despite 
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the tremendous progress being made toward achieving the UNAIDS 90-90-90 goals, the 
Zambian government and donors may consider HIVST too expensive and not cost-effective 
enough to incorporate into the national scale-up of testing. The Markov microsimulation 
model in Paper 3 follows individuals over time and accounts for heterogeneity by age and 
gender. It can, therefore, help address which specific age group and gender to target and how 
this can be achieved. The Zambian government may choose a stepwise approach to invest 
in expanding HIVST to a particular age-group or gender first (the most cost-effective option) 
then choose the next most cost-effective option and so on. 
 
I conducted a descriptive quantitative analysis of Zambian Demographic Health Survey 
(DHS) data to capture the proportion of HIV testing and refusal behaviour and utilisation 
of alternative HIV testing services by three age groups of both men and women (51). I also 
analysed the STAR ndline survey data to provide the proportion of community-based 
HIVST distribution to the three male and female age groups. The cost analyses of the STAR 
project expenditure provided unit costs for community-based HIVST distribution models. 
All research questions and objectives (Table 1) were drawn together to develop the 





Table 1.1 Summarising research questions, research objectives, and corresponding 
methods 
Research question (RQ) Objective  Main method 
RQ 1: What is the cost of 
providing HIV testing in sub-
Saharan Africa through 
different HIV testing models, 
and how does the scale of the 
service impact on the costs?  
 
Paper 1: To undertake a 
systematic literature review to 
assess the costs and the cost-
effectiveness of HIV testing 
services in sub-Saharan Africa.  
Systematic literature 
review. 
RQ 2: How much does it cost 
to add HIV self-testing into 
male circumcision, outpatient, 
and HIV testing services in 
Malawi, Zambia, and 
Zimbabwe?  
 
Paper 2: To estimate the costs 
of distributing HIVST through 




RQ3: Is community-based self-
test kits distribution cost-
effective compared to the 
standard of care HTS? 
 
Paper 3: To assess the cost-
effectiveness of community-
based HIVST kit distribution 











1.8.  Intellectual ownership  
This research was undertaken as part of the STAR project supported by Unitaid which 
covered the cost of data collection. The cross-country cost analyses (Paper 2) were 
conceptualised by the STAR Economics team with my input. I led all stages of the Zambian 
portion of data collection and cost analysis in collaboration with Lawrence Mwenge. 
 
I led all other elements of this DrPH research with the support of my supervisors, advisory 
committee members, and upgrading examiners. A summary of my role and contribution to 
the research activities in this thesis is provided in the Table 1.2. 
 
Table 1.2 Summary of the role of the candidate in research activities 
Component Activity  Responsibility Additional input 
Preparatory 
work 
Development of thesis objectives and 
work plan 
NA, FTP STAR 
Ethics submission and amendments STAR  
Local authority permissions  STAR  
Data 
collection 
Cost data collection NA, LM FTP 
Cost analysis NA, LM FTP 
Selection of survey sites  STAR  
STAR Endline survey enumeration STAR  











Analysis of model results  NA JO, FTP 
Interpretation of model results  NA JO, FTP 
Research 
Papers 
Paper 1: A systematic literature review 
of costs and cost-effectiveness 





Paper-2: Distributing HIV self-test 
kits through voluntary medical male 
circumcision services, outpatient 
departments, and integrated centres 







Paper-3: Cost-effectiveness of 
community-based (door-to-door) 
HIV self-testing distribution models 
for HIV testing in Zambia: Markov 





Overall STAR project FTP STAR 
Overall DrPH thesis FTP, JO, GM  
NA: Nurilign Ahmed, FTP: Fern Terris-Prestholt (Primary supervisor), GM: Graham 
Medley (Primary supervisor), JO: Jason Ong (Secondary supervisor), HH: Hendramoorthy 
Maheswaran (Advisory committee), STAR Project (Helen Ayles, Lawrence Mwenge, Marc 
d’Elbée, Valentina Cambiano, Elizabeth Corbett, Karin Hatzold, Cheryl Johnson) 
 
1.9. Ethical considerations 
Ethics approval  
This study was carried out according to the LSHTM standard on Good Research Practice 
(52). It was also approved by the University of Zambia biomedical research ethics committee 
and the National Health Research Authority (Zambia Ministry of Health) and is in line with 
applicable guidelines and regulations in Zambia. The Zambian DHS dataset was obtained 
upon consent from the DHS programme online database and was only used for this thesis.  
 
Funding  
The STAR research consortium funded by Unitaid partially supported this thesis. The 
National Institute of Health Fogarty Global Health Fellowship funded one year of doctoral 
work. 
 
1.10.  Conclusion  
 
This thesis sought to synthesize and examine the gaps in cost and cost-effectiveness studies 
of HTS in sub-Saharan Africa. The cost analysis calculated the unit cost of HIVST 
distribution using VMMC and outpatient department models. The Markov microsimulation 
model estimated the cost-effectiveness of community-based (door-to-door) self-test kits 
distribution in Zambia. A wide range of data analyses techniques were used, including 
collaboration in primary costing data collection and analysis and secondary data analysis using 
Zambian DHS and STAR endline survey datasets. Results from all research questions were 
synthesized to provide policy recommendations.
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CHAPTER 2 ECONOMIC EVALUATION OF NEW 
HEALTH INTERVENTIONS - PRINCIPLES AND USES 
This chapter presents background information on economic evaluation methods and a 
systematic literature review on cost and cost-effectiveness studies of HTS in sub-Saharan 
Africa (Paper 1). This chapter seeks to understand the advantages and the disadvantages of 
different economic evaluation methods, and the systematic literature review aims to 
synthesize the extant literature and identify gaps in cost and cost-effectiveness studies of 
HTS in sub-Saharan Africa. 
 
First, I present an overview of economic evaluation of new health interventions by 
summarizing key methodologies used to inform policymakers and funders. Second, I present 
a full systematic literature review paper along with the findings and rationale that inform the 





2.1.  Economic evaluation of new health interventions 
 
An economic evaluation of new health interventions systematically evaluates alternatives to 
optimize health gains within budget-constrained settings (53-55). This is achieved by 
evaluating the new intervention through the lens of cost and consequences (overall health 
benefits). Most policymakers and funders are willing to pay for an intervention whose 
specific cost and consequences are known. Consequently, economic evaluation is a tool that 
allows a comparison of the costs and consequences of alternative health interventions (53, 
54, 56). This is done to inform policymakers using empirical evidence about which 
intervention delivers the maximum health benefit with minimum cost before adopting and 
expanding the new intervention. The integration of costs and consequences can commonly 
be evaluated through cost-effectiveness analysis, cost-benefit analysis, or cost-utility analysis.  
 
2.2.  Cost analysis  
 
Cost analysis estimates the cost of a health intervention or service in a specific population, 
time, and location. The outcome of a measurement is expressed as a unit cost or an average 
cost of an intervention, service, or output (57). Unit costs are calculated as total cost divided 
by the unit of intervention for the service or output. The calculation of cost functions is 
applied when costs are determined by input cost, scale of production, or quality of the 
intervention being provided. Different types of costs are appropriate for different purposes: 
financial vs. economic cost, incremental vs. marginal unit cost. Financial costs capture the 
monetary values of the resources that are paid for while excluding the costs of donated goods 
and services. Thus, financial costs analysis focuses on money or health budgets that are 
planned to be spent or have been spent. Economic costs aim to capture the cost of paid 
resources, donated goods and services, and opportunity costs. In most functional markets, 
the price of resources reflects opportunity costs. Marginal cost is defined as the cost of 
producing an additional unit of output as service levels increase (57). Incremental cost 
captures the difference in cost between two or more interventions, services, or outputs (57). 
 
2.3.  Cost-benefit analysis  
 
Cost-benefit analysis (CBA) compares the benefits and costs of interventions in monetary 
terms. Monetary values can be estimated through a group of individuals or society’s 
willingness –to pay for years of life or improvement in health and well-being (53, 54). The 
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basic principle of CBA is that an intervention will improve a group of individuals or society 
as a whole if the benefit associated with the health intervention exceeds the costs. In CBA, 
both direct and indirect benefits and costs can be accounted for (53, 54). The advantage of 
CBA for decision making is that it allows for comparison across investments, e.g., education 
and health programmes. 
 
2.4.  Cost-effectiveness analysis 
  
Given the difficulty of placing monetary values on life and health benefits, cost-effectiveness 
analysis (CEA) often provides more practical evidence to facilitate the decision-making 
process for policymakers (53, 54, 56). For instance, CEA can compare the cost of achieving 
a non-monetary value or natural unit of outcomes such as lives saved, infection averted, or 
viral load suppressed. CEA conceptually aims to produce more health benefits among 
alternative health interventions at the lowest possible cost. CEA has been applied to 
determine the most cost-effective means of different HTS to optimize HIV testing at the 
population level (30-37, 58-64). Moreover, CEA is a key step before undertaking a cost-
benefit analysis, which compares the cost of intervention with its outcome valued in 
monetary terms. If there is a challenge in undertaking a CEA, it is improbable that cost-
benefit analysis will be feasible (53, 54).  
 
2.5.  Cost-utility analysis: QALYs and DALYs 
 
Cost-utility analysis (CUA) compares the cost of intervention with its outcome values in 
generic health outcomes (53, 54). Outcomes are presented either as cost per quality-adjusted 
life years (QALY) gained or cost per disability-adjusted life years (DALY) averted. The 
estimation of preferences for health states along with the cost is useful for decision-makers 

















Q is the health-related quality of life weight attached to the relevant period of life. 
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Qi is a vector of health-related quality of life weights predicted (or observed) for each time 
period t following the intervention, while r is the discount rate expressed as a decimal 
 
L is the duration of the disease in the absence of treatment, while Li is the period over which 
the individual enjoys the benefits of treatment 
a is the age of the individual 
r is the discount rate 
 
DALY 
DALYs are calculated by adding the number of years lived with disability (YLDs), and the 
number of years of life lost due to premature mortality (YLLs) (66).  
YLL = Number of deaths X life expectancy at the age of death    
 











        Equation 2 
 
Where: 
r = discount rate expressed as a decimal 
K = age weighting modulation factor  
C = constant  
B= parameter from the age weighting function  
a = age of death  
L = standard expectation of life at age a (age of death) 
 
A disability weight is a weight factor that reflects the severity of the disease on a scale from 
0 (perfect health) to 1 (death). 
YLD = Number of cases X duration till remission or death  
X disability weight for the condition         
  
The formula for YLDs [r, K, B] differs from YLLs [r, K, B] by incorporating D (the disability 
weight) and different interpretation of a and L as described below: 










(1 − +#,&)B 




r = discount rate expressed as a decimal 
K = age weighting modulation factor  
C = constant  
B = parameter from the age weighting function  
a = age of HIV diagnosed   
L = duration of disability   
 
DALY [r, K, B] = YLL [r, K, B] + YLD [r, K, B]     Equation (4) 
 
Therefore, the incremental cost-effectiveness ratio (ICER) of a health care intervention can 
be calculated by the difference in cost between two possible interventions divided by the 






C1 = Cost of the new intervention  
C0 = Cost of the status quo  
E1 = Effect of the new intervention  
E0 = Effect of the status quo   
 
2.6.  QALYs and DALYs - praise and criticism 
 
The advantage of applying QALY as a measure of health outcome is that it combines the 
reduced morbidity (quality gained) and reduced mortality (quantity gained) into a single unit 
of measure (65, 67-70). The quality gain is the gain in health-related quality of life during the 
time the individual benefits from the intervention. The quantity gain is the amount of life 
extension gained by the intervention (69). The challenge with QALY is that it conflicts with 
the basis of equal health provision for all because it favours more treatable conditions and 
those with the potential for more excellent health (71).   
 
On the other hand, DALY is a widely used measure of economic evaluations in low- and 
middle-income countries and is recommended by WHO for use in CEA (72).  In principle, 
DALY assumes that every person is born to live in optimal health for a certain number of 
years (66, 73, 74). However, people can lose these healthy life years due to illness or by dying 
before average life expectancy (75). Thus, DALYs capture lost years due to morbidity, 
mortality, or both (66, 72-74, 76). Challenges with DALY include its implication with age-
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weighting, discounting, and difficulties with distinguishing between measuring the burden of 
diseases and allocating resources (77, 78).  
 
2.7.  Modelling of health interventions – what is useful for 
policymakers? 
 
In economic evaluation, decision-analytic models synthesize data from randomized control 
trials (RCT), clinical trials, or observational studies, or the literature to model an intervention 
beyond the research population, settings, or time to evaluate the intervention at the 
population or cohort level (53, 54). The systematic literature review on the CEA of different 
HTS in this chapter will present different modelling approaches that evaluated varying 
models of HTS within diverse settings and target populations. Despite the differences in 
research objectives and design, economic evaluation models aim to extrapolate the 
intervention’s cost and health benefits over time while providing intermediate outcomes (for 
example number of positive cases identified, number of ART initiations, number retained in 
ART care, and number with viral load suppression) and a final utility measure (for example, 
cost per DALY averted). With the utmost transparency and sensitivity/uncertainty analysis, 
models often have to combine multiple data sources to parametrize the model.  
 
Modelling studies using microsimulations, discrete event simulation or dynamic transmission 
models have been used for CEA of different HTS (31-37, 60, 62-64)(31-37, 60, 62-64). The 
two decision-analytic models of interest are decision tree models and Markov models. A 
decision tree model provides a logical structure for a decision and possible events over a 
fixed time horizon (53, 54). A decision tree is important because it provides a simple, logical 
decision structure with all HIV testing approaches available to the decision-maker. Markov 
models are based on a series of ‘health states’ that an individual can occupy and it simulates 
a hypothetical cohort’s recurrent events through the set of health states over time (53, 54). 
One limiting assumption of the Markov model is that transitions to a state depend only on 
the current state and do not depend on the events that preceded, which makes the Markov 
model memoryless (53).  
 
Policymakers in low and middle-income countries face difficult decisions about which 
healthcare intervention to invest in and which cost-effectiveness threshold (CET) to apply 
that truly reflect the likely health effects of changes in healthcare expenditures (79, 80). The 
traditional “WHO-CHOICE threshold (81)” of 1-3x GDP per capita has been criticized for 
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doing more harm than good (79). In the absence of a locally defined CET, countries may 
consider using half of gross domestic product (GDP) per capita (82, 83) instead of the 
previously suggested 1x-3 GDP per capita rule (72). The current GDP per capita for Zambia 
is US$1,430 (80). The cost-effectiveness threshold needs to reflect the opportunity cost of 
the health service forgone to provide for other interventions (79, 80). Because Zambia does 
not have a defined local threshold, this study considered Zambia’s 1x GDP per capita per 





2.8.  A systematic literature review of costs and cost-effectiveness 
analyses of HIV testing services in sub-Saharan Africa (Paper 1)  
 
Overview of Paper 1  
 
Cost and cost-effectiveness data on HTS can be used to parametrize models to estimate the 
incremental cost-effectiveness ratio of existing HTS or new testing technology in a given 
population, time, and place. However, it is vital to understand the gaps before applying the 
cost and cost-effectiveness estimates in an economic evaluation of HTS.  
 
This research paper systematically reviews the cost and the cost-effectiveness of providing 
HIV testing in sub-Saharan Africa through various HIV testing modalities. 
 
This chapter provides evidence as well as information about the gaps on the cost and cost-
effectiveness estimates of various HIV testing modalities.  
 
This paper is in preparation to be submitted to AIDS in July 2020. One supplementary 
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Objective: To review the costs and cost-effectiveness of HIV testing services (HTS) in sub-
Saharan Africa. 
Design: A systematic literature review of costing and cost-effectiveness studies reported 
from January 2006 to June 2019.  
Methods: We searched ten electronic databases for studies that reported estimates for cost 
per person tested (US$pptested), cost per HIV-positive identified (US$ppositive), and cost-
effectiveness (CE) analysis where health outcomes were quantified in quality-adjusted life 
years (QALYs), disability-adjusted life years (DALYs), HIV infections averted, or life-years 
gained (LYG). We explored variations in costs and CE estimates by different testing 
modalities. All costs are presented in 2019 US$. 
Results: Fifty-four studies were identified: cost studies (n = 44), CE studies (n = 15), both 
cost and CE studies (n = 5), reporting estimates for six HIV testing modalities: health facility, 
home-based, mobile, self-testing, campaign-style, and stand-alone. The mean cost per test 
was lowest with self-testing services (US$11.94, range: US$8.89-US$14.23) and highest with 
campaign-style (US$40.64, range: US$13.78-US$57.93). The mean US$ppositive was lowest 
with self-testing services (US$79.583range: US$33.40-US$115.08) and highest with 
campaign-style (US$722.11). The 15 CE studies reported 31 estimates. For facility-based 
testing, the cost per HIV infection averted ranged from US$112.06 to US$44,203.96. 
Additionally, mobile-service compared to facility-based testing would cost US$1,952.23 per 
LYG. An additional provision of self-testing to the standard of care would result in ICER of 
US$280.23 and US$289.92 from a provider and societal perspective, respectively.  
Conclusion: Home-based HIV testing and self-testing in the community and through 
existing health facilities were the least costly approaches. In general, the costs of the different 
testing modalities were comparable. Providing a combination of these modalities is more 
likely to achieve universal awareness of HIV status. The few cost-effectiveness studies 
identified highlighted the value of averting HIV transmission in targeting pregnant women 






• The costs to test individuals through health facility, home-based, and mobile services 
were comparable; however, the costs were higher for campaign-style and stand-alone 
HTS. 
 
• Few studies have undertaken cost-effectiveness analyses of HTS models. Though 
expanding testing choice is likely to increase coverage, it comes at increased cost. 
More work is needed to identify the optimal combination of HTS models and 
funding strategies. 
 
• Future cost and CE studies should follow standardized guidelines for estimating and 
reporting cost and cost-effectiveness estimates using the Global Health Cost 
Consortium (GHCC) reference case and the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) checklist, respectively, to better allow 





Research in context 
 
Evidence before this study  
Previous systematic reviews (84-86) have assessed either the cost or cost-effectiveness of 
HIV prevention. They reported costs for different HIV testing modalities across different 
setting, populations, and contexts.  
 
Added value of this study    
In our study, we systematically reviewed the findings of previous costing and cost-
effectiveness studies of HIV testing services in sub-Saharan Africa. We explored how the 
costs of different testing modalities vary by the costs per person tested for HIV and costs 
per HIV-positive case identified. Our study systematically reviewed both the cost and cost-
effectiveness of HIV testing services to adequately inform HIV testing planning with the 
most up to date economic evidence by including studies published after the year 2006. We 
used the Global Health Cost Consortium (GHCC) reference case and the Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) statements to assess the 
quality of cost and cost-effectiveness studies, respectively. 
 
Implications of all the available evidence  
Our findings add to existing publications reviewing the cost-effectiveness of HIV testing 
services in sub-Saharan Africa. Together, they will help policymakers better understand 






HIV continues to be a major global health concern affecting 37.9 million people, with 1.7 
million newly infected every year (1). Eastern and Southern Africa (ESA) continue to be 
disproportionately affected, accounting for 45% of incident HIV infections and 53% of 
people living with HIV (PLWH) globally (87). Out of the 53% PLWH in ESA, 19% (3.1 
million PLHIV) remain undiagnosed (87). The UNAIDS 90-90-90 targets recommend that 
by 2020, 90% of all PLHIV should know their HIV status, 90% of individuals diagnosed 
with HIV infection should receive antiretroviral therapy (ART), and 90% of those on ART 
should be virally suppressed to end the HIV epidemic (88). At the end of 2017, only 81% of 
PLHIV knew their HIV status (87, 89). Disparities in HIV testing coverage, knowledge of 
HIV positive status among men and adolescents, and mortality from HIV in men remain 
major concerns (90-92). Universal access to HTS is also essential to ensure uninfected 
individuals at risk of HIV infection are referred to effective HIV prevention interventions, 
including voluntary male medical circumcision (VMMC) and pre-exposure prophylaxis (93-
102).  
 
HTS are abundant in many African countries with testing delivered in health facilities and 
various other testing modalities such as home-based, mobile-service, campaign-style, and 
stand-alone HTS, by a range of healthcare professionals and more recently with users able 
to self-test for HIV. These testing approaches have been found to have varying degrees of 
success, with evidence suggesting Africans prefer HIV testing to be delivered closer to their 
homes or provided through more convenient and confidential approaches like HIV self-
testing (103-114). Policymakers striving to ensure universal access to HTS in Africa need to 
balance these objectives with the financial pressures they face to ensure cost-efficient 
spending. In order to achieve this, they urgently need to better understand the costs and cost-
effectiveness of different HIV testing modalities. 
 
In this study, we sought to systematically review the findings of previous costing and cost-
effectiveness studies of HTS in sub-Saharan Africa. First, we explored how the costs of 
different testing modalities vary by outcomes, such as costs per person tested for HIV and 
costs per HIV-positive case identified. Second, we reviewed all cost-effectiveness studies and 
presented results such as  DALY, QALY, $/LYG, $HIA, $/DALY or $/QALY. The 
implications of the findings for the variation in reported cost and cost-effectiveness estimates 






This systematic review aims to review the costs and the cost-effectiveness of different HIV 
testing modalities in sub-Saharan Africa. The review was limited to sub-Saharan Africa 
because it experienced a generalized epidemic. A description of the different HIV testing 
approaches in sub-Saharan Africa is provided in Table 2-1 (29) and is used to classify studies 
into models. Study results are also categorized as cost or cost-effectiveness depending on 
how the results are presented.  
 
Table 2.1 Definition of model HTS included in the review (29) 
HTS model Description 
Health facility 
Health facility HIV testing includes the provision of pre-test 
counseling, HIV rapid tests, and post-test counseling offered to 
clients within the department of voluntary counseling and testing 
(VCT), antenatal clinic (ANC), and provider-initiated HIV 
counseling and testing (PICT) or outpatient department (OPD).  
HTS provided within voluntary medical male circumcision centres.  
Community-based 
Home-based HTS includes the provision of pre-test counseling, HIV 
rapid tests, and post-test counseling by trained HTS provider in the 
client’s home. 
Mobile HTS uses tents and mobile van to provide HIV testing in 
different community locations such as near markets, transport hubs, 
and open fields. The trained HTS provider selects the specific 
location on an ad hoc basis. 
Campaign-style HIV testing uses more accessible community spaces 
that are organized by the MoH or specific organizations. It is more 
connected to the community, and it is designed to address specific 
community needs. 
Stand-alone is immobile HTS located near transport hubs and 
markets where it serves community members. 
Self-testing  
Self-testing is where a person performs and interprets his or her own 
HIV test, often in private. Self-testing can be done within health 






Search strategy and identification of studies  
The literature searches were undertaken in December 2019 and updated on May 2020. We 
searched ten databases: Medline, PubMed, Embase, Popline, Scopus, Global Health, 
COCHRANE, Social Policy and Practice, Web of Science, and Tuft University cost-
effectiveness analysis registry (115). The search terms were formulated around the following 
three concepts: (1) HIV, (2) HIV testing (including couples testing and self-testing), and (3) 
cost and cost-effectiveness analysis. Authors and experts in HIV economics were contacted 
by email for any further references, missing outcomes, and clarifications. References of 
included studies were reviewed for additional relevant articles. The full search strategy is 
described in Supplementary Table S2. 
  
Inclusion and exclusion criteria 
Studies were eligible for inclusion if they reported any costs or cost-effectiveness estimates 
for HTS in a sub-Saharan African country. This included unit cost -- cost per person tested 
(US$pptested) and cost per HIV-positive case identified (US$ppositive) -- and for cost-
effectiveness studies cost per HIV infection averted (HIA), cost per life-year gained (LYG), 
cost per disability-adjusted life years (DALYs) averted or cost per quality-adjusted-life-years 
(QALYs) gained. Studies were included in the analysis more than once if they had reported 
the results of costs for more than one HIV testing model. We included studies that explored 
HIV testing in all population groups except those that focused on infant HIV testing. The 
language was limited to English, including original or translated sources. Supplementary 
Table S1 provides detailed PICOS (Population, Intervention, Comparators, Outcomes, and 
Study type), inclusion, and exclusion criteria. 
 
Study selection and data extraction 
Two independent reviewers (N.A. and S.R.) scrutinized titles and abstracts independently for 
eligibility according to the inclusion criteria. Discrepancies were resolved through discussion 
and consensus by reviewing the full study. N.A reviewed full studies and created the data 
extraction template using the Global Health Cost Consortium (GHCC) reference case (116) 
and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) (117) 
checklist to characterize eligible studies. This systematic review followed the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines 





For each included study, we first classified the studies by whether they undertook a cost 
analysis, cost-effectiveness analysis, or both. Studies were deemed to have undertaken a cost 
analysis if they only estimated the costs of delivering the HTS and related this to either the 
number of HIV tests performed, or a number of HIV-positive individuals identified. Studies 
were deemed to have undertaken a cost-effectiveness analysis if they compared one HIV 
testing modality to either provision of no HTS or another HIV testing modality and reported 
results such as (but not limited) DALY, QALY, $/LYG, $HIA, $/DALY or $/QALY.  
 
Cost studies  
For cost studies, we extracted data on the country of the study, HIV testing modality, costing 
year, costing perspective, costing method, the total number of HIV tests provided, the total 
number of HIV-positive cases identified, cost per person tested (US$pptested) and cost per 
HIV-positive individual identified (US$ppositive). For US$pptested, the total costs of a given 
HIV testing modality were divided by all individuals that were tested (the sum of person 
tested HIV negative and person newly tested HIV positive : US$pptested =
!6!$7	869!	$	:";*<	=>?		
(@ABCDE	FACFAG	HIJ#)%(@ABCDE	FACFAG	HIJ%)	
 . For US$ppositive, the total costs of a given HIV 
testing modality are divided by all individuals that newly tested HIV 
positive:	US$ppositive = !6!$7	869!	$	:";*<	=>?		
@ABCDE	FACFAG	HIJ%	
. For studies that reported costs for a 
package of interventions targeted at HIV testing services and other health provisions, such 
as family planning or TB, we subtracted cost for other health provisions and only reported 
costs that were part of the HIV testing services to improve the comparability of studies. For 
the costing year, we extracted the year the costing exercise was conducted, rather than the 
year the study was published. For studies that did not report the costing year, we assumed it 
to be the year before the publication date. The included studies reported costing perspectives 
using different terminologies. We categorized the costing perspective as provider, patient, or 
societal. A provider perspective captured the costs an organization spent to deliver the health 
intervention, a patient perspective only included the costs incurred by the users, and societal 
perspective included all the costs incurred by the organization delivering the intervention and 
by the users and possibly second or third parties affected (119). 
 
We classified the costing methods used at three levels. First, we determined whether the 
researchers had estimated incremental or full costs. The incremental costs estimate the cost 
of adding a new health intervention onto an existing health programme by reporting the 




infrastructure and overhead costs borne by the existing health programme. An incremental 
cost analysis may underestimate the cost of delivering a new health intervention or the 
investment needed to sustain current provision (54). By contrast, a full cost analysis includes 
the costs of all resources used to introduce the new health intervention, including the 
infrastructure and overhead costs. Second, we determined whether the costs represent 
financial or economic costs. Financial costs estimate the actual expenditure on goods and 
services purchased. Economic costing estimates the value of all resources used, including 
donated goods and services (120). Third, we determined whether the cost represented 
estimates from primary costing studies or modelled costs. Primary costing studies are ones 
that observed actual resource use in order to estimate costs, whilst modelled costs are ones 
that assumed likely resource use in order to estimate costs (120). 
 
Cost-effectiveness studies  
For studies that reported findings from a cost-effectiveness analysis, we extracted data on 
the country of the study, costing year, study perspective, HIV testing modalities compared, 
and the incremental cost-effectiveness estimate. We extracted the incremental cost-
effectiveness estimate for each comparison of HIV testing modality undertaken. Measures 
of effectiveness included HIA, LYG, DALY, and QALY.  
 
Study quality assessment  
Two independent reviewers (N.A. and M.D.) assessed the quality of the costing methods 
using the GHCC reference case (116). The GHCC is comprised of 17 principles to guide the 
process of cost estimation; for each cost study, we assessed whether the study had met these 
guidelines (Table S4). The CHEERS checklist consists of 24 items to guide the minimum 
amount of information that should be included when reporting economic evaluations (117). 
We applied the CHEERS checklist to summarise the quality of cost-effectiveness studies 
(Table S5). These two scoring systems explore reporting of different issues and therefore 
may result in discrepancies. A detailed quality assessment for individual studies is included in 
Supplementary Tables S6 and S7.  
 
Data analysis  
All cost and cost-effectiveness estimates were adjusted for inflation using local inflation rates 
and consumer price index and are expressed in 2019 US dollars based on the World Bank’s 
consumer price index (121) and the official exchange rate (122). First, costs expressed in US$ 




the time the cost analysis was done. Second, the costs were inflated using the World Bank’s 
consumer price index and converted back to US$ using the exchange rate of the base year 
(2019)(123). It is important to estimate costs using purchasing power parities and health care 
specific indices in different countries by applying purchasing power parities conversion 
factors to the non-tradable portion of the costs. This was impossible, because not all costs 
in the literature review were clearly presented into tradable and non-tradable cost inputs.  
This systematic literature review did not conduct a meta-analysis on cost and cost-
effectiveness estimates due to variation in HTS approaches, population served, costing 
perspective and costing methods in different African countries. Moreover, to conduct a 
meta-analysis of economic evaluation, Crespo et al. suggest using net monitory benefit. 
Unfortunately, in SSA, we don’t have a formal ICER threshold, which is required to 
determine NMB. Thus, it is not possible to conduct a meta-analysis (124).  
 
Results 
We identified 99 eligible studies out of 6,875 abstracts and the findings from 54 studies are 
included in our review (Figure 2-1). Table 2-2 summarizes the findings from studies that only 
undertook a cost analysis (n = 39), and Table 2-3 shows findings from studies that undertook 
cost-effectiveness analysis (n = 10). Five studies undertook both cost and cost-effectiveness 






1Cost estimates are defined as total cost, cost per test kit distributed, per person 
tested, and per HIV + person identified 
2Cost-effectiveness estimates are defined as having effect present in QALYs, DALYs, HIA 
or LYG 
Studies identified through 10 
databases search (n = 14,581) 
Additional studies identified through reference list review 
of existing systematic literature reviews (n = 1,826) 
Studies screened based on titles and abstracts (n = 6,875)  
Studies after duplicates and before the year 2006 removed (n = 6,875) 
Full studies assessed for eligibility (n = 99) 
Studies included (n = 54) 
Studies excluded (n = 6,777)  
2Cost-effectiveness estimates reported (n = 31)  1Cost analysis estimates reported (n =125) 
Cost studies (n = 39) Cost-effectiveness studies (n = 10) Both cost and CE studies (n = 5) 
Health facility (n = 59)  
Home-based (n = 29) 
Mobile-service (n = 17) 
Self-testing (n = 10) 
Campaign style (n = 6) 
Stand-alone (n = 4)   
Health facility (n = 21)  
Home-based (n = 3) 
Mobile-service (n = 1) 
Self-testing (n = 3) 
Campaign style (n = 3) 
Total number of HIV testing service costs or cost-effectiveness estimates reported (n = 156) 
• High income countries (n = 5) 
• Early diagnosis of infants (n = 5) 
• No original costs or cost-effectiveness 
estimates reported (n = 11) 
• Only reported ART costs (n = 23) 
• Data needed to be re-analysed (n = 1) 




Cost analysis studies  
The 44 studies (39+5) that undertook cost analysis represented findings from 13 countries 
in sub-Saharan Africa: 28 were from Southern Africa, 20 were from East Africa, three were 
from West Africa, and two were from sub-Saharan Africa. For costing perspectives, 43 
studies presented costs from the providers’ perspective, one study presented patients’ 
perspectives, and one study presented both provider and societal perspectives. For costing 
methods, 29 studies undertook incremental costing, 12 studies undertook a full costing 
method, and three studies modelled costs from another study. Twenty-four studies reported 
the financial costs, 17 studies reported the economic costs, and three studies modelled costs 
from another study. Of the 44 studies, primary (empirical) costing was undertaken to estimate 
costs in 41 studies, whilst in three studies estimates were modelled based on likely resource 
use. Ten studies did not report the costing year (Table 2-2). The 54 studies present 123 cost 
estimates of different HIV testing modalities. Out of the 123 reported cost estimates, 59 
reported costs for facility-based HTS, 29 home-based testing, 17 mobile services, 10 self-
testing, 5 campaign-style, and 4 stand-alone HTS. 
 
Figure 2-2 shows the estimates for US$pptested by HIV testing modalities from provider 
perspectives. For facility-based HTS, the mean US$pptested was US$20.30 (range: US$1.35-
US$80.48) (30, 32, 59, 61, 97, 125-141) and for home-based testing, the mean US$pptested 
was US$13.16 (range: US$1.01-US$54.10) (130-132, 137, 140, 142-151). For mobile-service 
services, the mean US$pptested was US$19.13 (range: US$4.43-US$36.22) (33, 125, 137, 145, 
146, 148, 149, 152-154). For self-testing, the mean US$pptested was US$11.94 (range: 
US$8.89-US$14.23) (50, 155, 156). For campaign-style, the mean US$pptested was US$40.64 
(range: US$123.78-US$57.93) (154, 157, 158). For stand-alone HTS the mean US$pptested 
was US$43.12 (range: US$20.52-US$74.63) (130, 153). For the one study that reported costs 
from patients’ perspective, the US$pptested ranged from US$1.35 to US$2.37 (138) (Figure 
2-2). Most results were identified from facility-based testing (n = 55) with only ten estimates 
for HIV self-testing. 
 
Figure 2-3 shows the estimates for US$ppositive by testing modality. For facility-based HTS, 
the mean US$ppositive was US$196.27 (range: US$9.69-US$1,823.04) (59, 127, 128, 130, 
132, 133, 139, 141) and for home-based testing, the mean US$ppositive was US$272.17 
(range: US$9.87-US$773.70) (130, 132, 143-151). For mobile-service services, the mean 
US$ppositive was US$365.33 (range: US$6.74-US$1,160.67) (127, 145, 146, 148, 149, 152-




(156). For campaign-style, the mean US$ppositive was US$723.11 (154). For stand-alone, the 
mean US$ppositive was US$215.11 (range: US$107.15-US$323.08) (130) (Figure 2-3).  
 
 
*One study reported the unit cost of US$200.63 per person tested for the second 
round of first-time testers for home-based testing (144).  


















































































*One study reported the unit cost of US$1823.04 per case identified for health facility 
PMTCT testing (128).  






























Table 2.2 Summary of HTS cost studies included 2006-2019 in 2019 USD (n = 43) 






































44.92 - 1,988 177 
Not specified 
Mobile 
service   
Mobile service-
referred clients  
9.49 - 14,726 480 
Mobile 
service   
Peer-led mobile 
service  
6.51 - 14,895 1,853 
Ahmed, 2018 (155) Zambia Self-testing  
Clients at a 




13.34 - 12,885 NA 
• Training 
• Sensitization 
• Building and 
storage 
• Equipment 
Clients at the 
VMMC centre 

































14.23 - 103,589 NA 
















Aliyu, 2012 (159) Nigeria  
Clients at a 
health facility1 
Provider Inc/Fin/Emp 9.69 - NS NA 
• Rapid test 

































Clients at a 
tertiary facility 








8.28 - NS NA 
• Rapid test 






























































Allen, 2014 (126) Zambia 
Health 
facility 
CHCT at a 
health facility  
Provider  Inc/Fin/Emp 
41.02 
 
- 68,000 NA 
• Overheads 
• Training in 
counseling  































































of the current 







9.11 - 91 NA 







































5.06 - 82 NA 
Home-based-
contact tracing 




4.05 - 184 NA 
Home-based-
contact tracing 









































1.52 - 82 NA 
Home-based-
contact tracing 




1.01 - 184 NA 




































Clients at VCT 
services 
  
7.66 11.47 1,414 463 





• Salaries  
• Space 










23.83 25.46 18,870 939 
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• Administrativ














8.09 168.80 1,270 491 
•  
• Capital 
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Clients at VCT 
services 
28.03 156.45 808 1,019 




Clients at VCT 
services 
13.92 89.35 242 291 
Clients at ANC 35.89 413.81 618 104 
Bogart, 2017 (160) Uganda  
Home-based 
Clients tested at 
home 
Provider  Inc/Eco/Emp 
37.63 - 822 - 
• Personnel 
• Per-diems 
• Transport  





39.62 - 344 - 
























































12.27 329.38 4,260 153 
• Capital and 
equipment 










15.46 86.47 2,969 519 
Campaign-non-
attenders 
36.22 203.97 832 136 













• Personnel  
• Vehicles 
• Equipment  
• Supplies 
• Per diems 
Community 
members-new 
person tested  





45.69 323.08 14,634 2,063 
Community 
members-new 
person tested  





































26.78 367.17 126,208 9,196 
• Administratio
n 
• Personnel  
• Transport 




25.43 692.20 136,966 4,921 







Clients at the 
community 




15.05 - NS NA 
• Personnel  
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primary health 
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Clients at the 
STI clinics  
11.71 - NS NA 








• Training  
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• Consumables  
Second round 
client tested 




200.43 - 40 NA 









- 476.26 NA 15 
• Not 
specified*  
Clients at ANC  - 349.54 NA 44 
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Kahwa, 2008 (161) Tanzania 
Health 
facility 
Clients at health 
facility  
Provider  Inc/Eco/Emp 16.14 - 53,926 NA 
• Vehicle  
• Building  













Provider   
Inc/Fin/Emp 
 



































12.87 206.60 1,207 75 
• Transportatio
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Lasry, 2019 (146) Botswana Home-based 
Household 
members 




































34.70 583.85 12,820 766 
• Equipment 
and supplies 
• Facilities and 
administratio
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• Events and 
travel  
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8.89 79.47 6,759 756 
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Clients at health 
facility-2 











Clients at health 
facility-3 
10.50 33.40 9,488 2,984 
Self-testing  
Clients at health 
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Zambia  Self-test Home-based  14.23 - 103,589 - 
































Zimbabwe Self-test Home-based  13.84 - 93,459 - 
• Equipment 
• Personnel 
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20.52 107.15 8,391 1,616 
• Building and 
utilities 
• Equipment  
• Personnel 
• HIV testing 
supplies 
• Vehicles 






12.44 45.91 21,755 5,872 
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6.62 107.01 3,404 304 • Building and 
storage 

































8.87 180.55 1,542 93 
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Negin, 2009 (147) Kenya Home-based 
Household 
members 
Provider  Inc/Fin/Emp 8.18 116.80 2,780 209 



















































• Building  
• Furniture and 
equipment 
• Staff training  
• Personnel  





• Diagnostics  
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• Building  
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maintenance 
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Clients at ANC Provider  Inc/Fin/Emp 67.82 - 5,457 - 
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on, food, and 
airtime) 
Perchal, 2006 (136) Ethiopia 
Health 
facility  
Clients tested at 
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• Indirect cost  
 












9.88 - 22,152 699 
• Diagnostics 






• Equipment  
Health 
facility 
Clients at a 
health facility  




6.78 - 48,330 896 





Clients tested in 
a centralized 




2.37 - 120 NA 
• Travel cost 
• Income loss  
• Additional 
costs (food & 
medication) 
Clients tested in 
a decentralized 
health facility  
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transport  
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4.43 6.74 890 381 • Programme 
cost of 
mobile HTS Home-based 
Household 
members 








































Provider  Inc/Eco/Emp 
33.99 - NS NA 
• Personnel  
• Transportatio
n  
• Equipment  
• Supplies 







































































































Provider  Inc/Fin/Emp 7.08 19.01 NA NA 










• Data capture 
and use 





Clients at the 





30.60 - 3,818 NA 
• Startup 









































• Field material  










































Provider Inc/Eco/Emp 39.18 - 1,526 NS 
• Buildings 



















Clients at VCT- 
Chawama 
health facility  
Provider  Ful/Eco/Emp 31.01 95.76 1,381 455 
• Buildings 































Clients at VCT- 
Matero health 
facility  
32.83 46.51 239 166 


























































12.48 - 238,290 NA 








Cost-effectiveness analysis studies 
We identified 15 (10+5) studies that undertook cost-effectiveness analysis (Table 3) across 
seven countries in sub-Saharan Africa: eight from Southern African, four from East Africa, 
one from West Africa, and two studies that stated the location as sub-Saharan Africa. For 
these 15 studies, 12 studies undertook the analysis from the provider’s perspective, one from 
both provider and societal perspectives, and two did not specify their perspective. On the 
analytical approach, all the 15 studies applied different types of modeling approaches to 
measuring cost-effectiveness estimates and impacts (Table 2-3). The 15 studies presented 31 
cost-effectiveness estimates for different HIV testing modalities. Out of the 31 reported cost-
effectiveness estimates, 21 reported estimates for health facility testing, three for home-based 
testing, one for mobile service, three for self-testing, and three for campaign-style HTS. 
 
Thielman et el. undertook cost-effectiveness analysis regarding removing user fees to access 
HIV testing at community-based HIV services in Tanzania. The estimated cost per HIV 
infection averted with standard fee VCT, with two-weeks free VCT campaign, and with 
sustained free VCT service were US$242.43, US$149.73 and US$131.20, respectively (62). 
The Kahn and colleagues study in Kenya found that integrating HIV testing, malaria, and 
diarrhea prevention interventions would be more effective and less costly than delivering 
them separately, suggesting economic of scope in community screening programmes (31). 
 
Two studies modelled the cost-effectiveness of couples HIV testing and counseling (CHCT) 
at health facilities (58, 60). Allen et al. estimated that CHCT would cost US$359.71 per HIV 
infection averted compared to the standard individual VCT in sub-Saharan Africa (58). John 
et al. estimated cost per DALY averted for individual VCT (US$26.20) to be comparable to 
that estimated for CHCT (US$26.29) at ANC in Kenya (60). Ibekwe et al. estimated the cost-
effectiveness of delivering HIV testing to pregnant women through ANC services and 
routine VCT in Nigeria (59). The authors estimated the cost per HIV infected averted for 
HIV testing through ANC services and routine VCT as US$2,040.58 and US$1,519.02 
respectively (59).  
 
Rutstein et al. undertook a cost-effectiveness analysis of different partner notification 
strategies amongst HIV-positive cases attending an STI clinic in Malawi (61). The authors 
estimated that contract notification (while maintaining index case anonymity) would cost 
US$3,060.35 per HIV infection averted compared to the passive notification, whilst provider 




notification (61). Sharma and colleagues undertook cost-effectiveness analysis of adding a 
home-based partner education and HIV testing (HOPE) intervention amongst pregnant 
women attending ANC clinics in Kenya (32). They estimated the cost-effectiveness of adding 
the HOPE intervention to be US$978.46 per DALY averted. However, if community health 
workers delivered the HIV testing (task-shifting) rather the intervention the additional cost 
per DALY averted would be US$679.18 (32). 
 
Hausler et al. estimated the cost-effectiveness of delivering HIV testing in community health 
centres, primary health care clinics, and sexually transmitted infection (STI) clinics (30). The 
authors reported that HIV testing at community health centres, primary healthcare clinics, 
and STI clinics would cost US$155.55, US$187.33, and US$112.06 per HIV infection 
averted, respectively (30). 
 
Two studies (Bassett and Walensky) used the Cost-Effectiveness of Preventing AIDS 
Complications-International (CEPAC-I) computer simulation model, which is a stochastic 
microsimulation model for undertaking cost-effectiveness analysis of mobile testing services 
(33) and periodic HIV screening (63) in South Africa. Bassett et al. estimated it would cost 
an additional US$1,952.23 per life-year saved to add a mobile HIV testing service to standard 
VCT (33). Walensky reported incremental cost-effectiveness ratios (ICER) of US$1,732.78 
per QALY saved for HIV screening every 5 years compared to ICER of US$1,898.33 per 
QALY saved for annual screening (63). Waters et al. estimated the cost-effectiveness of 
different retesting intervals (3 months to 30 years) amongst those who tested HIV-negative 
(64). The authors reported the most cost-effective strategy in low-risk populations (i.e., HIV 
incidence of 0.8%) was re-testing every 7.5 years (US$773.68 per QALY gained), in medium-
risk populations (i.e., HIV incidence of 1.3%) every 5 years (US$751.61 per QALY gained), 
and in high-risk populations (i.e., HIV incidence of 4.0 %) every 2 years (US$700.84 per 
QALY gained) (64). 
 
Three studies estimated the cost-effectiveness of providing HIV self-testing in addition to 
routine facility-based HTS in Zimbabwe (34, 35) and Malawi (36). Cambiano et al. found that 
implementing self-testing would be cost-saving if it could be delivered at the full cost of 
US$3 per unit, and only cost-effective at ICER thresholds above US$10,000 per DALY 
averted if the cost of providing each episode was below US$9 (34) Maheswaran et al. 
estimated the additional provision of self-testing was associated with an ICER of US$280.23 




(36). Leigh and colleagues estimated the cost-effectiveness of self-testing in the context of 
antenatal partner testing and home-based testing (37). The authors reported the incremental 
cost of US$1,941.72 and US$1,111.85 per life-year gained for providing self-testing for the 
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Table 2.4 Quality assessment: Proportion of the cost and cost-effectiveness studies compliant with GHCC and CHEERS guidelinesa,b 
Quality assessment of cost studies (n = 44) following the GHCC principles (116) in % 
Reported cost 














Unit cost, time 
horizon, scope, 










































Health facility (n = 59) 100 80 73 87 87 22 26 17 91 
Home-based (n = 29) 100 85 77 88 77 8 8 31 100 
Mobile-services (n = 17) 100 93 91 100 86 0 14 71 100 
Self-testing (n = 10) 100 100 100 100 100 33 33 100 100 
Campaign style (n = 6) 100 100 100 100 100 0 50 50 100 
Stand-alone (n = 4) 100 100 83 50 100 0 0 0 100 
Quality assessment of cost-effectiveness studies (n = 15) following the CHEERS guidelines (117) in % 
Reported CE 































































Health facility (n = 21) 88 83 100 83 63 81 63 80 79 
Home-based (n = 3) 100 100 100 100 100 100 100 100 100 
Mobile-service (n = 1) 100 100 100 83 83 100 100 50 100 
Self-testing (n = 3) 100 100 100 100 100 100 100 100 100 
Campaign style (n = 3) 100 50 50 33 33 50 0 0 33 





This review adds to existing reviews on the effectiveness of HIV testing (84, 85, 104, 164) 
by exploring the costs and cost-effectiveness of HIV testing strategies in sub-Saharan Africa. 
We identified cost estimates for six different HIV testing modalities. We found the costs to 
test individuals through health facility, home-based, and mobile services were comparable: 
US$20.33, US$11.16, and US$19.13 respectively. The costs were higher for campaign-style 
and stand-alone HTS: US$40.64 and US$43.12 per person tested respectively. The costs were 
lowest for HIV self-testing: US$11.94 per person tested. The cost per HIV-positive 
individual identified varied across the six HIV testing modalities. The mean cost per HIV-
positive identified at the health facility, home-based, and mobile services were US$196.27, 
US$272.17, and US$365.33, respectively. Although there were a small number of cost studies 
for campaign-style and stand-alone HIV testing modalities, the mean costs were US$723.11 
and US$215.11 per HIV-positive identified, respectively. The mean cost per HIV-positive 
individual identified was lowest through HIV self-testing at US$79.53.  
 
Interpreting these cost estimates should be done with caution. Some of the differences 
observed in cost estimates are likely to be explained by variation in HIV prevalence across 
settings. For example, low HIV prevalence in Rwanda led to low yields, and higher cost per 
HIV+ case identified (128). One study presented cost estimates for two rounds of home-
based HIV testing and reported the cost per HIV-positive person tested nearly doubled 
between the two rounds (first round US$367.17 vs second round US$692.20) and this was 
partly explained by a reduction in the HIV positivity rate. The authors also stated costs are 
sensitive to community specific factors such as service delivery and population characteristics 
(143).     
 
Additionally, we observed variation in costing methods used (incremental vs. full, economic 
vs. financial). Studies that used incremental costing methods will likely under-estimate costs 
as they do not include the existing infrastructure and overhead costs borne by the existing 
health programme. These costs would potentially be incurred by those wishing to implement 
the same testing service in another setting where existing infrastructure may not be available. 
Studies that estimated the financial costs might have costed a service that utilized donated 
goods or volunteer staff. The same service in another setting may have to purchase these 




We found that, in general, the costs of the different testing modalities were comparable. This 
should encourage policymakers wishing to provide different options of HTS modalities in 
their populations. The choice of one testing modality over another can be driven by which 
HIV testing approach is most feasible to implement and most likely to reach their untested 
and under-served populations. Additionally, the cost findings may encourage policymakers 
to consider delivering a mixture of testing modalities.  
 
We identified a few cost-effectiveness studies of HIV testing services. These studies did 
identify a few important issues. Removing user fees to access HIV testing improved their 
cost-effectiveness (62). Delivering HIV testing services alongside other health interventions 
was more cost-effective than delivering either HIV testing or the other intervention alone 
(30, 31). Couples testing and ensuring pregnant women have access to HIV testing were 
potentially a cost-effective approach to preventing new infections (58, 59). In comparison, 
partner notification was associated with a higher cost per HIV infection averted (61) unless 
it targeted pregnant women and offered partners HIV testing in their homes (32). A recent 
study in Malawi provided further evidence to support this approach (106). Studies found the 
provision of either home-based HIV testing (32), mobile testing services (33), or HIV self-
testing (34-37), in addition to routine facility-based HIV testing, potentially cost-effective at 
a cost-effectiveness thresholds equivalent to one to three times gross domestic product per 
gain in DALY, QALY, or life year (38). Implementing these testing models may be cost-
effective but will increase total spending on HIV testing. Finally, amongst those who have 
tested, the cost-effective time to the next HIV test is 5-8 years depending on the population’s 
risk (63).  
 
We used the GHCC, and the CHEERS statements to assess the quality of cost and cost-
effectiveness studies, respectively (116, 117) (Table S4 & Table S5). Though there has been 
a significant improvement in adherence to best practices for conducting and reporting 
findings from economic evaluations, the wide variability of unit costs is partly due to the 
non-standardized definition of unit cost and approaches to data collection, cost analysis, and 
reporting. The included cost components varied considerably. Not only cost components 
but sources for cost data collection also varied, including estimating cost from a single health 
facility and aggregating data from all regions in a country without accounting for variations 




The paucity of standardized cost and CEA estimates for different HIV testing modalities in 
sub-Saharan African countries imposes technical challenges in translating the resource needs 
and findings from one country to another. It is apparent that high-quality cost and CE studies 
are crucial for sub-Saharan Africa, where scarce resources must be allocated efficiently. Thus, 
we strongly recommend that cost and CE data collection, estimation, and reporting should 
follow the GHCC reference case, and reporting of published findings adhere to CHEERS 
guidelines (116, 117) to improve the validity and comparability of studies across the region. 
The scarcity of cost-effective estimates for home-based, mobile-service, self-testing, and 
campaign-style testing modalities highlights the need for more studies. Also, it is essential to 
do more CE analysis of the different combinations of testing modalities to inform HIV 
testing policies better. 
 
Limitations 
This review has several limitations. This review acknowledges the diversity and complexity 
of healthcare systems in sub-Saharan Africa. Thus, the review presented the costs and the 
CE results following the study perspective. Furthermore, there is no consensus on what 
should be reported as direct and indirect costs, and studies might have defined direct and 
indirect costs differently. In no one single country were all six HIV testing modalities 
assessed, which made the comparison of different testing modalities difficult. The methods 
used to undertake the economic analysis were not always comprehensive or comparable, 
limiting the generalizability of findings. Some studies proposed checklists of transferability 
of economic evaluations (165-168). Moreover, this review acknowledges the diverse 
published data sources, for example, peer-reviewed papers, posters, abstracts, and 
presentations, which limited the quality assessment and comparison between studies.  
 
Conclusion 
In summary, our review identified a large number of studies reporting the costs of different 
testing modalities but few studies that undertook full cost-effectiveness analysis. Although 
we found cost and cost-effectiveness estimates to vary widely, we did identify that in general, 
the costs of the different testing modalities were comparable. The few cost-effectiveness 
studies identified highlighted the value in ensuring users do not pay fees and in targeting 
pregnant women and their sexual partners potentially through couples testing, home-based 
testing, or HIVST. Finally, home-based and mobile are potentially cost-effective if providers 
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are willing to pay the additional money needed to deliver these services and thereby realize 
the potential health benefits from their use. 
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Table S1 PICOS Inclusion and exclusion criteria 
PICOS Inclusion criteria Exclusion criteria 
Population  Adolescents, adult men, and adult women  Infants and children (<age 
16) 
Intervention  Different types of HIV testing services 
(differentiated HIV testing services)   
Infant and children HIV 
testing approaches 
Comparators Any stated comparators None 
Outcomes Cost estimates are cost per person tested, 
and per HIV + person identified 
Cost-effectiveness estimates are cost per 
infection averted, cost per DALY averted, 
cost per QALYs gained 
Not stating costs measures or 
units of health outcomes in 
the study  
Study types Costing and cost-effectiveness analysis of 
HTS in sub-Saharan Africa   
Costing: where no new 
primary costs data are 
presented.  
Cost-effectiveness: where 
outcomes are not presented 
in generic health outcomes, 
including QALYs, DALYs, 




Table S2 Systematic literature review search strategy and strings 
Searched 
databases 
Search terms Result 
Medline 
Concept 1(C1) HIV Infections OR HIV OR hiv OR hiv-1 OR hiv-2 OR hiv1 OR 
hiv2 OR hiv infect* OR human immunodeficiency virus OR 
human immunedeficiency virus OR human immuno-deficiency 
virus OR human immune-deficiency virus OR ((human immun*) 
AND (deficiency virus)) OR acquired immunodeficiency 
syndrome OR acquired immunedeficiency syndrome OR acquired 
immuno-deficiency syndrome OR acquired immune-deficiency 
syndrome OR ((acquired immun*) AND (deficiency syndrome)) 
OR Sexually Transmitted Diseases 
211,320 
Concept 2(C2) Counselling OR Counseling OR Counse*OR Testing OR Test* 386,102 
Concept 3 (C3) Cost OR Costs OR Costing OR Cost-effectiveness OR Cost-
effectiveness analysis OR Cost effectiveness analysis OR Effec* 
OR effectives* OR Cost* 
1,800,445 
C1 AND C2 AND 
C3 
 461 
Concept 4 hiv self-testing OR self-test* OR “self test” OR hiv self-test OR 
hivst OR home test* 
1,581 
Pubmed* 
C1 AND C2 AND 
C3 
HIV Infections OR HIV OR hiv OR hiv-1 OR hiv-2 OR hiv1 OR 
hiv2 OR hiv infect* OR human immunodeficiency virus OR 
human immunedeficiency virus OR human immuno-deficiency 
virus OR human immune-deficiency virus OR ((human immun*) 
AND (deficiency virus)) OR acquired immunodeficiency 
syndrome OR acquired immunedeficiency syndrome OR acquired 
immuno-deficiency syndrome OR acquired immune-deficiency 
syndrome OR ((acquired immun*) AND (deficiency syndrome)) 
OR Sexually Transmitted Diseases AND Counselling OR 
Counseling OR Counse* OR Testing OR Test* AND Cost OR 




analysis OR Cost effectiveness analysis OR Effec* OR effectives* 
OR Cost* 
Concept 4 hiv self-testing OR self-test* OR “self test” OR hiv self-test OR 
hivst OR home test* 
639 
EMBASE 
Concept 1 HIV Infections OR HIV OR hiv OR hiv-1 OR hiv-2 OR hiv1 OR 
hiv2 OR hiv infect$ OR human immunodeficiency virus OR 
human immunedeficiency virus OR human immuno-deficiency 
virus OR human immune-deficiency virus OR ((human immune$) 
AND (deficiency virus)) OR acquired immunodeficiency 
syndrome OR acquired immunedeficiency syndrome OR acquired 
immuno-deficiency syndrome OR acquired immune-deficiency 
syndrome OR ((acquired immune$) AND (deficiency syndrome)) 
OR Sexually Transmitted Diseases 
256,689 
Concept 2 Counselling OR Counseling OR Counse*OR Testing OR Test* 495,348 
Concept 3 Cost OR Costs OR Costing OR Cost-effectiveness OR Cost-
effectiveness analysis OR Cost effectiveness analysis OR Effec* 
OR effectives* OR Cost* 
2,320,362 
C1 AND C2 AND 
C3 
 569 




C1 AND C2 AND 
C3 
HIV Infections* OR HIV OR human immunodeficiency virus* 
OR acquired immunodeficiency syndrome* OR AIDS And 
Counselling OR Counseling OR Counse*OR Testing OR Test* 
AND Cost OR Costing OR Cost-effectiveness OR Cost-








C1 AND C2 AND 
C3 
HIV Infections OR HIV OR hiv OR hiv-1 OR hiv-2 OR hiv1 OR 
hiv2 OR hiv infect$ OR human immunodeficiency virus OR 
human immunedeficiency virus OR human immuno-deficiency 
virus OR human immune-deficiency virus OR ((human immune$) 
AND (deficiency virus)) OR acquired immunodeficiency 
syndrome OR acquired immunedeficiency syndrome OR acquired 
immuno-deficiency syndrome OR acquired immune-deficiency 
syndrome OR ((acquired immune$) AND (deficiency syndrome)) 
OR Sexually Transmitted Diseases AND Counselling OR 
Counseling OR Counse*OR Testing OR Test* AND Cost OR 
Costs OR Costing OR Cost-effectiveness OR Cost-effectiveness 
analysis OR Cost effectiveness analysis OR Effec* OR effectives* 
OR Cost* 
2,452 
Concept 4 HIV* OR hiv self-testing OR hiv self-test* OR hivst OR home 
test* OR rapid test* 
1,536 
Global Health  
Concept 1 HIV Infections OR HIV OR hiv OR hiv-1 OR hiv-2 OR hiv1 OR 
hiv2 OR hiv infect* OR human immunodeficiency virus OR 
human immunedeficiency virus OR human immuno-deficiency 
virus OR human immune-deficiency virus OR ((human immun*) 
AND (deficiency virus)) OR acquired immunodeficiency 
syndrome OR acquired immunedeficiency syndrome OR acquired 
immuno-deficiency syndrome OR acquired immune-deficiency 
syndrome OR ((acquired immun*) AND (deficiency syndrome)) 
OR Sexually Transmitted Diseases 
110,964 
Concept 2 Counselling OR Counseling OR Counse*OR Testing OR Test* 62,706 
Concept 3 Cost OR Costs OR Costing OR Cost-effectiveness OR Cost-
effectiveness analysis OR Cost effectiveness analysis OR Effec* 
OR effectives* OR Cost* 
338,534 





Concept 4 hiv self-testing OR self-test* OR “self test” OR hiv self-test OR 
hivst OR home test* 
972 
COCHRANE* 
C1 AND C2 AND 
C3 
HIV Infections OR HIV OR hiv OR hiv-1 OR hiv-2 OR hiv1 OR 
hiv2 OR hiv infect* OR human immunodeficiency virus OR 
human immunedeficiency virus OR human immuno-deficiency 
virus OR human immune-deficiency virus OR ((human immun*) 
AND (deficiency virus)) OR acquired immunodeficiency 
syndrome OR acquired immunedeficiency syndrome OR acquired 
immuno-deficiency syndrome OR acquired immune-deficiency 
syndrome OR ((acquired immun*) AND (deficiency syndrome)) 
OR Sexually Transmitted Diseases AND Counselling OR 
Counseling OR Counse*OR Testing OR Test* AND Cost OR 
Costs OR Costing OR Cost-effectiveness OR Cost-effectiveness 
analysis OR Cost effectiveness analysis OR Effec* OR effectives* 
OR Cost* 
51 
Concept 4 hiv self-testing OR self-test* OR “self test” OR hiv self-test OR 
hivst OR home test* 
0 
Social policy and practice  
Concept 1 HIV Infections OR HIV OR hiv OR hiv-1 OR hiv-2 OR hiv1 OR 
hiv2 OR hiv infect* OR human immunodeficiency virus OR 
human immunedeficiency virus OR human immuno-deficiency 
virus OR human immune-deficiency virus OR ((human immun*) 
AND (deficiency virus)) OR acquired immunodeficiency 
syndrome OR acquired immunedeficiency syndrome OR acquired 
immuno-deficiency syndrome OR acquired immune-deficiency 
syndrome OR ((acquired immun*) AND (deficiency syndrome)) 
OR Sexually Transmitted Diseases 
5,138 
Concept 2 Counselling OR Counseling OR Counse*OR Testing OR Test* 18,579 
Concept 3 Cost OR Costs OR Costing OR Cost-effectiveness OR Cost-
effectiveness analysis OR Cost effectiveness analysis OR Effec* 




C1 AND C2 AND 
C3 
 161 
Concept 4 hiv self-testing OR self-test* OR “self test” OR hiv self-test OR 
hivst OR home test* 
0 
Web of Science  
C1 AND C2 AND 
C3 
HIV Infections OR HIV OR hiv OR hiv-1 OR hiv-2 OR hiv1 OR 
hiv2 OR hiv infect* OR human immunodeficiency virus OR 
human immunedeficiency virus OR human immuno-deficiency 
virus OR human immune-deficiency virus OR ((human immun*) 
AND (deficiency virus)) OR acquired immunodeficiency 
syndrome OR acquired immunedeficiency syndrome OR acquired 
immuno-deficiency syndrome OR acquired immune-deficiency 
syndrome OR ((acquired immun*) AND (deficiency syndrome)) 
OR Sexually Transmitted Diseases AND Counselling OR 
Counseling OR Counse*OR Testing OR Test* AND Cost OR 
Costs OR Costing OR Cost-effectiveness OR Cost-effectiveness 
analysis OR Cost effectiveness analysis OR Effec* OR effectives* 
OR Cost* 
513 
Concept 4 hiv self-testing OR self-test* OR “self test” OR hiv self-test OR 




analysis registry  
HIV 98 
*Pubmed, SCOPUS, COCHRANE and Web of Science databases search were conducted 




Table S3 PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported in section  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title section  
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 




INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Introduction  
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
Introduction 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
Systematic literature 
review not registered 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria 
for eligibility, giving rationale.  
Methods and 
supplemental table  
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact with 
study authors to identify additional studies) in the search and date last searched.  
Methods and 
supplemental table 
Search  8 Present full electronic search strategy for at least one database, including any limits 





Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 




10 Describe method of data extraction from reports (e.g., piloted forms, independently, 
in duplicate) and any processes for obtaining and confirming data from 
investigators.  
Methods 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
Methods 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 




13 State the principal summary measures (e.g., risk ratio, difference in means).  Methods 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
Methods and 
supplemental table  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 




16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
Supplemental table 
 
RESULTS   
Study 
selection  
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 





18 For each study, present characteristics for which data were extracted (e.g., study size, 
PICOS, follow-up period) and provide the citations.  
Results and 
supplemental table 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment 







20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence intervals, 





21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
Meta analysis not done 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  Discussion 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression- see Item 16).  
Results 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Discussion 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
Discussion 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
Discussion 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of 
data); role of funders for the systematic review.  
Funding statement 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org
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Table S4 Quality assessment using the GHCC’s principles and methods reporting checklist for cost studies (57) 
Principle Item No GHCC reference case checklist items included  
Principle 1 P1 
The purpose of the study, the population, and the intervention and/or service/output being 
costed should be clearly defined. 
Principle 2 P2 
The perspective (extent of the resource use captured) of the cost estimation should be stated 
and justified relevant to purpose. 
Principle 3 P3 
The type of cost being estimated should be clearly defined, regarding economic vs. financial, 
real-world vs. guideline, and incremental vs. full cost, and whether the cost is 'net of future 
cost,' should be justified relevant to purpose. 
Principle 4 P4 
The ‘units’ in the unit costs for strategies, services, and interventions should be defined, relevant 
for the costing purpose, and generalizable.   
Principle 5 P5 
The time horizon should be of sufficient length to capture all costs relevant to the purpose, 
and consideration should be given to disaggregating costs into separate periods where 
appropriate. 
Principle 6 P6 
The scope of the inputs to include in the cost estimation should be defined and justified 
relevant to purpose. 
Principle 7 P7 
The methods for estimating the number of inputs should be described, including data sources 
and criteria for allocating resources (Describe the measurement of each input as either top-
down or bottom-up, a method to allocate human resources inputs, overhead and other 
resources and methods for excluding research costs). 
Principle 8 P8 
The sampling strategy used should be determined by the precision demanded by the costing 
purpose and designed to minimize. 
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Principle 9 P9 
The selection of the data source(s) and methods for estimating service use should be described, 
and potential biases reported in the study limitations.    
Principle 10 P10 
Consideration should be given to the timing of data collection to minimize recall bias and, 
where relevant, the impact of seasonality and other differences over time. 
Principle 11 P11 
The sources for price data should be listed by input, and clear delineation should be made 
between local and international price data sources, and tradeable, non-tradeable goods (Report 
the sources of price data by input and where local and international prices were uses). 
Principle 12 P12 
Capital costs should be appropriately annuitized or depreciated to reflect the expected life of 
capital inputs (Describe the depreciation approach, discount rate used from capital goods, and 
expected life years of capital goods and data source). 
Principle 13 P13 
Where relevant an appropriate discount rate, inflation and exchange rates should be used, and 
clearly stated (discount rate used for future costs, currency year, conversion made and inflation 
type, and rate used). 
Principle 14 P14 
The use and source of shadow prices for goods and for the opportunity cost of time should be 
reported (Report methods for valuing volunteer time and adjustments for input prices for 
donated or subsidized goods). 
Principle 15 P15 
Variation in the cost of the intervention by site size/organization, sub-populations, or by other 
drivers of heterogeneity should be explored and reported. 
Principle 16 P16 
The uncertainty associated with cost estimates should be appropriately characterized (describe 
sensitivity analyses conducted and list of possible sources of bias). 
Principle 17 P17 
Cost estimates should be communicated clearly and transparently to enable decision-maker(s) 




Table S5 Quality assessment using Consolidated Health Economics Evaluation Reporting Standard (CHEERS) statement for 
published costs and CEA studies [105] 
Section Item No 




Title and abstract 
Title Q1 
Identify the study as an economic evaluation or use more specific terms such as “cost-
effectiveness analysis,” and describe the interventions compared 
Included 
Abstract Q2 
Provide a structured summary of objectives, perspective, setting, methods (including study 
design and inputs), results (including base case and uncertainty analyses), and conclusions. 
Included 
Introduction 
Background and objectives Q3 
Provide an explicit statement of the broader context for the study. Present the study 
question and its relevance to health policy or practice decisions. 
Included 
Methods 
Target population and 
subgroups 
Q4 
Describe the characteristics of the base case population and subgroups analyzed, including 
why they were chosen. 
Included 
Setting and location Q5 State relevant aspects of the system(s) in which the decision(s) need(s) to be made. Included 
Study perspective Q6 Describe the perspective of the study and relate this to the costs being evaluated. Included 
Comparators Q7 Describe the interventions or strategies being compared and state why they were chosen. Included 
Time horizon Q8 
State the time horizon(s) over which costs and consequences are being evaluated and say 
why appropriate. 
Included 
Discount rate Q9 Report the choice of discount rate(s) used for costs and outcomes and say why appropriate. Included 
Choice of health outcomes Q10 
Describe what outcomes were used as the measure(s) of benefit in the evaluation and their 







Single study-based estimates: Describe fully the design features of the single effectiveness 
study and why the single study was a sufficient source of clinical effectiveness data. 
Included 
Did the study describe 





Synthesis-based estimates: Describe fully the methods used for identification of included 
studies and synthesis of clinical effectiveness data. 
Measurement and valuation 
of preference-based 
outcomes 
Q12 If applicable, describe the population and methods used to elicit preferences for outcomes. Not applicable 
Estimating resources and 
costs 
Q13a 
Single study-based economic evaluation: Describe approaches used to estimate resource 
use associated with alternative interventions. Describe primary or secondary research 
methods for valuing each resource item regarding its unit cost. Describe any adjustments 
made to approximate to opportunity costs. 
Included 
Did the study describe 
approaches to 
estimate resources 




Model-based economic evaluation: Describe approaches and data sources used to estimate 
resource use associated with model health states. Describe primary or secondary research 
methods for valuing each resource item regarding its unit cost. Describe any adjustments 
made to approximate to opportunity costs. 
Currency, price date, and 
conversion 
Q14 
Report the dates of the estimated resource quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of reported costs if necessary. Describe methods 
for converting costs into a common currency base and the exchange rate 
Included 
Choice of model Q15 
Describe and give reasons for the specific type of decision-analytical model used. 
Providing a figure to show the model structure is strongly recommended. 
Included 
Assumptions Q16 Describe all structural or other assumptions underpinning the decision-analytical model. Included 
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Analytical method Q17 
Describe all analytical methods supporting the evaluation. This could include methods for 
dealing with skewed, missing, or censored data; extrapolation methods; methods for 
pooling data; approaches to validate or make adjustments (such as half-cycle corrections) 
to a model; and methods for handling population heterogeneity and uncertainty 
Included 
Results 
Study parameters Q18 
Report the values, ranges, references, and, if used, probability distributions for all 
parameters. Report reasons or sources for distributions used to represent uncertainty 
where appropriate. Providing a table to show the input values is strongly recommended. 
Included 
Incremental costs and 
outcomes 
Q19 
For each intervention, the report means values for the main categories of estimated costs 
and outcomes of interest, as well as mean differences between the comparator groups. If 




Single study-based economic evaluation: Describe the effects of sampling uncertainty for 
the estimated incremental cost and incremental effectiveness parameters, together with the 
impact of methodological assumptions (such as discount rate, study perspective). 
Included 




Model-based economic evaluation: Describe the effects on the results of uncertainty for 
all input parameters, and uncertainty related to the structure of the model and assumptions. 
Included 
Did the study 
characterize 
uncertainty? Q21 
Characterizing heterogeneity Q21 
If applicable, report differences in costs, outcomes, or cost-effectiveness that can be 
explained by variations between subgroups of patients with different baseline 







Study findings, limitations, 
generalizability, and current 
knowledge 
Q22 
Summarize key study findings and describe how they support the conclusions reached. 
Discuss limitations and the generalizability of the findings and how the findings fit with 
current knowledge 
Included 
Source of funding Q23 
Describe how the study was funded and the role of the funder in the identification, design, 
conduct, and reporting of the analysis. Describe other non-monetary sources of support 
Included 
Conflicts of interest Q24 
Describe any potential for conflict of interest of study contributors in accordance with 
journal policy. In the absence of journal policy, we recommend authors comply with the 
International Committee of Medical Journal Editors recommendations 
Included 
Did the study describe 
any potential conflict 
of interest? 
*Not applicable refers the CHEER assessment question, which is not applicable for that given study; for example, Q11 is assessing if the study 




Table S6 Findings from a quality assessment using the GHCC’s principles and methods reporting checklist for cost studies included 
in review [47] (n=44) 





Adebajo, 2013 (125) Y N N N N N N N N N N N/A N/A N N N N Slides 3/17 
Ahmed, 2018 (155)  Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N Y Y Poster 15/17 
Aliyu, 2012 (159) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N Y N Y PRP 15/17 
Allen, 2014 (126) Y Y N N Y N N N N N Y N N/A N N N N Abstract 5/17 
Armbruster, 2010 (142) Y Y N Y N N N N Y Y N N N N N N Y PRP 6/17 
Bassett, 2007 (127) Y Y Y Y Y Y Y Y Y Y N N/A N N N N Y PRP 12/17 
Bassett, 2014 (33)  Y Y N Y Y Y Y Y N Y Y N/A Y N N Y Y PRP 13/17 
Bautista-Arredondo, 2016 
(128) 
Y Y Y Y Y Y Y Y Y Y Y N/A N/A Y Y N Y PRP 16/17 
Bogart, 2017 (160) Y Y Y Y Y Y Y Y Y Y Y N/A N/A Y Y N Y PRP 16/17 
Chang, 2016 (152) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N N Y PRP 14/17 
Grabbe, 2010 (153) Y Y Y Y Y Y Y Y Y Y Y Y Y N N N Y PRP 14/17 
Hauck, 2018 (143) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N Y Y Slides 15/17 
Hausler, 2006 (30) Y Y Y Y Y Y Y Y Y Y Y Y Y N N N Y PRP 14/17 
Helleringer, 2013 (144) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N N Y PRP 14/17 
Ibekwe, 2017 (59) Y N N Y N N N N N N N N/A N/A N N N N Abstract 4/17 
Kahn, 2011(157) Y Y Y Y Y Y Y Y Y Y Y Y Y N N N Y PRP 14/17 
Kahwa, 2008 (161) Y Y Y Y Y Y Y Y Y Y Y Y N/A N N N Y PRP 14/17 
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Labhardt, 2014 (145) Y Y Y Y N Y N Y Y Y Y N/A N/A N N N Y PRP 12/17 
Lasry, 2019 (146) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N Y Y PRP 15/17 
Liambila, 2008 (129) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N Y N Y Report 15/17 
Maheswaran, 2016 (156) Y Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y PRP 17/17 
Meehan, 2009 (154) Y Y Y Y N Y Y Y Y Y Y Y Y N N N Y PRP 13/17 
Mangenah, 2019 (50) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N Y Y PRP 15/17 
Menzies, 2009 (130) Y Y Y Y Y Y Y Y N Y N N/A N/A N N N Y PRP 12/17 
Muhumuza, 2012 (131) Y N N Y Y N N N N Y N N N N N N Y Abstract 5/17 
Mulogo, 2013 (132) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N N Y PRP 14/17 
Mwenge, 2017 (133) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N Y Y PRP 15/17 
Negin, 2009 (147) Y N Y Y Y Y N Y N Y Y N/A N/A N N N Y PRP 11/17 
Obure, 2015 (134) Y Y Y Y Y Y Y Y Y Y Y Y N/A Y N N Y PRP 16/17 
Obure, 2012 (135) Y Y Y Y Y Y Y Y Y Y Y Y N/A Y N N Y PRP 15/17 
Orlando, 2010(162) Y Y Y Y Y Y Y Y Y Y Y Y N/A N N Y Y PRP 15/17 
Parker, 2015 (148) Y Y Y Y Y Y Y N N Y Y N N N N N Y PRP 10/17 
Perchal, 2006 (136) Y N Y Y Y N Y N Y Y Y N/A N/A N N N Y Slides 11/17 
Perez, 2016 (137) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N N Y Poster 14/17 
Pinto, 2013 (138) Y Y Y Y Y Y Y Y Y Y Y N/A N/A Y Y N Y PRP 16/17 
Rutstein, 2013 (61) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N N Y PRP 14/17 
Shade, 2013 (139) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N Y N Y PRP 15/17 
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Sharma, 2016 (32) Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y PRP 16/17 
Sharma, 2014 (149) Y Y N Y N Y N Y Y Y N N N N N N Y Abstract 8/17 
Smith, 2015 (150) Y Y Y Y Y Y Y Y Y Y Y N/A N/A N N Y Y PRP 15/17 
Tabana, 2015 (140) Y Y Y Y Y Y Y Y Y Y Y Y Y N N Y Y PRP 15/17 
Terris-Prestholt, 2006 (163) Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y PRP 16/17 
Terris-Prestholt, 2008 (141) Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y PRP 14/17 
Tumwesigye, 2010 (151) Y Y Y Y Y N N Y N Y N Y Y Y N N Y PRP 11/17 
1Non applicable = N/A was assigned to discount if the analysis was limited to one year. Additional points were awarded to the “Score” column 
if the cost principle(s) was/were N/A for the study. 




Table S7 Findings from a quality assessment using Consolidated Health Economics Evaluation Reporting Standard (CHEERS) 
statement for published CEA studies included in the review [105] (n=15) 




Allen, 2010 (58) N Y Y Y Y Y Y N N Y Y N/A Y N N N N N Y Y N Y N N Abstract 13/24 
Bassett, 2014 (33) Y Y Y Y Y Y Y Y Y Y Y N/A N Y Y Y Y Y Y Y N Y Y Y PRP 22/24 
Cambiano, 2015 (34) Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y Y Y PRP 24/24 
Cambiano, 2019 (35) Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y Y Y PRP 24/24 
Hausler, 2006 (30) N Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y Y N Y N N Y Y Y PRP 20/24 
Ibekwe, 2017 (59) Y Y N N Y Y Y N N Y Y N/A N N N N N N Y N N N N N Abstract 9/24 
John, 2008 (60) Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y Y Y Y N Y Y Y Y PRP 23/24 
Leigh, 2018 (37) Y Y Y N N Y Y Y N Y N N/A N N Y N N N Y N N Y N N Abstract 11/24 
Kahn, 2012 (31) Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y N Y Y Y N/A Y Y Y PRP 23/24 
Maheswaran, 
2017(36) 
Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y Y Y PRP 24/24 
Rutstein  2013 (61) Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y Y Y PRP 24/24 
Sharma, 2016 (32) Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y Y Y PRP 24/24 
Thielman, 2006 (62) Y Y Y Y Y Y Y Y Y Y Y N/A Y N N N N Y Y Y N Y Y Y PRP 19/24 
Walensky, 2011 (63) Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y Y Y PRP 24/24 
Waters, 2011 (64) Y Y Y Y N Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y Y Y PRP 23/24 
1No discount if the analysis was limited to one year. Non applicable =N/A was assigned to discount if the analysis was limited to one year. 
Additional points were awarded to the “Score” column if the cost principle(s) was/were N/A for the study. 
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2.9.  Implication for thesis  
 
The systematic leterature review demostaated that few studies estimated the cost-
effectiveness of providing HIV self-testing in addition to routine facility-based HTS in 
Zimbabwe (34, 35) and Malawi (36). Cambiano et al. applied Individual-based stochastic 
model from provider perspective to demonstrate implementing self-testing at the health 
facility would be cost-saving if it could be delivered at the full cost of US$3 per unit, and 
only cost-effective at ICER thresholds above US$10,000 per DALY averted if the cost of 
providing each episode was below US$9 (34). Maheswaran et al. applied stochastic 
microsimulation model  to estimate the additional provision of self-testing was associated 
with an ICER of US$280.23 and US$2389.92 per QALY gained from a provider and societal 
perspective, respectively (36). In South Africa, Leigh and colleagues again applied stochastic 
microsimulation model to estimate the cost-effectiveness of self-testing in the context of 
antenatal partner testing and home-based testing (37). The authors reported the incremental 
cost of US$1,941.72 and US$1,111.85 per life-year gained for providing self-testing to the 
partner of a pregnant women at antenatal care and home-based self-testing, respectively (37). 
 
This thesis will use a Markov microsimulation model (Paper 3) that accounts for the steps in 
HIV prevention and HIV care cascade to estimate the cost-effectiveness of HIVST 
compared with standard HIV testing services in Zambia. The HIV prevention cascade is an 
emerging approach and is similar to the HIV treatment cascade (169, 170). This prevention 
cascade can facilitate how those at risk of acquiring HIV can avoid infection through HIV 
interventions (such as HIV testing) and how to reach the optimal gain in impact on the 
demand side, supply-side (supporting linkage) or combination of both (169, 171)(168, 170). 
 
This model is selected because it can help model different scenarios for each of the respective 
testing options being compared. Therefore, the Markov microsimulation model can assist 
policymakers in formulating informed scale-up plans of HIVST to reach adult populations 
who are unaware of their HIV status. Because HIVST is an emerging technology in Zambia, 
there is insufficient understanding of the use of alternative HIV testing approaches for 
HIVST distribution, and of the costs and effectiveness of HIVST. Thus, applications of 
Markov microsimulation model to inform programmatic decisions based on cost-effective 





CHAPTER 3 HOW MUCH DOES IT COST TO ADD HIV 
SELF-TESTING INTO MALE CIRCUMCISION, 
OUTPATIENT, AND HIV TESTING SERVICES IN 
MALAWI, ZAMBIA, AND ZIMBABWE? AN ECONOMIC 
EVALUATION (PAPER 2) 
 
Overview of Paper 2 
 
The systematic literature review Paper 1 in chapter 2 demonstrated the cost of different HIV 
testing services in sub-Saharan Africa; however, only three studies estimated the cost of 
HIVST. This chapter presents the cost analysis of distributing HIVST within voluntary 
medical male circumcision services and health facilities in Malawi, Zambia, and Zimbabwe.  
 
In this cost analyses, I refine the allocation factors that were applied in Mwenge et al. 2017 
and Mangenah et.al 2019 papers that I co-authored (Appendix I & II). The formulation of 
different allocation factors of different cost inputs was guided by a bottom-up costing 
approach in each country.   
 
This paper is in preparation to be submitted to The Journal of the International AIDS Society in 
July 2020. Two supplementary tables are included at the end of the thesis. 
 
This paper fulfils research question two: calculating the cost of HIVST distribution within 
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Background: HIV self-testing (HIVST) is a novel approach to HIV testing where people 
can perform and interpret their own HIV test. This study presents the cost of delivering 
HIVST within 13 voluntary medical male circumcision (VMMC) services and 21 health 
facilities in Malawi, Zambia, and Zimbabwe.   
 
Methods: The annual incremental economic costs of distributing HIVST kits were estimated 
from a providers’ perspective. We performed a prospective cost analysis between 2016 and 
2018, using expenditures analysis and field observations. A sensitivity analysis was conducted 
to test key assumptions, and scenario analyses explored potential programmatic and setting 
specific variations on unit costs.  
 
Results: Across the 34 sites implementing these models, the intensity of distribution varied 
widely, achieving distribution from as low as 733 HIVST kits through VMMC mobilizers in 
Malawi to 14,886 kits distribution within integrated testing service in Zimbabwe. The costs 
of distributing these kits ranged from $7.71 in the Zimbabwean VMMC model to $24.83 in 
the less intensive mobilizer distribution model in Zambia. The smallest sites experienced the 
highest costs, and the largest sites observe lower costs.  
 
Conclusions: The cost analysis has shown that for both models the costs are slightly higher 
than the standard facility-based finger prick testing. It also demonstrated the importance of 
cost reduction on the HIVST kit price to ensure access to HIVST and the scalability of the 
intervention. Continued efforts are needed to reach new testers, particularly men and 
adolescents to achieve national and global goals – including the 90-90-90 targets and soon to 
be 95-95-95 goals. 
 
Trial registration numbers: Malawi (NCT02793804), Zambia (NCT02718274); and 
Zimbabwe (PACTR201607001701788) 
Keywords: HIV self-testing; costs; cost analysis; HIV testing services; Malawi; Zambia; 




Despite substantial progress towards combating the HIV epidemic globally, the greatest 
burden continues to be in Eastern and Southern Africa (ESA). In 2017, it was estimated that 
45% of all new HIV infections occurred in ESA, where 53% of people living with HIV 
(PLHIV) live (87). Despite substantial scaled-up of HIV testing in Malawi, Zambia, and 
Zimbabwe, 90%, 72% and 85% of PLHIV, respectively are aware of their status (87). 
Particularly, disparities in HIV testing and knowledge of HIV positive status among young 
people (ages 15-24) and men remain critical (90, 92, 172). Men have not benefited as much 
from this scale-up in conventional HIV testing services (HTS) because most are integrated 
into sexual and reproductive health and antenatal services focused on women. While HIV 
related mortality has decreased among women it has flat-lined for men in ESA (87), largely 
due to delayed diagnosis, with men often diagnosed during the late disease stage. 
 
To reach undiagnosed groups and achieve the United Nation’s 90-90-90 targets by 2020, 
which starts with diagnosing 90% of all PLHIV (88), innovative HIV testing approaches are 
needed. HIV self-testing (HIVST) is one such approach recommended by WHO (42) and 
has been shown to be acceptable, safe, accurate, and effective in reaching those who may not 
test otherwise (27, 49, 106, 108, 156, 173-183). Recent studies of community-based HIVST 
suggest that wide-scale distribution successfully reached first-time testers, particularly men 
and young people in ESA (46) at a providers’ cost of slightly more than conventional HTS 
(49, 184-187), and is likely to significantly reduce user costs, particularly among men (188). 
This study complements the existing costings of HIVST by presenting the costs of HIVST 
distribution within the following health services: voluntary medical male circumcision 
(VMMC) and provider-initiated testing services within the outpatient department (OPD) and 
integrated into other clinical services.  
 
It was hypothesized that HIVST distribution could increase uptake of VMMC services by 
providing men the opportunity to test for HIV themselves, either prior to presenting for 
VMMC or in private at the VMMC clinic. Additionally, using facility-based counsellors and 
health care workers to promote HIVST, the health facility model was designed to reach 
undiagnosed HIV positive people while at their routine OPD in Zambia and HTS visits in 
Zimbabwe, successfully increasing uptake by men in Zambia and Zimbabwe, with 45.8% 
and 29.0% of HIVST kits taken by men, respectively (46). Moreover, facility-based 
distribution of HIVST in outpatient waiting rooms in Malawi increased HIV testing uptake 
and identified more HIV positive cases than provider-initiated testing (189). While these 
approaches may achieve impact, it is increasingly challenging to maximize HIV testing 
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coverage because of limited and declining domestic and donor resources for additional 
testing. As more countries work to implement HIVST effectively and efficiently, efforts to 
understand the cost of HIVST implementation are critical. In this study, we examine the 
full programme costs (including a share of central PSI costs) of distributing HIVST within 
VMMC services in Malawi, Zambia, and Zimbabwe, to the OPD model in Zambia, and 
integrated model with existing HTS (New Start Centres) in Zimbabwe. 
 
Methods 
The intervention and setting 
The aim of community-based distribution using VMMC mobilizers and distribution at the 
VMMC clinic focused on VMMC demand creation to reduce barriers for men (age 16 years 
and older) who fear to get tested for HIV before VMMC at the VMMC clinic and to improve 
time and efficiency efforts by offering HIVST to adult males who are mobilized for VMMC 
to self-test at home or at the clinic before accessing the VMMC services. The VMMC model 
for HIVST kits distribution varied across countries. In Malawi, the VMMC model applied 
distribution at the VMMC clinic as well as community-based distribution using VMMC 
mobilizers. In Zambia and Zimbabwe, the VMMC model implemented HIVST kits 
distribution at the VMMC clinics. In Zimbabwe, 40.2% of men have received HIVST kits 
from VMMC mobilizers before going for male circumcision (46).  
 
The aim of the OPD model (Zambia) and integrated model (Zimbabwe) was a case finding 
among clients (age 16 years and older) who were accessing health facilities to maximize HIV 
diagnosis, ART initiation, and increase prevention service uptake. In Zambia, the OPD 
model assigned a trained HIVST distributor to provide information about the option of 
HIVST in OPD and to demonstrate on how to use the HIVST kits and interpret positive, 
negative, and inconclusive results. In Zimbabwe, the integrated model provided an 
instructional video on how to use HIVST and interpret results. Figures 3.1 and 3.2 provide 
an overview of the VMMC, OPD, and integrated models, respectively. Additional 
implementation details have been published elsewhere (46, 190). 
 
This study costed a total of 13 VMMC clinics (two in Malawi, eight in Zambia and three in 
Zimbabwe), and a total of 21 health facilities (16 in Zambia and five in Zimbabwe). The 
characteristics of the VMMC clinics and the health facilities included both urban and semi-





Figure 3.1 Flow diagram for VMMC demand creation after HIVST and client flow – VMMC model 
Malawi*(Community-based HIVST kits distributed by VMMC mobilisers and HIVST kits distributed at VMMC clinic 
Zambia and Zimbabwe*(HIVST kits distributed at VMMC 
clinic 
  
Client can choose to take the HIVST kit and self-test at his convenience 
and bring the used HIVST kits to the VMMC centre or bring unused 
HIVST kit and self-test at the VMMC centre. Clients are also given an 
opportunity to self-test at the centre to reduce their waiting time  
Demonstration on how to use HIVST kit and interpret positive, 
negative, and inconclusive results  
VMMC mobilisers provide group or individual VMMC counselling in 
the community 
If  HIVST shows positive result, client is referred for confirmatory RDT 
at the VMMC centre and given a referral letter to the nearest health 
facility of  his choice for ART initiation 
Nurse screens client further for any chronic health conditions that may preclude the procedure. If  none, clients are referred to surgery 
Trained clinicians perform the circumcision procedure 
Nurse provides client with pain medication and guidance on post-operative care. 
Client is advised to return for follow-up two, seven, and 21 days after surgery to 
ensure no infections or complications. 
VMMC service delivery 
For both positive and negative results, client can proceed to VMMC  
 HIVST                
 Routine VMMC 
Demonstration on how to use HIVST kit and interpret positive, 
negative, and inconclusive results  
Client can self-test on site in private space 
If  either of  the HIV testing options shows positive result, client 
is referred for confirmatory RDT at the VMMC centre and given 
a referral letter to the nearest health facility of  his choice for ART 
initiation 
  
If  negative result, client proceed to VMMC  
When the VMMC client arrives at the VMMC centre, he has the 
option to choose either HIVST or RDT for HIV testing  
*Both in Zambia and Zimbabwe, all clients were advised to places used kits together with the result form in a drop box located at health facility  
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Trained HIVST distributor provides information about 
the option of  HIVST in OPD. 
Demonstration on how to use the HIVST kit and 
interpret positive, negative, and inconclusive results. 
  
Client can choose HIVST or RDT and if  they choose 
HIVST they can take the HIVST kit and self-test at 
their convenience or self-test at the health facility. 
Trained HIVST distributor provide information about the option of  
HIVST in the New Start centres. 
Clients are invited to watch an instructional video about HIVST on 
how to use HIVST kit and interpret positive, negative, and 
inconclusive results. 
Client can choose to self-
test on site in cubicle/room 
in private  
  
HIVST 
Confirmatory RDT (PDHTC) 
Client can choose to take 
the HIVST kit and self-
test at their convenience  
Negative self-test result  Positive self-test result  
• Assessed for PrEP 
• Male clients are 
referred for VMMC 
• Advised for retest 
according to the 
national guidelines 
• Referral for care and 
treatment 
• Offered HIVST kit for 
partner  
If  client is willing to disclose results 
HIVST at the health facility (OPD) 
Negative self-test result  Positive self-test result  
• Male clients are 
referred to 
VMMC 
• Advised to retest 




Referral for care and 
treatment 
RDT 
Zambia* (Public OPD) Zimbabwe* (Integrated to static New Start Centres) 
*Both in Zambia and Zimbabwe, all clients were advised to places used kits together with the result form in a drop box located at health facility  
  
Figure 3.2 Flow diagram for HIVST kits distribution using OPD and integrated models 
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Table 3.1 Characteristics of setting and overview of HIVST kits distribution models (in 2017 US$) 
Characteristics VMMC model Facility model 
Source 
Malawi Zambia Zimbabwe Zambia Zimbabwe 
    OPD model Integrated 
model 
National HIV prevalence among 
adults 15 to 49 years (%) 
10% 12% 14.1% 12% 14.1% (90, 92, 172) 
 
Number of districts 1 3 2 4 5  
Number of sites 2 8 3 16 5  
Catchment population* 181,549 311,566 79,369 182,655 89,480 (133, 191-193) 
Location (Urban/Semi-
urban/Rural) 
Urban Semi-urban Urban Semi-urban Urban  
Average number of VMMC 
mobilizers 
39 13 5 16 38  
Number of community-based 
HIVST kits distributed by VMMC 
mobilizers 
733 NA NA NA NA  
Number of HIVST kits distributed   2,742 11,330 2,870 12,885 14,886  
Services offered to HIV self-test 
clients 
Demonstration of how to use the HIVST kits and how to interpret positive, negative and inconclusive 
results 























Allowances Salaried  




Using a provider’s perspective, we estimated the annual incremental economic costs of each 
intervention model by country. The incremental costs for the VMMC model only included 
costs for community-based VMMC demand creation and distribution at the VMMC clinic 
and did not include the costs for VMMC services. For the OPD and integrated models, all 
resources used were accounted for including donated resources by calculating the 
opportunity cost for the unpaid voluntary time (54). Annual financial expenditures (in USD) 
were collected from Population Services International (PSI) country offices and their sub-
grantees over one year: ranging from February 2017 to January 2018 for Malawi and July 
2016 to June 2017 for Zambia and Zimbabwe. Field observations were conducted during 
this period to further document implementation; capture donated goods and services, and 
derived allocation factors for apportioning shared costs.  
 
The activity-based allocation factors applied are presented in Table 3.2 and are consistent 
with those used in the cost analysis of HIVST kits distribution using community-based 
distributing agents (49). Table 3.2 was developed over two years using activity-based 
allocation in which we assigned cost of each activity to all products and services to specific 
cost inputs. This cost inputs are used to present the cost analysis results in Table 3.3 and 3.4. 
The activity-based allocation factor could offer a practical approach to estimating unit costs 
from project expenditures (i.e., using a top-down method). Drummond detailed the four 
methods for allocating shared costs: direct allocation, step-down allocation, step-down 
allocation with interactions, and simultaneous allocation (54). The direct allocation methods 
“ignores the interaction of overhead department.” Moreover, step-down allocation and step-
down allocation with interactions and simultaneous allocation methods apply allocations to 
account for all unallocated costs (54). The activity-based allocation aim to guide the process 
of calculating the unit cost for new intervention implementation at the site level in detail. 
Although this study used both bottom-up and top-down approaches to construct cost inputs 
using the activity-based allocation, it is vital to recognize the prominent role of the unit cost 
calculation in scaling up of the intervention. For example, costs for supplies such as t-shirt 
and bags might be important during the pilot stage of HIVST distribution; however, these 
costs can be exempted when the programme matures and moves to the scale-up stage.  
 
The expenditure analysis started by categorizing each expenditure line item by cost input type 
and resource use level (central, warehouse and site level). Capital costs included project start-
up costs, such as initial training and sensitization, and equipment and building space. The 
start-up period was defined as including all costs which were incurred before the first day of 
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HIVST kit distribution. Capital goods were annualized over their useful years of life using a 
3% discount rate. Recurrent costs included costs of training, personnel, HIVST kits, and 
other supplies, building utilities, vehicle operation, and maintenance, and other recurrent 
costs such as project administration and coordination. Using standardized allocation factors 
adapted from Mangenah [26] (see Table 3.2) each cost input line item was allocated across 
each HIVST distribution model. Lastly, we applied costs from the HIVST distribution model 
to site level (individual VMMC clinic, OPD, and integrated New Start centres). Overheads, 
including centrally shared costs were shared across models and sites by their respective share 
of direct site level expenditures.  
 
The cost per HIVST kit distributed was estimated by dividing the total cost by the total 
number of HIVST kits distributed. We have used nominal exchange rates rather than 
purchasing power parities as this are the most important for projecting costs and informing 




Table 3.2 Cost allocation factors across the interventions by cost input type 
Cost input type Allocation factors to site level 
Malawi Zambia Zimbabwe 
Training % of direct expenditure % of distributors % of distributors 
Sensitization % of direct expenditure % of direct expenditure % of direct expenditure 
Other Start-up N/A % of HIVST kits distributed % of HIVST kits distributed 




   
% of HIVST kits distributed % of direct expenditure % of direct expenditure 
N/A % of HIVST kits distributed % of HIVST kits distributed 
Equally between sites % of direct site level expenditure % of direct site level expenditure 
Equipment 
- Central equipment 
- Site-level 
   
% of HIVST kits distributed % of direct expenditure % of direct expenditure 
Equally between sites % of direct site level expenditure % of direct site level expenditure 
Vehicles and bicycles % of mileage/distance (in km) N/A N/A 
Other capital N/A % of HIVST kits distributed % of HIVST kits distributed 
Personnel % Staff time allocations % of distributors % of distributors 
HIVST Kits observed HIVST kits distributed by site observed HIVST kits distributed by site observed HIVST kits distributed by site 
Supplies 
- T-shirts, bags, 
flipcharts 
- Other supplies 
   
% of HIVST kits distributed % of distributors % of distributors 
% of HIVST kits distributed % of HIVST kits distributed % of HIVST kits distributed 
Vehicle maintenance and 
transportation 
% of mileage/distance (in km) % of mileage/distance (in km) % of mileage/distance (in km) 
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% of direct expenditure % of direct expenditure % of direct expenditure 
N/A % of HIVST kits distributed % of HIVST kits distributed 
Equally between sites % of direct site level expenditure % of direct site level expenditure 
Waste management N/A N/A % of HIVST kits returned 
Other recurrent % of HIVST kits distributed % of HIVST kits distributed % of HIVST kits distributed 
 
 149 
Sensitivity and scenario analyses  
Sensitivity and scenario analyses were conducted to explore the robustness of the cost 
analysis by examining the extent to which the unit costs are affected by changes in key 
assumptions (unmeasured cost inputs) and how these would vary under different scenarios. 
Univariate sensitivity analyses focused on: discount rate (base case 3%, range 0% to 15%); 
allocation of central cost (base case % of direct expenditures range % of HIVST kits 
distributed to % of distributors); economic life years of other capital (base case 5 years, range 
2.5 years to 7.5 years); economic life years of start-up training and sensitization (base case 
two years, range one to three years); HIVST kit price (base case US$2.78 range US$1 to 
US$5.56). A multivariate sensitivity analysis applied the values of the most optimistic (best-
case scenario) and pessimistic (worst-case scenario) parameters. The scenario analysis was 
used to explore the impact of higher and lower resource costs or service outputs. This 
included varying personnel salary costs (+/-10%), the quantity of HIVST kits distributed 




VMMC model  
Table 3.3 presents the total number of HIVST kits distributed, the incremental total and unit 
costs of HIVST distribution through community-based distribution using VMMC mobilizers 
and distribution at the VMMC clinic across the three countries over the 12-month study 
period. Table 3 presents the outputs, total, and unit costs for the 13 VMMC clinics. The 
community-based distribution by VMMC mobilizers distributed 733 HIV kits in Malawi 
across two VMMC clinics at a total cost of US$18,198 and an average cost of US$24.83. The 
initial training of distributors was relatively intensive with 39 distributors trained at an 
annualized cost of $8075. The recurrent cost of the VMMC mobilizer model is just $12.83 
per kit distributed. The distribution at the VMMC clinic distributed 2,742 HIVST kits in 
same two sites in Malawi, and 11,330 HIVST kits in eight VMMC clinics in Zambia, and 
2,870 HIVST kits in three VMMC clinics in Zimbabwe. The country average costs per 
HIVST kit distributed at the VMMC clinics were US$9.65, US$13.01 and US$7.71 for 





Table 3.3 HIV self-test kit distribution cost breakdown and key cost contributors VMMC model (in 2017 US$) 
Cost input type 
















































Total Cost Total Cost Total Cost Total Cost Total Cost Total Cost Total Cost 
Start-up 
Training $5,383 $8,075 $0 $3,067 $0 $0.11 $0 
Sensitization $722 $722 $0 $2.79 $0 $1.82 $0 
Other start-up $0 $0 $0 $7,356 $0 $1,234 $0 
Total start-up $6,105 $8,797 $0 $10,426 $0 $1,236 $0 
Capital costs 
Building & storage $195 $0 $1722 $0 $133 $59 $190 
Equipment $0 $0 $0 $0 $0 $267 $0 
Central equipment $1,244 $0 $0 $1,186 $0 $554 $0 
Site level $0 $0 $598 $0 $160 $0 $180 
Vehicles and 
bicycles 
$249 $0 $0 $0 $91 $0.64 $22 
Other capital $0 $0 $0 $0 $43 $882 $0 
Total capital costs $1,688 $0 $2,320 $1,186 $427 $1,763 $392 
Total start-up and 
capital costs 




Recurrent training $0 $0 $0 $1,416 $0 $879.58 $0 
Test kits $7,617 $2,036 $4,078 $20,561 $3,421 $6,745 $1,826826 
Other supplies $362 $97 $3,802 $6,940 $450 $0 $441 
Other supplies $0 $0 $0 $0 $0 $1,490 $203 
Sensitization $0 $0 $0 $4,468 $0 $0 $0 
Building & storage        
   Central $0 $0 $0 $4,528 $0 $0 $0 
   Site level $103 $0 $0 $0 $0 $0 $0 
Personnel $3,623 $5,435 $1,568 $74,900 $6,678 $10,045 $7,670670 
Vehicle operation & 
maintenance 
$4,665 $1,247 $710 $14,461 $0 $237 $0 
Building 
operation/maintenance 
       
   Central $103 $0 $0 $1,690 $0 $0 $56 
   Warehouse $0 $0 $0 $0 $0 $250 $0 
   Site level $0 $0 $84 $0 $751 $0 $0 
Other recurrent $2,196 $587 $2,720 $6,781 $309 $352 $2 
Waste Management $0 $0 $1,187 $0 $0 $0 $0 
Total recurrent costs $18,698 $9,402 $14,149 $135,745 $11, 609 $19,999 $10,198 
Total costs $26,491 $18,198 $16,469 $147,357 $12,036 $22,998 $10,590 
Total costs without start 
up 
$20,386 $9,402 $16,468 $136,931 $12,036 $21,762 $10,590 
Cost per HIVST kits 
distributed 
$9.65 $24.83  $13.01  $7.71  
Cost per person tested 
using facility-based HIV 
finger prick test 




Figure 3.3 shows the number of HIVST kits distributed and cost per kit distributed at site level across 
the three countries via VMMC model. A wide variation in cost across sites was identified. The site-
level costs per HIVST kit distributed by VMMC mobilizers were US$19.24 and $32.04, while lower 
costs were seen where kits were distributed within the VMMC service, at US$9.47 and US$9.72, 
respectively. In VMMC clinics in Zambia, the cost per kit distributed across the sites ranged from 
US$8.08 to US$29.13, and in Zimbabwe, it ranged from US$6.09 to US$11.93 (Figure 3.3). For more 
detailed information, see Table 3.6 at the end of this paper. 
 
Figure 3.3 VMMC model site-level unit costs by the quantity of HIVST kits distributed (in 2017 
US$) 
 
OPD and integrated models 
Table 3.4 presents the economic costs of incorporating HIVST distribution into OPD services in 
Zambia and into the integrated model in Zimbabwe. In Zambia, the OPD model distributed 12,885 
HIVST kits across 16 sites. The total cost was US$203,659, and the average cost per kit distributed 
was US$15.81. In Zimbabwe, the integrated HTS model distributed 14,886 HIVST kits across five 






































Table 3.4 HIV self-test kit distribution cost breakdown and key cost contributors facility-based models (in 2017 US$) 








finger prick test 
Kits distributed: 
12,885 




Number of people 
tested: 1,542 
Total Cost Total Cost Total Cost Total Cost 
Start-up 
Training  $3,670 $0 $0.73 $0 
Sensitization  $3.86  $0 $12.05 $0 
Other start-up $10,144 $0 $8,278 $0 
Total start-up $13,818 $0 $8,291 $0 
Capital costs 
Building & storage     
Central  $0 $0 $392 $0 
Site level  $0 $133 $0  $190 
Equipment     
Central equipment  $1,632 $0 $1,772 $0 
Site level  $0 $160 $2,898 $108 
Vehicles and bicycles $0 $91 $0 $22 
Other capital  $0 $43 $4.22 $0 
Total capital costs $1,632 $427 $5,067 $320 
Total start-up and capital costs $15,450 $427 $13,357 $320 
Recurrent Costs 
Recurrent training  $2,377 $0 $5,618 $0 
HIV Self-Test Kits $28,417 $3,421 $34,982 $1,826 
Sensitization $6,729  $0 $0 $0 
Building & storage     
Central $6,413 $0 $0 $0 
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Personnel $105,544  $6,678 $82,047 $0 
Supplies $0 $450 $0 $441 
T-shirts, bags, flipcharts $9,467 $0 $0 $0 
Other supplies $0 $0 $6,353 $203 
Vehicle operation & maintenance $17,953 $0 $1,028 $0 
Building operation/maintenance     
- Central  $2,304 $0 $0 $56 
- Warehouse $0 $0 $1,081 $0 
Other recurrent  $9,005 $309 $2,111 $0 
Total recurrent costs $188,209 $11, 609 $133,220 $2.01 
Total costs  $203,659 $12,036 $146,577 $10,198 
Total costs without start up $189,841 $12,036 $138,286 $10,518 
Cost per HIVST kits distributed $15.81  $9.85  
Cost per person tested using 
facility-based HIV finger prick test 




Figure 3.4 suggests that unit costs drop as the quantity of kits distributed on-site increases using the OPD 
model. Variation in site costs again show a 10- and 3-fold variation in cost per kit distributed, ranging 
from US$5.20 to US$58.92 and US$6.49 to US$22.78 in Zambia and Zimbabwe, respectively. More detail 
is provided at the end of the chapter in Table 3.7). Table 3.5 provides the unit cost for each distribution 
modality without start-up cost and the unit cost for facility-based finger prick testing to reflect the 

































OPD model (Zambia) and integrated model (Zimbabwe) number of 
HIVST kit distributed 
Zambia Zimbabwe
Figure 3.4 OPD and integrated model site-level unit cost by the quantity of HIVST kits 
distributed (in 2017 US$) 
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Table 3.5 Summary of costs and annual HIV testing outputs 
HIV testing 
outputs  




























































































733 2,742 152,671 NA  11,330 12,885 103,589 NA  2,870 14,886 93,459 NA 
Average annual 
number of 
people tested  




$9,401 $20,356 $1,065,734 $16,468.28  $136,931 $189,841 $1,526,677 $12,036  $20,879 $138,286 $1,211,348 $10,518 
Unit cost $24.83 $9.65 $8.15 NA  $13.01 $15.81 $16.42 NA  $7.71 $9.85 $13.84 NA 
Unit costs 
without start-up 
$12.82 $7.43 $6.98 $ 2.93  $12.08 $14.73 $14.73 $4.24  $7.58 $9.29 $12.96 $8.79 
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Sensitivity and scenario analysis  
VMMC model  
Figure 3.5 shows the findings from the sensitivity and scenario analyses undertaken for 
VMMC models in each of the three countries. In Malawi, for the community VMMC 
mobilizers distribution, the greatest impact scenarios/assumptions on the cost per kit 
distributed were the life years of capital items (range: US$21.28-US$35.48) and allocation of 
central costs (range: US$23.91-US$24.83). For VMMC clinic distribution sensitivity analysis, 
the allocation of central costs (range: US$8.85-US$9.61) and HIV self-test kit price (US$7.84-
US$12.40) had a large influence. Applying all most advantageous and least advantageous 
assumption generates an estimate of the best and worst-case unit costs. In Malawi, the best-
worst case scenario ranged from US$16.09-US$45.66 and US$5.54-US$16.23 for 
community-based and VMMC clinic HIVST kits distribution, respectively. For Zambia, the 
VMMC clinic model ranged from US$11.12 to US$16.05, primarily driven by allocation of 
central costs. For Zimbabwe, the two scenarios/assumptions that had the greatest impact on 
the cost per kit distributed were how central costs were allocated (range: US$6.80-US$10.28) 
and the HIVST kit price (range US$6.52-US$8.87) (see supplemental Table 3.10 for more 
detail).  
 
OPD and integrated HST models  
For Zambia, in the OPD model, the two scenarios/assumptions that had the greatest impact 
on the cost per kit distributed were the HIVST kit price (range: US$14.59-US$16.95 per kit 
distributed) and the number of kits distributed (range: US$14.79-US$17.10 per kit 
distributed). Similar patterns were observed in the sensitivity and scenario analyses for the 
integrated models (Figure 3.6). In Zambia and Zimbabwe, the best-case scenarios were 
US$13.47 and US$6.45 per kit distributed, and the worst-case scenarios resulted in US$19.36 
and US$16.91 per kit distributed in Zambia, and Zimbabwe, respectively (see supplemental 






















$12.00 $16.00 $20.00 $24.00 $28.00 $32.00 $36.00 $40.00 $44.00 $48.00
Economic life years of other capital 5 yrs (2.5,7.5yrs)
Vehicle operation (-10%,+10%)
Allocation of central cost (% of HIVST kits distributed, % of distributors)
Salary (-10%,+10%)
Discount rate 3% (1%,15%)
HIV Self Test Kit Price $2.78 ($1,double)
Kit quant up and down (-10%,+10%)
Economic life years of of start up training and sensitisation 2yrs (1,3yrs)
Best & worse case scenario
Cost per HIV self-kit distributed (US$ 2017)
Malawi Community-based HIVST kits distributed by VMMC mobilisersBase Case = US$24.83
High Low


















$5.00 $7.00 $9.00 $11.00 $13.00 $15.00 $17.00
Economic life years of other capital 5 yrs (2.5,7.5yrs)
Salary (-10%,+10%)
Vehicle operation (-10%,+10%)
Discount rate 3% (1%,15%)
Allocation of central cost (% of HIVST kits distributed, % of distributors)
Kit quant up and down (-10%,+10%)
Economic life years of of start up training and sensitisation 2yrs (1,3yrs)
HIV Self Test Kit Price $2.78 ($1,double)
Best & worse case scenario
Cost per HIV self-kit distributed (US$ 2017)

























$10.00 $11.00 $12.00 $13.00 $14.00 $15.00 $16.00 $17.00
Allocation of central cost (% of HIVST kits distributed, % of distributors)
Vehicle operation (-10%,+10%)
Discount rate 3% (1%,13%)
Economic life years of of start up training and sensitisation 2yrs (1,3yrs)
Economic life years of other capital 5 yrs (2.5,7.5yrs)
Salary (-10%,+10%)
Kit quant up and down (-10%,+10%)
HIV Self Test Kit Price $2.24 ($1,$3.4)
Best & worse case scenario
Cost per HIV self-kit distributed (US$ 2017)
Base Case = US$13.01
High Low




















$3.00 $5.00 $7.00 $9.00 $11.00 $13.00 $15.00
Economic life years of start up training and sensitisation 2yrs (1,3yrs)
Vehicle operation (-10%,+10%)
Discount rate 3% (1%,13%)
Economic life years of other capital 5 yrs (2.5,7.5yrs)
Salary (-10%,+10%)
Kit quant up and down (-10%,+10%)
HIVST kit price $2.24 ($1,$3.4)
Allocation of central cost (% of HIVST kits distributed, % of distributors)
Best & worse case scenario
Cost per HIVST-kit distributed (US$ 2017)
Base Case = US$7.71
High Low






















$12.00 $14.00 $16.00 $18.00 $20.00
Allocation of central cost (% of HIVST kits distributed, % of distributors)
Vehicle operation (-10%,+10%)
Economic life years of of start up training and sensitisation 2yrs (1,3yrs)
Discount rate 3% (1%,13%)
Economic life years of other capital 5 yrs (2.5,7.5yrs)
Salary (-10%,+10%)
Kit quant up and down (-10%,+10%)
HIV Self Test Kit Price $2.24 ($1,$3.4)
Best & worse case scenario
Cost per HIV self-kit distributed (US$ 2017)
Base Case = US$15.81
High Low



















$3.00 $8.00 $13.00 $18.00
Economic life years of of start up training and sensitisation 2yrs (1,3yrs)
Vehicle operation (-10%,+10%)
Discount rate 3% (1%,13%)
Economic life years of other capital 5 yrs (2.5,7.5yrs)
Salary (-10%,+10%)
Kit quant up and down (-10%,+10%)
HIVST kit price $2.24 ($1,$3.4)
Allocation of central cost (% of HIVST kits distributed, % of distributors)
Best & worse case scenario
Cost per HIVST-kit distributed (US$ 2017)
Base Case = US$9.85
High Low




In this study, we presented the costs of distributing HIVST kits integrated into VMMC 
services and in facility-based services in the OPD and HST services. Costs of adding HIVST 
to service’s testing offer could be as low as $7.71, such as in Zimbabwe’s VMMC model, and 
comparable to conventional HTS, but could be relatively high if only few kits are distributed, 
such as through the VMMC mobilizers model in Malawi. These full costs include the initial 
start-up costs and central support. These fixed costs are expected to substantially decrease 
as they are more fully incorporated into routine activities and as operations scale up. In the 
facility integrated models, costs ranged from US$5.20 to US$58.92 per kit distributed. 
 
The estimated unit costs of HIVST distribution through these models are within the wide 
range of standard facility-based counselor-led HIV testing services (US$2.60-22.42) (133), 
and to HIVST delivery through community-based distribution agents (US$8.15-16.42) (49), 
that we previously estimated using the exact same methods across the same sites in these 
three countries (49, 133). While the unit cost of these three distribution models may be 
higher, the implementation trials across these countries suggests HIVST has value in reaching 
first-time testers (men and adolescent boys) (46, 194) and groups that are underserved 
including key populations as well as underserved truck drivers (106, 175, 195-197).  
 
Estimated unit costs for these four HIVST distribution models may not be comparable with 
the cost of standard HTS or HIVST distribution through community-based distribution 
agents (49, 133) (Table 3.5). The distribution numbers were relatively small for these four 
models compared to community-based distribution, which accounted for 82.7% of HIVST 
kit distribution (46). The current estimated unit costs for VMMC, OPD, and integrated 
models should be interpreted with caution. For example, the aim of HIVST distribution 
through community-based distribution by VMMC mobilizers and distribution at the VMMC 
clinic focused on VMMC demand creation among men to increases uptake of VMMC 
services as it reduces the barrier of men to test for HIV. The OPD model aims to expand 
HIV testing capacity within OPD to increase coverage of targeted provider-initiated testing, 
maximize HIV diagnosis, ART initiation, and uptake of prevention service. For example, 
across the two countries personnel cost accounted for close to 50% of the recurrent costs. 
It is likely that real-world integration of HIVST into OPD could be achieved with fewer 
human resources and routine training reduces additional costs of future integrated HIVST 
distribution. Additionally, start-up and capital costs are likely to be dependent on PSI’s 
different implementation strategies across the three countries. Thus, the scaling-up processes 
need more detailed planning and budgeting to reduce cost.  
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Currently, in all three countries, the HIVST kit was available through the funded STAR 
project for US$2.00 – which is only available for 50 low- and middle-income countries for 
four years. In our study, the sensitivity analysis demonstrated important cost reductions when 
the HIVST kit price is lowered to near the standard HIV kit price of around US$1.00. To 
ensure access to HIVST and the ability to scale-up implementation, continued efforts are 
needed to make affordable HIVST kits available, including partnerships with donors. 
Emerging evidence suggests opportunities in the private sector, public-private partnerships, 
and through workplace programmes may be promising for broader and affordable HIVST 
scale-up. 
 
The sensitivity analysis showed the impact of different rates of uptake of HIVST (+/-10%) 
on the unit cost and the total cost. The impact of lower than optimal uptake on unit costs, 
resulted in an eight-fold increase in the OPD model (i.e., ranging from US$5.20 to US$42.24 
per kit distributed). However, among non-testers who refuse to access health facility testing, 
the OPD model case-finding approach is unlikely to achieve large scale, and additional 
innovative approaches need to be identified for HIVST to be integrated within health 
facilities. For instance, offering of HIVST kits to HIV positive index to take to a sexual 
partner or partners and giving HIVST kits to all pregnant women regardless of HIV status 
to take to male partners (secondary distribution) are being explored (46).  
 
Limitations 
This study has a number of limitations. First, we reported unit costs per kit distributed, but 
do not have observed data linking our costs to numbers of new people linked to care, etc. 
Since HIVST is intended to be used in private, we were unable to estimate the unit cost per 
person tested or per HIV positive individuals linked to care and treatment after self-testing 
or negative person linked to prevention – notably in this case VMMC. Second, STAR is the 
first implementation project that introduced HIVST in the Southern Africa region. Thus the 
distribution numbers were relatively small for these three models compared to community-
based distribution, which accounted for 82.7% of HIVST kit distribution (46). If respective 
MOHs scale-up HIVST using these two distribution modalities, it is likely that unit costs 
would be significantly lower due to the higher number of test kits distributed and spreading 
of fixed costs.  
 
Conclusions 
The cost analysis has shown that the costs, though slightly higher, fit within the range of 
estimated costs of HIV testing. If shown to increase coverage of new testers, particularly 
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men and adolescents, or reducing barriers to VMMC, it is likely that adding HIVST into 
routine service delivery will support the achievement of the 90-90-90 and soon to be 95-95-
95 goals. Continued efforts are needed to optimize HIVST particularly around alternative 
models that motivate trained distributors to deliver more kits to the right people.  
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List of abbreviations  
ART  - Antiretroviral therapy 
COMREC - Malawi College of Medicine Research Ethics Committee 
FSWs  - Female sex workers 
ESA  - Eastern and southern Africa 
HIVST  - HIV self-testing  
LSHTM - London School of Hygiene and Tropical Medicine 
HTS  - HIV testing services 
MRCZ  - Medical Research Council of Zimbabwe 
NSC  - New Start Centre  
OPD  - Outpatient department  
PrEP  - Pre-exposure prophylaxis 
PITC  - Provider-initiated testing and counseling 
PSI  - Population Services International 
PSI/Z  - Population Services International Zimbabwe  
RDT  - Rapid diagnostic test 
SFH  - Society for Family Health 
STAR  - HIV-Self-Testing AfRica 
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prick unit cost 
per person 
tested(133)  
Malawi (Community-based HIVST kits distributed by VMMC mobilizers model) 
1 413 $7,947 $19.24 1,899 $9,250 $4.81 
2 320 $10,251 $32.04 2,727 $9,520 $3.45 
Malawi (HIVST kits distributed at VMMC clinic) 
1 1174 $11,121 $9.47    
2 1568 $15,238 $9.72    
Zambia (HIVST kits distributed at VMMC clinic model) 
1 540 $11,740 $21.74    
2 1862 $18,830 $10.11    
3 631 $12,343 $19.56 1,976 $11,705 $6.14 
4 478 $11,034 $23.08 3,196 $12,195 $3.87 
5 5467 $44,151 $8.08    
6 1663 $36,954 $22.22    
7 318 $3,246 $10.21    
8 371 $10,806 $29.13 4,673 $8,684 $3.64 
Zimbabwe (HIVST kits distributed at VMMC clinic model) 
1 963 $5,862 $6.09 24,126 $77,611 $3.22 
2 553 $6,598 $11.93 5,051 $82,728 $16.38 




Table 3.7 Total & site level unit costs of HIVST kits distribution OPD and integrated 






































Zambia (OPD model)      
1 596 $12,266 $20.58    
2 992 $13,148 $13.25    
3 484 $11,021 $22.77 1,976 $11,705 $6.15 
4 208 $8,568 $41.19 3,196 $12,195 $3.87 
5 3175 $16,495 $5.20    
6 1136 $8,834 $7.78    
7 1124 $9,988 $8.89    
8 670 $7,232 $10.79    
9 556 $15,529 $27.93    
10 231 $13,611 $58.92 4,192 $10,860 $2.64 
11 887 $20,768 $23.41    
12 311 $13,136 $42.24    
13 656 $13,331 $5.30    
14 416 $12,599 $30.29 2,691 $6,344 $2.49 
15 841 $15,376 $18.28    
16 602 $13,306 $22.10 4,673 $8,684 $3.64 
Zimbabwe (Integrated model)      
1 7,576 $56,592 $7.47 85,725 $346,805 $4.05 
2 1,278 $29,109 $22.78 13,204 $98,241 $7.44 
3 3,184 $20,668 $6.49 24,126 $199,222 $8.26 
4 303 $3,473 $11.46 2,855 $69,607 $24.38 




Table 3.8 Sensitivity analysis data input and output for HIVST kits distribution 
VMMC model (in 2017 US$) 
Malawi Cost per Community-based HIVST kits distributed by VMMC mobilisers Base Case = 
US$24.83 
  Input Output 
Sensitivity analysis inputs Low Base case High Low Base case High 
Discount rate 3% (1%, 13%) 1% 3% 13% $24.51 $24.83 $26.77 
Allocation of central cost (% of 
HIVST kits distributed, % of 
distributors) 
   
$23.91 $24.83 $24.83 
Economic life years of start-up 
training and sensitization 2yrs (1,3yrs) 
1yr 2yrs 3yrs $21.28 $24.83 $35.48 
Economic life years of other capital 5 
yrs. (2.5,7.5yrs) 
2.5yrs 5yrs 7yrs $24.83 $24.83 $24.83 
Best & worst-case scenario 
   
$16.09 $24.83 $45.66 
HIV Self-Test Kit price $2.24 ($1, 
$3.4) 
$1.00 $2.24 $3.40 $23.05 $24.83 $27.61 
Salary (-10%, +10%) 90% 100% 110% $24.08 $24.83 $25.56 
Kit quant up and down (-10%, 
+10%) 
90% 100% 110% $22.57 $24.83 $27.58 
Vehicle operation (-10%, +10%) 90% 100% 110% $24.66 $24.83 $25.00 
 
Malawi cost per HIVST distributed via VMMC clinic distribution Base Case = US$9.61 
  Input Output 
Sensitivity analysis inputs Low Base 
case 
High Low Base 
case 
High 
Discount rate 3% (1%, 13%) 1% 3% 13% $9.55 $9.61 $9.98 
Allocation of central cost (% of HIVST kits 
distributed, % of distributors) 
   
$8.85 $9.61 $9.61 
Economic life years of start-up training and 
sensitization 2yrs (1,3yrs) 
1yr 2yrs 3yrs $8.93 $9.61 $11.65 
Economic life years of other capital 5 yrs. 
(2.5,7.5yrs) 
2.5yrs 5yrs 7yrs $9.61 $9.61 $ 9.61 
Best & worst-case scenario 
   
$5.64 $9.61 $16.23 
HIV Self-Test Kit price $2.24 ($1, $3.4) $1.00 $2.24 $3.40 $7.84 $9.61 $12.40 
Salary (-10%, +10%) 90% 100% 110% $9.48 $9.61 $ 9.75 
Kit quant up and down (-10%, +10%) 90% 100% 110% $8.74 $9.61 $10.68 





Zambia cost per HIVST distributed via VMMC clinic distribution Base Case US$13.01 
  Input Output 
Sensitivity analysis inputs Low Base case High Low Base case High 
Discount rate 3% (1%, 13%) 1% 3% 13% $12.95 $13.01 $13.27 
Allocation of central cost (% of HIVST 
kits distributed, % of distributors) 
   
$13.01 $13.01 $13.01 
Economic life years of start-up training 
and sensitization 2yrs (1,3yrs) 
1yr 2yrs 3yrs $12.90 $13.01 $13.31 
Economic life years of other capital 5 yrs. 
(2.5,7.5yrs) 
2.5yrs 5yrs 7yrs $12.77 $13.01 $13.71 
Best & worst-case scenario 
   
$11.12 $13.01 $16.05 
HIV Self-Test Kit price $2.24 ($1, $3.4) $1.00 $2.24 $3.40 $12.00 $13.01 $13.95 
Salary (-10%, +10%) 90% 100% 110% $12.36 $13.01 $13.65 
Kit quant up and down (-10%, +10%) 90% 100% 110% $12.17 $13.01 $14.07 
Vehicle operation (-10%, +10%) 90% 100% 110% $12.86 $13.01 $13.15 
 
Zimbabwe cost per HIVST distributed via VMMC clinic distribution Base Case US$7.71 
  Input Output 
Sensitivity analysis inputs Low Base 
case 
High Low Base case High 
Discount rate 3% (1%, 13%) 1% 3% 13% $7.64 $7.71 $7.84 
Allocation of central cost (% of HIVST 
kits distributed, % of distributors) 
   
$6.80 $7.71 $10.28 
Economic life years of start-up training 
and sensitization 2yrs (1,3yrs) 
1yr 2yrs 3yrs $7.71 $7.71 $7.71 
Economic life years of other capital 5 
yrs. (2.5,7.5yrs) 
2.5yrs 5yrs 7yrs $7.53 $7.71 $8.21 
Best- & worst-case scenario 
   
$4.81 $7.71 $14.83 
HIV Self-Test Kit price $2.24 ($1, $3.4) $1.00 $2.24 $3.40 $6.52 $7.71 $8.87 
Salary (-10%, +10%) 90% 100% 110% $7.36 $7.71 $8.06 
Kit quant up and down (-10%, +10%) 90% 100% 110% $6.99 $7.71 $8.59 




Table 3.9 Sensitivity analysis data input and output for HIVST kits distribution OPD 
and integrated models (in 2017 US$) 
Zambia cost per HIVST distributed via OPD Base Case US$15.81 
  Input Output 
Sensitivity analysis inputs Low Base case High Low Base 
case 
High 
Discount rate 3% (1%, 13%) 1% 3% 13% $15.75 $15.81 $16.11 
Allocation of central cost (% of HIVST 
kits distributed, % of distributors) 
   
$5.81 $15.81 $15.81 
Economic life years of start-up training 
and sensitization 2yrs (1,3yrs) 
1yr 2yrs 3yrs $15.72 $15.81 $16.07 
Economic life years of other capital 5 yrs. 
(2.5,7.5yrs) 
2.5yrs 5yrs 7yrs $15.52 $15.81 $16.65 
Best & worst-case scenario 
   
$13.47 $15.81 $19.36 
HIV Self-Test Kit price $2.24 ($1, $3.4) $1.00 $2.24 $3.40 $14.59 $15.81 $16.95 
Salary (-10%, +10%) 90% 100% 110% $14.98 $15.81 $16.63 
Kit quant up and down (-10%, +10%) 90% 100% 110% $14.79 $15.81 $17.10 
Vehicle operation (-10%, +10%) 90% 100% 110% $15.67 $15.81 $15.95 
 
Zimbabwe cost per HIVST distributed via OPD Base Case US$9.85 
  Input Output 
Sensitivity analysis inputs Low Base case High Low Base case High 
Discount rate 3% (1%, 13%) 1% 3% 13% $9.78 $9.85 $10.01 
Allocation of central cost (% of HIVST 
kits distributed, % of distributors) 
   
$8.83 $9.85 $11.95 
Economic life years of start-up training 
and sensitization 2yrs (1,3yrs) 
1yr 2yrs 3yrs $9.85 $ 9.85 $9.85 
Economic life years of other capital 5 
yrs. (2.5,7.5yrs) 
2.5yrs 5yrs 7yrs $9.64 $9.85 $10.43 
Best & worst-case scenario 
   
$6.45 $9.85 $16.91 
HIV Self-Test Kit price $2.24 ($1,$3.4) $1.00 $2.24 $3.40 $8.70 $9.85 $10.98 
Salary (-10%, +10%) 90% 100% 110% $9.30 $9.85 $10.40 
Kit quant up and down (-10%, +10%) 90% 100% 110% $8.93 $9.85 $10.97 





3.1.  Implication for thesis  
The results presented in this paper offer important insights regarding how to optimize 
HIVST distribution to reach different population groups. For instance, the VMMC model is 
designed to reach men and the health facility model to identify HIV positive cases.  
 
The most practical implication of these unit costs of different HIVST distribution models 
will fully inform policy. 
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CHAPTER 4 COST-EFFECTIVENESS OF COMMUNITY-
BASED (DOOR-TO-DOOR) HIV SELF-TESTING 
DISTRIBUTION MODELS FOR HIV TESTING IN 
ZAMBIA: MARKOV MICROSIMULATION (PAPER-3)  
Overview of Paper 3  
 
The cost-effectiveness model on HTS can be used to estimate cost and effectiveness 
measurements to understand its impact in a given population, time, and place. No modelling 
work assessed the cost-effectiveness of door-to-door HIVST distribution in Zambia.  
 
This research paper applies a microsimulation model to estimate the incremental cost-
effectiveness of adding home-based HIVST distribution to conventional facility-based HIV 
testing services (HTS) to reach people who otherwise would not access HTS while visiting 
health facilities. 
 
This paper is in preparation to be submitted to AIDS in July 2020. One supplementary 
document is included at the end of the thesis.  
 
This chapter provides the ICERs per DALY averted as well as the gaps on cost-effectiveness 
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Background: Adult HIV prevalence in Zambia is approximately 12%, and it is estimated 
that 28% of people living with HIV remain undiagnosed. In 2016 Zambia adopted HIV self-
testing (HIVST) as an additional approach to expand coverage and access to those in need 
of testing and who might not otherwise test. While early introduction focused on small-scale 
HIVST distribution in specific districts and regions, the programme seeks to expand 
nationwide. This study evaluates the incremental cost-effectiveness of adding home-based 
HIVST distribution to conventional facility-based HIV testing services (HTS) to reach 
people who otherwise would not access HTS while visiting health facilities.  
 
Methods: This study developed a sex- and age-specific Markov microsimulation model for 
Zambia. Costs and health outcomes were evaluated for a one-year door-to-door HIVST 
programme over a 20-year time horizon using a discount rate of 3%. The model applied Self-
test in Africa (STAR) endline survey data to reflect uptake of facility HTS and assumed that 
only those untested in the past year were eligible for home-based HIVST and could accept 
or reject HIVST with its accompanying costs and consequences. Costs are presented from 
the health providers’ perspective and effects in terms of disability-adjusted life year (DALY) 
averted. All costs are reported in 2017 US$.  
 
Results: The model applied 100,000 simulations to estimate the incremental cost-
effectiveness ratio (ICER) per DALY averted of a one-year HIV testing service of door-to-
door HIVST compared with facility-based HTS for men and women across three age groups. 
The ICERs (cost per DALY averted) for men and women ages 15-24, 25-34, and 35-49 were 
$101.81 & $154.73, $35.26 & $25.18 and $32.10 & $23.03, respectively. The sensitivity 
analyses showed increasing the uptake of HIVST, linkage to ART initiation, ART retention 
and viral load suppression could lower the ICER. 
 
Conclusion: Overall, to reach the 28% who remain undiagnosed at facility testing, door-to-
door HIVST provides a cost-effective complement to current testing approaches and can 
play an essential role in reaching national testing targets.  
 
Keywords: Modelling; microsimulation; Markov model; HIV testing; HIV self-testing; cost-




Zambia has one of the highest HIV prevalence rates in the world. Adult HIV prevalence in 
Zambia is approximately 12% (4), yet it is estimated that 28% of people with HIV remain 
undiagnosed. In 2014, the joint United Nations Programme on HIV/AIDS (UNAIDS) put 
forward the 90-90-90 targets recommending that by 2020, 90% of all people living with HIV 
should know their HIV status, 90% of all individuals with diagnosed HIV infection should 
be enrolled and receive antiretroviral therapy (ART), and 90% of those receiving ART should 
achieve viral suppression (88). Moreover, Zambia adopted the 2015 World Health 
Organization (WHO) test and treat guidelines for immediate ART initiation for all HIV 
positive adults and adolescents (198). These ambitious targets have brought changes in 
Zambia and are likely to require increasing innovative and alternative HIV testing services 
(HTS).  
 
The government of Zambia continues its effort to increase HIV testing using alternative 
HTS, including community-based testing, mobile services, home-based testing, voluntary 
medical male circumcision (VMMC), prevention of mother to child transmission (PMTCT), 
and integrating HTS to centres offering sexually transmitted infection (STI) services (20). 
The most considerable gaps in meeting the 90-90-90 targets are adolescents and men who 
do not know their HIV status. Therefore, the Zambian Ministry of Health (MOH) has 
recognized that HTS coverage remains below the UNAIDS targets and it has supported 
research to investigate HIV self-testing (HIVST) to complement conventional HTS in order 
to increase uptake of HIV testing (21).  
 
Since 2015, the HIV-Self Testing Africa (STAR) project has been leading the implementation 
of HIVST (using oral-fluid) in Zambia. The STAR project also aimed to understand the costs 
of distributing HIVST kits using different distribution modalities to ensure the efficient use 
of financial and human resources. Careful costing and cost analysis of various HIVST 
distributing modalities were conducted, including door-to-door (50) and static site HIV self-
test kit distribution (199) to ensure the provision of HIVST to achieve high testing coverage. 
Evidence from other African countries has demonstrated the accuracy, acceptability, and 
performance of HIVST in general and key populations (22, 23, 25, 26, 28, 195, 200). In 
Zambia, results from a cluster-randomized trial on a community-based distribution of 
HIVST kits at population level among those whom HIV tested in the last 12 months did not 
identify a significant impact on recent or lifetime testing (RR 1.08, Adj 95% CI 0.94-1.24; p 
= 0.15) (47). However, more studies are needed to generate evidence on efficient approaches 
to reaching ambitious targets and the cost-effectiveness of each HTS to consider distributing 
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as HIVST kits in Zambia. These data are critical to inform the programmatic decision of 
HIVST scale-up in Zambia.    
 
To inform this evidence gap, this study used a Markov microsimulation model to determine 
the cost-effectiveness of a package of standard facility based HTS with an addition of a door-
to-door HIVST kit distribution model compared with standard facility-based HTS from the 
health providers’ perspective in Zambia.  
 
Methods and Materials   
Cost analysis 
This study analysed the annual cost incurred between June 2016 and July 2017 for HIVST 
kit distribution in Zambia using a door-to-door community-based distribution model. This 
includes the cost of reaching communities, demonstration of how HIVST works, and 
distribution of HIVST kits (50). The cost data collection employed both ingredients-based 
(bottom-up) costing for allocation factors and direct resource use and top-down costing for 
overhead and administrative costs allocation. The detailed financial expenditure for the 
project period was readily available through the Society for Family Health (SFH) Lusaka 
office. In this study, the financial costs represented actual STAR project expenditures, and 
the economic costs represented the estimated market value of all resources that were used in 
expanding the HIVST intervention, including donated goods and services. Cost data were 
disaggregated by specific input types. For instance, capital costs included the costs of project 
start-up, including initial training, sensitization, and equipment. Recurrent costs included 
costs of recurrent training, personnel, HIVST kit price, building and vehicle operation and 
maintenance, utilities, and other recurrent costs such as project administration and 
coordination. We adjusted for cost and converted all costs into 2017 US$ (201). Capital costs, 
including start-up and training costs were annualized over their economic life year using a 
3% discount rate in the base case costs.  
 
The cost per HIVST kit distributed was estimated by dividing the total cost by the total 
number of HIVST kits distributed using a door-to-door community-based distribution 
model for those individuals who accepted the HIV self-test kit to be used at home. The cost 
that is used in this model is the unit cost per HIV self-self-kit distributed. This is discussed 
as a limitation to highlight that this analysis did not consider unit cost for individuals who 
refused to test. The intervention cost for HIV testing using HIVST and status quo were only 
incurred once (one-year intervention cost, see Table 4.1 along with Supplementary Table S2). 
The annual ART cost (US185.86) included the cost of provider, health facility visit and the 
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drug (36), and the costs were incurred for a 20-year time horizon (sensitivity analysis: 5, 10, 
15 20 years, and lifetime) in the model. This cost does not include the cost of hospitalization 
or receiving end of life care. 
 
Cost-effectiveness analysis  
To examine the potential impact of the introduction of a one-year HIVST campaign and its 
impact over 20 years, we developed a Markov microsimulation model using TreeAge Pro 
2017, R2.0 TreeAge Software, Williamstown, MA, USA (202). This model used the primary 
observed cost data from the STAR project to parameterize the intervention cost and 
extrapolated missing parameters from a systematic literature review (203).  
 
The model simulated a heterosexual population representing Zambian adults ages 15 to 49 
from the point of offer of HIV testing to viral load suppression and death (if it occurred 
within the 20-year time horizon). Thus, the model incorporated the HIV care cascade, which 
included individuals going through confirmatory rapid diagnostic HIV testing (RDT), 
accepting HIV positive status, initiating ART, being retained in ART care, and obtaining viral 
load suppression. This is described in the Markov health states (Figure 4.1). The age- and 
sex-specific HIV prevalence and mortality data were obtained from the Zambia Population-
Based HIV Impact Assessment (ZAMPHIA) (91) and the Zambia Demographic Health 
Survey (DHS) respectively (51). When an individual is confirmed to be HIV positive, they 
would be initiated on ART without the consideration of CD4 cell count in accordance with 
the Zambian national ART guidelines (204). In the HIV care cascade, individuals could be 
lost to follow-up at any stage. Those who refused to initiate ART after the HIV-positive 
confirmatory test or those lost to follow-up after initiating ART could subsequently re-enter 
the care cascade (Table 4.1, Supplementary Tables S3-S14). 
  
This study calculated the incremental cost-effectiveness ratio (ICER) for adding a door-to-
door HIVST kit distribution model to the facility-based standard HTS (status quo). The 
ICER was calculated as incremental costs divided by the incremental health benefit (DALYs 
averted). The observed costs and health effects (DALYs averted) related to door-to-door 
HIVST kit distribution model was compared to inform which one was likely to represent the 
most cost-effective modality for HIVST kit distribution for three age groups for both men 
and women. This includes adolescent male/female 15-24 years of age, male/female 25-34 
years of age and male/female 35-49 years of age. Indirect health effects, such as secondary 










Status quo or standard 
facility-based HTS: 
PITC, ANC, VCT 
(Comparator) 
PITC - health facility provider-initiated 
testing and counselling  
ANC - health facility antenatal care HIV 
testing  
VCT - health facility voluntary counselling 





self-testing to the 
status quo (offered 
only to those who did 
not accept HTA) 
Community-based (door-to-door) self-test 
kit distribution via community-based 
distributing agents 
Once/year  
Figure 4.1 The structure of the Markov microsimulation model for the provision of 
HIV self-testing for those not tested in the last 12 months. 
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Model structure  
Individuals entered in one of two health states: 1) HIV negative individuals who do not know 
their HIV status, and 2) HIV positive individuals who do not know their HIV status (Figure 
4.1). The transitions between health states experienced by individuals were assigned health 
utility and cost pertinent to each of these health states. The transition probabilities were 
extracted from ZAMPHIA (91) and the Zambia DHS respectively (51). The model has ten 
mutually exclusive health states: 1) HIV negative individuals who know their HIV status, 2) 
HIV negative individuals who do not know their HIV status, 3) HIV positive individuals 
who do not know their HIV status, 4) HIV false positive (misdiagnosed), 5) HIV false 
negative (misdiagnosed), 6) HIV true positive viral load suppressed, 7) HIV true positive 
viral load not suppressed, 8) HIV true positive lost to follow-up, 9) death from HIV without 
treatment, and 10) death from other natural causes (Figure 4.1). 
  
Model calibration 
The model was calibrated to match the most recently available HIV prevalence estimates, 
mortality rate, ART, and viral load suppression data from ZAMPHIA and Zambian DHS 
(51, 91). The population was divided by age, gender, and risk of HIV infection (91). Both 
HIV specific and other causes of mortality were incorporated into the model (51, 91).  
 
Model validation  
The model was developed after reviewing the literature, descriptive analysis of Zambian HIV 
epidemiology (local survey), demographics, and mortality from natural cause stratified by age 
and gender (Zambian DHS). The model validation was done to ensure the model’s fidelity 
to satisfy the analysis objectives and by visiting HIV testing facilities in Zambia. The internal 
validity of the model was tested using extreme numbers in the parameters. 
 
Status quo HTS 
The current status quo (comparator) HTS available at the government health facilities are 
provider-initiated testing and counselling (PITC), voluntary counselling and testing (VCT) 
and antenatal care (ANC) HIV testing using RDT (Table 4.1). In the status quo scenario, 
individuals (HIV negative individuals who do not know their HIV status, and HIV positive 
individuals who do not know their HIV status) accessed a health facility for HIV screening 
through either PITC, VCT, or ANC. We calculated the proportion of  men and women who 
tested at the status quo across the three age stratifications using the STAR endline survey. 
Uni-Gold is the confirmatory rapid diagnostic test (RDT) used in Zambia (205). The 
sensitivity and specificity for Uni-Gold were 99.8% and 99.9% (206). Per Zambian HIV 
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treatment guidelines, individuals identified as HIV positive were initiated with ART 
regardless of  CD4+ cell count (204). Following HIV diagnosis and initiation with ART, it 
was estimated that 83% of  the patients would be retained in ART care for the subsequent 
two years (207). The 83% ART retention was extended to the 20-year time horizon. We 
applied ZAMPHIA’s published average coverage of  ART for males and for females across 
the three age categories (91).  
 
Intervention strategies  
We compared the impact of adding door-to-door HIVST kits distribution onto existing 
standard HTS, and these were compared with the standard facility-based HTS at the 
government health facility (Table 4.1). In the intervention arm, individuals (HIV negative 
individuals who do not know their HIV status, and HIV positive individuals who do not 
know their HIV status) who did not test at a health facility through PITC, VCT, or ANC in 
the last 12 months were offered HIVST kits. This is different from the STAR trial and avoids 
substitution. The sensitivity and specificity of OraQuick among intended users were 94.2% 
and 99.7%, respectively (208). Specifically, we compared the 20-year impact of adding a one-
year targeted intervention of HIVST onto the existing HTS on healthcare cost, DALYs 
averted, and the ICER.  
 
HIV prevention and treatment cascades 
The HIV prevention cascade helps identify the people who are unaware of their HIV 
negative status and people unaware of their HIV infection (169, 171, 209). The HIV 
treatment cascade helps monitor people after they enrol in HIV care services. This includes: 
1) initiating ART, 2) alive and remaining in care for 90 or more days, and 3) alive and viral 
load suppressed (210-213). We modelled the steps between becoming HIV positive to 
achieving viral load suppression as provided within government-approved HIV programmes. 
All input parameters for the model are listed in Table 4.2.  
 
Discounting and time horizon 
As standard practice, future costs and effects were discounted and expressed in present 
values in order to better inform current decision making (54). The 3% per year discount rate 
for costs (in 2017 US$) and health benefits were applied as a central estimate (214). The 
impact of varying the discount rate was explored in a sensitivity analysis. A 20-year time 
horizon was used in the model to adequately capture both the benefits and cost associated 




Uncertainty and sensitivity analysis  
Deterministic (univariate and multivariate (best/worst-case scenarios)), and probabilistic 
sensitivity analyses (PSA) were performed to ensure the robustness of the input parameters 
and assumptions in the decision model (53, 54). Using sensitivity analyses, we also explored 
the impact of using a 5-, 10-, and 15-year time horizon. A deterministic sensitivity analysis 
was applied to identify parameters that affected the ICER the most. The following 
parameters were varied in the deterministic sensitivity analyses: discount rate of cost (base 
case 3%, range 1% to 13%), discount rate of effects (base case 3%, range 1% to 13%), ART 
initiation (base case 78%, range 37% to 90%), ART retention (base case 78%, range 60% to 
90%), viral load suppression (base case 78%, range 60% to 90%), and sensitivity of OraQuick 
among intended users (base case 94%, range 90% to 99%). In any age category, if the base 
case ART initiation, retention, or viral load suppression had already reached 90%, the one-
way sensitivity analysis applied high targets of ART initiation (95%), ART retention (95%), 
and viral load suppression (95%).  
 
Scenario analyses were used to explore the impact of higher and lower resource cost or 
service outputs. This included varying the cost of HIVST (base case US$16.42, range 
US$7.91 to US$50.01) as observed in STAR; lifetime ART cost after (base case US$185.86, 
range from US$139.39 to US$232.32), and uptake of HIVST (+/- 25%). 
 
PSA using Monte Carlo simulations for 10,000 trials (individual patient simulation) was 
conducted to assess combined uncertainty related to any number of parameters. We used 
gamma distributions for costs and beta distributions for health utility (215). By randomly 
sampling from each parameter distribution, 10,000 simulations of incremental costs and 
incremental effects were obtained. The results of the PSA are presented as the cost-
effectiveness acceptability curve (CEAC). The CEACs summarize the impact of uncertainty 
in relation to different possible values of the cost-effectiveness threshold (CET) (54). In the 
absence of a locally defined CET, countries may consider using half of gross domestic 
product (GDP) per capita (82, 83) instead of the previously suggested 1-3x GDP per capita 
rule (72). The current GDP per capita for Zambia is US$1,430 (216). Until Zambia defines 





Table 4.2 HIV testing, treatment, and cost input parameters 
Variable Base-case assumption Sensitivity 
analysis range 
Source 
Population and testing 
Proportion of HIV-negative 
individuals who do not their 
status 
Male ages 15-24: 0.96 
Male ages 25-34: 0.90 
Male ages 35-49: 0.86 
Female ages 15-24: 0.96 
Female ages 25-34: 0.87 
Female ages 35-49: 0.85 
 (51) 
Proportion of HIV-positive 
individuals who do not know 
their status 
Male ages 15-24: 0.04 
Male ages 25-34: 0.10 
Male ages 35-49: 0.14 
Female ages 15-24: 0.04 
Female ages 25-34: 0.13 
Female ages 35-49: 0.15 
 (51) 
Annual self-reported HIV 
testing (status quo-proportion) 
PITC 
Male ages 15-24: 0.46 
Male ages 25-34: 0.56 
Male ages 35-49: 0.65 
Female ages 15-24: 0.53 
Female ages 25-34: 0.55 
Female ages 35-49: 0.65 
ANC  
Male ages 15-24: 0.02 
Male ages 25-34: 0.06 
Male ages 35-49: 0.06 
Female ages 15-24: 0.11 
Female ages 25-34: 0.16 
Female ages 35-49: 0.10 
VCT 
Male ages 15-24: 0.12 
Male ages 25-34: 0.12 
Male ages 35-49: 0.09 
Female ages 15-24: 0.09 
Female ages 25-34: 0.08 




Annual uptake of door-to door 
HIV self-testing (proportion) 
Male ages 15-24: 0.57 
Male ages 25-34: 0.57 
Male ages 35-49: 0.53 
Female ages 15-24: 0.41 
Female ages 25-34: 0.60 






Variable Base-case assumption Sensitivity 
analysis range 
Source 
Mortality rates of HIV 
uninfected person (proportion 
per year) 
Male ages 15-24: 0.03 
Male ages 25-34: 0.08 
Male ages 35-49: 0.14 
Female ages 15-24: 0.02 
Female ages 25-34: 0.07 
Female ages 35-49: 0.11 
 (217) 
Testing frequency Once per year - Assump
tion 
Discount rate for cost and 
utility outcomes 
3% per year (0%-13%) for 
cost  
(1%,- 13%) for 
utility 
(214) 
HIV care and treatment 
Initiation of ART care for 
intervention-door-to-door 
HIVST (%) (~ annual) 
Male ages 15-24: 0.78 
Male ages 25-34: 0.72 
Male ages 35-49: 0.86 
Female ages 15-24: 0.78 
Female ages 25-34: 0.78 
Female ages 35-49: 0.88 
(37%a, -90%) (218) 
Initiation of ART care for 




On treatment among those 
diagnosed (annual) for both 
intervention and status quo (%) 
Male ages 15-24: 0.78 
Male ages 25-34: 0.72 
Male ages 35-49: 0.86 
Female ages 15-24: 0.78 
Female ages 25-34: 0.78 
Female ages 35-49: 0.88 
 (4) 
VL suppression among those 
on treatment (annual) for 
intervention and status quo (%) 
Male ages 15-24: 0.78 
Male ages 25-34: 0.91 
Male ages 35-49: 0.88 
Female ages 15-24: 0.78 
Female ages 25-34: 0.88 
Female ages 35-49: 0.91 
 (4) 
Annual lost to follow-up from 
HIV care (%) 
17% 
(10-31) (207) 
Annual lost to follow-up from 
HIV care and died (%) 
2.9% 
(1.5- 6) (207) 
Annual mortality rates while on 
HIV care (%) 
8.8% 
(6.40-12.10) (207) 
Cost of intervention and status quo HTS in 2017 US$* 
Intervention (Community-based 
door-to-door self-test kit 
distribution)- average 






Variable Base-case assumption Sensitivity 
analysis range 
Source 




Status quo – ANC-average 
cost/person tested  
57.59 
 (128) 
Status quo – VCT- average 
cost/person tested  
4.41 
 (133) 
Average cost of false-positive 
confirmatory test  
1.60 
 (133) 
Cost of HIV care and treatment in 2017 US$*  
Intervention (door-to-door self-test following linkage into care) and Status quo 
Annual cost of ART per client  185.86 (139.39-232.32) (36) 
Health-related quality of life-utility description (disability weight) 
HIV negative individuals 0 - (76) 
HIV/AIDS receiving 
antiretroviral treatment 0.053 
(0.034-0.079) (76) 
HIV asymptomatic (also don’t 
know their HIV positive status) 
0.221 
(0.146-0.310) (76) 
AIDS not receiving 
antiretroviral treatment (viral 
load not suppressed) 
0.547 
(0.382-0.715) (76) 
* The costs for the prevention cascade include the costs for HIV testing at the health facility 
in three departments: provider-initiated testing and counselling (PITC), antenatal care (ANC) 
and voluntary counselling and testing (VCT). The costs for the treatment cascade include the 
costs to identify a HIV positive individual and link to the treatment cascade. See 
supplemental tables for further explanation on the variables 
a37% is calculated by dividing 181 adults who self-tested and initiated ART at home by 490 





Table 4.3 shows the total costs for intervention (HIVST) and standard of care for the three 
age groups stratified by men and women in Zambia. The intervention arm, which includes 
the provision of HIVST, incurred an additional total cost for reaching additional people. 
One-year community-based HIV self-testing reached an additional 22,722 new men (ages 
15-24), 14,925 (ages 25-34) and 10,695 (ages 35-49) and 11,192 new women (ages 15-24), 
12,594 (ages 25-34) and 10,879 (ages 35-49) who had not tested for HIV in the previous 12 
months. The one-year provision of HIV self-testing for those who did not test for HIV in 
the previous year resulted in identifying an additional 921 (ages 15-24), 1,462 (ages 25-34), 
and 1,494 (ages 35-49) HIV positive cases for men and 449 (ages 15-24) 1,612 (ages 25-34), 
and 1,605 (ages 35-49) for women. The cost per case identified using HIV self-testing for 
the adolescent age group was US$409.29 for men (age 15-24) and US$ 405.29 for women 
(ages 15-24), which differed substantially from $167.63 for men (ages 25-34), $117.54 for 
men (ages 35-49), $128.28 for women (ages 25-34), and $111.30 for women (ages 35-49) 
(Table 4.3), Figure 4.2 and 4.3. 
 

















15-24 22,722 $16.42 $373,095 921 $405.10 
25-34 14,925 $16.42 $245,069 1,462 $167.63 
35-49 10,695 $16.42 $175,612 1,494 $117.54 
Women 
15-24 11,192 $16.42 $183,773 449 $409.29 
25-34 12,594 $16.42 $206,793 1,612 $128.28 
35-49 10,879 $16.42 $78,633 1,605 $111.30 
 
In Table 4.4, we present the ICERs (cost-per DALY averted) of door-to-door HIVST 
compared with the status quo, for 100,000 simulations over 20 years for both men and 
women by the three age categories. The ICERs for adolescent men and women ages 15-24 
were $101.81 and $154.73 per DALY averted. The ICERs for men and women were $35.26 































Figure 4.2 (A-C) Men HIV treatment cascade 
# of PLHIV tested= Number of HIV positive individuals who tested 
for the HIV for the first-time using HIV self-test kit. 
 
Positive case identified= Number of confirmed HIV positive cases 



























A. Men aged 15-24 treatment cascade
Standard of Care RDT,PITC &VCT Intervention RDT,PITC, VCT & HIVST






















B. Men aged 25-34 treatment cascade
Standard of Care RDT,PITC &VCT Intervention RDT,PITC, VCT & HIVST

























C. Men aged 35-49 treatment cascade
Standard of Care RDT,PITC &VCT Intervention RDT,PITC, VCT & HIVST
PLWH don’t know their HIV status n=14,000 
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# of PLHIV tested= Number of HIV positive individuals who 
tested for the HIV for the first-time using HIV self-test kit. 
 
Positive case identified= Number of confirmed HIV positive 




























A. Women aged 15-24 treatment cascade
Standard of Care RDT,PITC &VCT Intervention RDT,PITC, VCT & HIVST

























B. Women aged 25-34 treatment cascade
Standard of Care RDT,PITC &VCT Intervention RDT,PITC, VCT & HIVST

























C. Women aged 35-49 treatment cascade
Standard of Care RDT,PITC &VCT Intervention RDT,PITC, VCT & HIVST
PLWH don’t know their HIV status n=15,000 
Figure 4.3 (A-C) Women HIV treatment cascade 
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Status quo $1,004,359.78 
$534,842.81 
26,243 83,104 109,348 
5,253.301 $101.81 5 
Intervention $1,539,202.59 28,356 75,738 104,094 
25-34 
Status quo $2,100,248.17 
$451,887.20 
34,341 132,253 166,594 
12,816.971 $35.26 4 
Intervention $2,552,135.37 35,140 118,637 153,777 
35-49 
Status quo $2,100,248.17 
$413,887.20 
21,196 95,484 116,680 
12,881.731 $32.10 3 
Intervention $3,155,537.04 21,682 82,116 103,798 
Women 
15-24 
Status quo $1,666,298.07 
$262,736.87 
29,850 100,353 130,203 
1,698.071 $154.73 6 
Intervention $1,929,034.95 32,204 96,301 128,505 
25-34 
Status quo $3,061,346.61 
$449,887.89 
44,613 173,602 218,216 
17,870.251 $25.18 2 
Intervention $3,511,234.50 44,445 155,900 200,346 
35-49 
Status quo $3,122,012.18 
$442,989.40 
34,156 131,626 165,783 
19,237.381 $23.03 1 
Intervention $3,565,001.58 26,234 120,311 146,545 
1DALYs are unfavourable utilities and the negative incremental DALYs averted are the inverse of incremental DALYs. 




Sensitivity analyses  
Figure 4.5 shows one-way sensitivity analyses for men and women by age group. The base-
case values are shown, and the red-right and the blue-left bars demonstrate the ICER 
estimates at the upper and lower assumptions, respectively. In all age groups for both men 
and women, varying the discount rate of effects from 13% to 1% lowered the ICERs. Per 
our previously published study of onsite level cost per HIVST kit distributed (50) 
(Supplementary Table S-3), we varied cost per HIVST kit distributed between $7.91 and 
$50.01, and in all age groups, this significantly affected the ICERs on both lower and higher 
values. For adolescent men aged 15-24, the upper values for ART initiation (90%) resulted 
in higher ICER ($105.40 per DALY averted). ART retention (90%) and viral load 
suppression (90%) could bring down the base-case ICER (US$ 101.81 per DALY averted) 
to US$43.85 and US$93.70, respectively. If the ART initiation was 37%, ICER lowered from 
US$105.40 to US$93.73. For adolescent women, increasing ART initiation, retention, and 
viral load suppression to 90% resulted in higher ICERs of US$239.66, US$230.27, and 
US$240.14, respectively. In almost all age groups for both men and women, increasing the 
sensitivity of OraQuick among intended users from 94% to 99% resulted in lower ICER per 
DALY averted. Moreover, lowering the lifetime ART cost results lowered ICERs. Varying 
the uptake of HIVST by +25% lowers the ICER for both adolescent men and women. 
 
The multivariate (best/worst-case scenarios) analysis applied the values of the most 
optimistic (best-case scenario) and pessimistic (worst-case scenario) parameters, and this 
resulted in lower and higher ICER per DALY averted, respectively. For adolescent men, the 
best-case scenario lowered the base-case ICER from $101.81 to $13.16 per DALY averted. 
The worst-case scenario resulted in negative ICER of $1028.32 with fewer DALYs averted. 
For adolescent women, the best-case scenario lowered the base-case ICER from $154.73 to 
$23.26 per DALY averted. The worst-case scenario resulted in a higher ICER of $318.34 per 
DALY averted. The sensitivity analysis also explored the impact of 5, 10, and 15-year time 
horizons, and the five-year time horizon resulted in lower ICER per DALY averted in all age 
groups (Supplementary Figure S5-4). 
 
Figure 4.5 presents cost-effectiveness acceptability curves for each age group for both men 
and women. The simulation plots on the cost-effectiveness plane are included in 
Supplementary Figure S5 and S6. For all age groups, HIVST is less likely to be cost-effective 
relative to the status quo. The PSA also shows that for all age groups for both men and 
women, HIVST is less cost-effective and   each group was approximately 50% probability 

























$0.00 $100.00 $200.00 $300.00 $400.00 $500.00 $600.00
Discount rate of cost: 3% (0%, 13%)
Annual ART cost: $185.86 (+/- 25%)
ART initiation: 78% (-37%,+90%)
Uptake of HIVST: 57% (+/-25%)
Sensitivity of oraquick: 94% (90%,99%)
VL suppression: 78% (70%, 90%)
Best & worse-case scenario
ART retention: 78% (70%, 90%)
Cost of per HIVST kit distributed: $16.42 ($7.91, $50.01)
Discount rate of effects: 3% (1%, 13%)
One-way sensitivity analysis: Men aged 15-24 






















$0.00 $50.00 $100.00 $150.00
Uptake of HIVST: 57% (+/-25%)
Cost of per HIVST kit distributed: $16.42 ($7.91, $50.01)
ART initiation: 72 % (-37%, +90%)
Annual ART cost: $185.86 (+/- 25%)
Discount rate of cost: 3% (0%, 13%)
ART retention: 72% (70%, 90%)
Best & worst-case scenario
Cost of per HIVST kit distributed: $16.42 ($7.91, $50.01)
Discount rate of effects: 3% (1%, 13%)
VL suppression: 91% (70%, 95%)
One-way sensitivity analysis: Men aged 25-34
























$0.00 $20.00 $40.00 $60.00 $80.00 $100.00
Uptake of HIVST: 53% (+/-25%)
Discount rate of cost: 3% (0%, 13%)
Sensitivity of oraquick: 94% (90%,99%)
VL suppression: 88% (70%,90%)
Annual ART cost: $185.86 (+/- 25%)
ART initiation: 86% (-37%,+90%)
Best & worst-case scenario
ART retention: 86% (70%, 90%)
Cost of per HIVST kit distributed: $16.42 ($7.91, $50.01)
Discount rate of effects: 3% (1%, 13%)
One-way sensitivity analysis: Men aged  35-49

























$0.00 $40.00 $80.00 $120.00 $160.00 $200.00 $240.00 $280.00 $320.00 $360.00 $400.00
Discount rate of cost: 3% (0%, 13%)
Annual ART cost: $185.86 (+/- 25%)
Uptake of HIVST: 41% (+/-25%)
ART initiation: 78% (37%, 90%)
Discount rate of effects: 3% (1%, 13%)
ART retention: 78% (70%, 90%)
VL suppression: 78% (70%, 90%)
Sensitivity of oraquick: 94% (90%,99%)
Cost of per HIVST kit distributed: $16.42 ($7.91, $50.01)
Best & worst-case scenario
One-way sensitivity analysis: Women aged 15-24 






















$0.00 $10.00 $20.00 $30.00 $40.00 $50.00 $60.00 $70.00 $80.00 $90.00 $100.00
Uptake of HIVST: 60% (+/-25%)
Discount rate of cost: 3% (0%, 13%)
Sensitivity of oraquick: 94% (70%, 99%)
VL suppression: 88% (70%, 90%)
ART initiation: 78 % ( - 37%,+90%)
Annual ART cost: $185.86 (+/- 25%)
Best & worst-case scenario
ART retention: 78% (70%, 90%)
Cost of per HIVST kit distributed: $16.42 ($7.91, $50.01)
Discount rate of effects: 3% (1%, 13%)
One-way sensitivity analysis: Women aged 25-34 


























$0.00 $50.00 $100.00 $150.00 $200.00 $250.00
Discount rate of cost: 3% (0%, 13%)
Uptake of HIVST: 60% (+/-25%)
VL suppression: 91% (70%, 95%)
Sensitivity of oraquick: 94% (+99%)
ART initiation: 88% (-37%,+90%)
Annual ART cost: $185.86 (+/- 25%)
Cost of per HIVST kit distributed: $16.42 ($7.91, $50.01)
ART retention: 88% (70%, 95%)
Discount rate of effects: 3% (1%, 13%)
Best & worst-case scenario
One-way sensitivity analysis: Women aged  35-49 
ICER= US$23.03 per DALY averted 
High Low
Figure 4.4 One-way sensitivity analyses 
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Weight on Effect. (WTP)
CE Acceptability Curve: Men aged 15-24


















































































































Weight on Effect. (WTP)
CE Acceptability Curve: Men aged 25-34


















































































































Weight on Effect. (WTP)
CE Acceptability Curve: Men aged 35-49
Intervention (HIVST) Standard of care (RDT),PITC &VCT
1X GDP= $1,430 
 
1X GDP= $1,430 
1X GDP= $1,430 
 
1X GDP= $1,430 
1X GDP= $1,430 
 
1X GDP= $1,430 
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Weight on Effect. (WTP)
CE Acceptability Curve: Women aged 15-24


















































































































Weight on Effect. (WTP)
CE Acceptability Curve: Women aged 25-34


















































































































Weight on Effect. (WTP)
CE Acceptability Curve: Women aged 35-49
Intervention (HIVST) Standard of care (RDT),PITC &VCT
1X GDP= $1,430 
 





1X GDP= $1,430 
 
1X GDP= $1,430 
1X GDP= $1,430 
 




This study is the first to estimate the cost-effectiveness of HIVST in Zambia. At the 
population level, HIVST may not be very cost-effective; however, HIVST is a promising 
intervention to reach those who do not come to a health facility to test for HIV that is 
targeted at those not reached at the health facility. These estimates of cost and cost-
effectiveness are comparable to published studies (35, 50, 156, 219-221). Our results are 
modelled from empirical data from a trial, costing exercises, and nationally representative 
population-based studies. This model simulates the provision of HIVST for those who did 
not test for HIV in the past 12 months using facility-based HTS and calculates six ICERs 
per DALY averted. For adolescent men and women, we reported higher ICER per DALY 
averted. These population groups have been reported to not access facility-based HIV 
testing. Thus, reaching them to distribute HIVST kits would incur more cost as would 
reaching them through other testing approaches. 
 
Based on the uptake evidence, HIVST reached a higher proportion of men (all age groups) 
and adolescents (both men and women) than conventional testing, including some of who 
may not test otherwise as shown in Malawi, Zambia, and Zimbabwe (222). Our results also 
suggest which age group to prioritize to identify the newest HIV positive cases. Although 
the implementation of HIVST for adolescent men and women resulted in higher ICER per 
DALY averted relative to those ages 25-34 and 35-49 in the 20-year analysis, the ICERs were 
cost-effective at the 1x GDP per DALY averted threshold. However, despite being cost-
effective, our HIV care cascade projection suggests that HIVST is unlikely to result in a 
dramatic increase in the absolute numbers of those who initiated ART, were retained in care 
or had viral load suppression. These results suggest that to lower the cost and maximize the 
health effect of HIVST, a higher number of individuals need to initiate ART, be retained, 
and have their viral load suppressed in the care cascade. These care cascade outcomes are 
highly dependent on the Zambian government effort to achieve UNAIDS’ 90-90-90 targets 
(88). One study suggested the importance of immediate ART initiation after HIVST at 
homes or in community-based HIVST strategies (221). However, there should also be 
additional efforts to achieve high ART retention rates at the government health facilities in 
Zambia.  
 
This study has an important programmatic contribution to previous studies. In Zambia, a 
nested cluster-randomized trial for door-to-door HIVST kits distribution demonstrated that 
68% of the HIVST group had knowledge of their HIV status compared with 65% in the 
non-HIVST group (110). The effect was higher among men in the HIVST group (OR = 
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1.31) (110). The results from STAR’s cluster-randomized trial found no evidence that HIVST 
significantly increased HIV testing at the population level in Zambia (47). The authors 
speculated that sampling challenges at the time of endline survey might be the reason for 
ineffective results. Thus, this allowed the cost effectiveness study to assess the impact of 
HVST. From the health providers’ perspective, the prioritization of HIVST is likely to 
increase programme cost-effectiveness for two reasons. First, the self-testing nature of the 
product, in which one can perform the HIV test and interpret the result in a private setting, 
makes it more attractive especially to populations with low access to a health facility. Second, 
averting years lost to disability and years of life lost due to undiagnosed HIV could increase 
the benefit of DALYs averted, but cost-effective criteria tell us that more DALYs could be 
averted for a given budget by targeted testing.  
 
This study has several limitations. First, we used a static Markov microsimulation model 
instead of a dynamic transmission model because the STAR research design did not collect 
impact data such as data on the number of people who initiated ART after positive HIVST 
result, the impact of reducing secondary HIV transmissions over time, or the prevention 
benefit of identifying and treating new HIV positive cases. With these data limitations, a 
Markov model was the appropriate model choice to answer the cost-effectiveness research 
question. Our model thus provides conservative values of the ICER of HIVST, 
underestimating its full impact. Although dynamic transmission models are designed for 
infectious diseases (such as HIV) to capture the long-term health benefits of an intervention 
and secondary infections averted, the numerous assumptions involved can make the 
estimated result uncertain. Second, we estimated the total cost for HIVST additively, which 
may underestimate the true cost by not accounting for the total fixed cost that is needed to 
sustain the programme and variations in health care practices and relative prices of resource 
inputs. This means that our estimate for the total cost of HIVST may be too low and make 
HIVST seem more cost-effective than the status quo. Although the estimated ICER per 
DALY averted for the adolescent groups are substantially higher in this study, they are 
significantly lower than other cost-effectiveness studies of HIVST in Southern Africa (16, 
35, 37, 156). Third, the ICERs were sensitive to the probability of ART initiation. This model 
applied uniform ART initiation rate across by age and gender in the intervention and status 
quo. This was done because no previous studies reported the ART initiation proportion after 
following HIVST by age and gender. This was tested in the one-way sensitivity analyses: 
lowering the ART initiation to 37% results in lower ICER per DALY averted, and increasing 
the ART initiation to 90% results in higher ICER per DALY averted. The latter 
demonstrated that reaching the first 90% of the UNAIDS targets might cost more because 
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of additional costs related to ongoing ART costs. Fourth, this study acknowledges as a 
limitation on the generalizability of the cost and cost-effectiveness results to other settings 
because of variations in health care practices including patient flows and behaviour, different 
approaches to reaching people with HIV testing, and cross-country salary differences. 
 
This study has important programmatic implications. The six ICERs show that in all age 
groups the additional cost of HIVST provision can result in a lower cost per DALY averted 
relative to the threshold of 1x GDP per DALY averted. Thus, targeted HIVST provision (by 
age and gender) among those who do not regularly test at the standard of care could be 
prioritized. The Zambian Ministry of Health and implementing partners could start scaling-
up HIVST first among women ages 35-49 years, second among women ages 25-34 years, 
third among men ages 35-49 years, fourth among men ages 25-34 years, fifth among men 
ages 15-24 years, and sixth among women ages 15-24 years. The scaling-up of HIVST might 
be expensive, but it might be necessary to reach 90-90-90 and fast-track 95-95-95. Insights 
from this cost-effectiveness analysis can inform policymakers in Zambia and other 
comparable African countries with similar HIV testing targets. 
 
Conclusion  
This study estimates the cost-effectiveness of HIVST in Zambia. Our estimates of ICERs 
per DALY averted for all age groups are substantially below half of Zambian 1xGDP of 
US$1,430 threshold. However, when modelling costs from pilots for national scale-up, it is 
important to consider how costs change, as screening programmes are successful in 
identifying those easily reached. To identify the remaining undiagnosed HIV cases, testing 
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Cost-effectiveness of community-based (door-to-door) HIV self-testing distribution models 
for HIV testing in Zambia: Markov microsimulation model  
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We developed a Markov microsimulation model of a heterosexual population representing 
Zambians ages 15 years and over. This analysis aimed to evaluate the health impact and cost-
effectiveness of one year of community-based (door-to-door) HIV self-test screening to 
reach those who did not test at the health facility in the last 12 months compared to a ‘status 
quo’ scenario of standard health facility testing. The model incorporated both HIV 
prevention and antiretroviral therapy (ART) cascades, which included individuals going 
through confirmatory rapid diagnostic HIV testing (RDT), receiving HIV positive results, 
initiating on ART, being retained in ART care, and attaining viral load suppression. The costs 
and health impacts of one year of screening were calculated over a time horizon of 20 years 
from a health provider perspective. The model was developed using TreeAge Pro 2017, R2.0 






Table S1 Overview of the cost-effectiveness analysis 
Key element Reference case 
Introduction  
Background of the problem Introduction of HIV self-testing in Zambia.  
Study Design and Scope  
Objectives To assess the cost-effectiveness of a one-year community-
based (door-to-door) HIVST kit distribution model 
compared to the standard of care HTS from a health 
provider’s perspective in Zambia 
Audience Zambia Ministry of Health (MoH), implementing 
partners, funders  
Type of analysis Cost-effectiveness analysis 
Target populations Men and women aged 15 and above in the Zambian 
population 
Intervention One-year community-based HIV self-testing screening   
Comparator Standard HIV testing services: provider-initiated testing 
and counselling (PITC), antenatal care (ANC) and 
voluntary counselling and testing (VCT) 
Time horizon Twenty years. (Sensitivity analysis: 5, 10,15, 20 years and 
lifetime) 
Analytic perspective Health provider 
Whether this analysis meets the 
requirements of the reference 
case 
It meets the Consolidated health economic evaluation 
reporting standards (CHEERS) statement  
A measure of health effects  Disability-adjusted life years (DALYs) 
Primary analysis plan Cost per DALY averted  
Methods and data  
Description of the model  Markov microsimulation model 
Software used TreeAge Software, Williamstown, MA, USA 
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Methods for obtaining 
estimates of costs  
Society for Family Health annual Self-testing in Africa 
project expense data  
Both ingredients based (bottom-up) and top-down 
costing data of HIV testing services in Zambia 
Preference disability weights HIV symptomatic, pre-AIDS- 0.221[0.146-0.310](76) 
HIV/AIDS: receiving antiretroviral treatment- 
0.053[0.034-0.079](76) 
AIDS: not receiving antiretroviral treatment-0.547[0.382-
0.715](76) 
Statement of discount rates All costs (in 2017 US$) and health benefits discounted by 
3% per year  
Results of sensitivity analysis Deterministic (one-way univariate), multivariate, 






The Markov microsimulation model started the simulation using two groups of individuals: 
1) HIV negative individuals who do not know their HIV status, and 2) HIV positive 
individuals who do not know their HIV status (Figure S1). The health states experienced by 
individuals were assigned disability weights and costs pertinent to each of these health states. 
The model has ten mutually exclusive health states: 1) HIV negative individuals who know 
their HIV status, 2) HIV negative individuals who do not know their HIV status, 3) HIV 
positive individuals who do not know their HIV status, 4) HIV false positive (misdiagnosed), 
5) HIV false negative (misdiagnosed), 6) HIV true positive viral load suppressed, 7) HIV true 
positive viral load not suppressed, 8) HIV true positive lost to follow-up, 9) death from HIV 















Figure S 1 The structure of the Markov microsimulation model for the 




The Markov microsimulation model incorporates both HIV prevention and treatment cascades. The costs for the prevention cascade include the 
costs for HIV testing at the health facility in three departments: provider-initiated testing, counselling (PITC), antenatal care (ANC), voluntary 
counselling, and testing (VCT). The costs for the treatment cascade include the costs to identify HIV positive individual and link to the treatment 
cascade (Table S2).  
 
Table S2 Cost inputs 























Cost of intervention and Status quo HTS in 2017 US$ 
Intervention Community-based (door-to-door) self-test kit distribution 
Average cost per 
negative person 
tested 




Status quo - Provider initiated testing and counselling 
Average cost per 
negative person 
tested 




Status quo - Antenatal care HIV testing 
Average cost per 
negative person 
tested 




Status quo - Voluntary counselling and testing 
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Average cost per 
negative person 
tested 




Average cost of false 
positive 
confirmatory test 
1.6 0.24 1.12 2.08 0.037 26.68 42.68 Gamma (133) 
Cost of HIV care and treatment in 2017 US$ 
Intervention (door-to-door self-test following linkage into care) 
Annual cost of ART 
per client  




Status quo- Linkage to care 




SE = (d-b)/3.92 is applied when there is no SE data available
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Site-level unit cost for community-based HIVST distribution  
Table S3 shows the site level cost per HIVST kit distributed in 16 health facilities in Zambia. 
The average cost $16.42 is applied in the model per Table S2. The table below is included to 
show the unit cost variation by health facility (site-level) where it ranged from $7.90 to $50.01 
per HIVST kits distributed. These two minimum and maximum values are applied in the 
one-way sensitivity analysis and for best & worst-case scenario (Table S3).  
 







Total cost for HIVST 
distribution 
(Full)  
Site-level unit cost 
per HIVST kit 
distributed 
1 5587 $      105,822.48 $                  18.94 
2 7370 $      101,485.07 $                  13.77 
3 3113 $        81,341.94 $                  26.13 
4 3090 $        61,563.63 $                  19.92 
5 20450 $      161,774.90 $                   7.91 
6 8029 $        76,522.03 $                   9.53 
7 8759 $        93,243.83 $                  10.65 
8 8768 $        70,206.19 $                   8.01 
9 7752 $      158,721.75 $                  20.47 
10 1758 $        87,921.17 $                  50.01 
11 5030 $      130,696.73 $                  25.98 
12 7270 $      157,551.93 $                  21.67 
13 4902 $      116,784.17 $                  23.82 
14 2452 $        81,773.42 $                  33.35 
15 5895 $      121,294.01 $                  20.58 
16 3364 $        90,732.00 $                  26.97 
Min 1758 $        61,563.63 $                   7.91 





Population-level HIV testing uptake 
Intervention - Adding community-based HIV self-test distribution to the status quo 
The community-based HIV self-test distribution enumerated all individuals in a community 
of four provinces of Zambia. Self-testing kits were distributed only to those ages 15 and over. 
The Self-test in Africa (STAR) endline survey data were analysed to calculate the proportion 
of community-based HIV self-test distribution by males/females age 15-24 years, 25-34 
years, and 35-49 years who did not test in the last 12 months (Table S4).  
 
Table S4 Observed proportion of community-based HIV self-test distribution uptake 
by male and female in (n = 314) (STAR endline Survey) 
Age Community-based (door-to-door) self-test distribution 
Men Women  
15-24 0.57 0.41 
25-34 0.57 0.60 
35-49 0.53 0.60 
 
Comparator ‘status quo’ health facility testing 
The ‘status quo’ health facility testing provided testing to individuals age 15 and above who 
did not test in the past 12 months. The STAR endline survey data were analysed to calculate 
the proportion of men/women age 15-24 years, 25-34 years, and 35-49 years of age who 
tested at the standard of care in the last 12 months (Table S5). 
 
Table S5 Proportion of men and women HIV testing through the standard of care 









and testing (VCT) 
Men Women Men Women Men Women 
15-24 0.46 0.53 0.02 0.11 0.12 0.09 
25-34 0.56 0.55 0.06 0.16 0.12 0.08 





Epidemiology of HIV  
The model starts the simulation by allocating individuals into two health states: HIV negative 
people who do not know their HIV negative status and HIV positive people who do not 
know their HIV positive status, stratified by age and gender. These proportions were 
calculated using the Zambia DHS 2013-14 dataset. The proportion for HIV negative and 
HIV positive who do not know (stratified by age and gender) (Table S7) were calculated by 
cross tabulating of those who responded ‘No’ to ever been tested for HIV (stratified by age 
and gender) (Table S6 and S7). 
 
Table S6 Proportion of men and women ever been tested for HIV (51) 
Age Men ever been tested for 
HIV (n = 13,574) 
Women ever been tested for 
HIV (n = 15,388) 
No Yes No Yes 
15-24 0.54 0.46 0.33 0.67 
25-34 0.22 0.78 0.07 0.93 
35-49 0.23 0.77 0.14 0.86 
 
 
Table S7 Proportion of HIV status for men and women who never been tested for 
HIV in the last 12 months and their HIV status (51) 
Age Men never been tested for HIV 
in the last 12 months 
Women never been tested for 
HIV in the last 12 months 
HIV negative HIV positive HIV negative HIV positive 
15-24 0.96 0.04 0.96 0.04 
25-34 0.90 0.10 0.87 0.13 






Population-level HIV treatment 
In the model, after confirmed HIV testing, individuals who were tested HIV positive were 
linked to care for both intervention and standard of care arm. Since there is a data gap on 
linkage after confirmed HIV positive test per PITC, ANC, and VCT testing services, self-
reported ART status from Zambia population-based HIV impact assessment (ZAMPHIA) 
were used to parametrize the model (Table S8). The model assumed the same proportion of 
linkage (Table S8) regardless of testing modality. 
 
Table S8 Proportion of Men and women self-reported antiretroviral therapy (ART) 
status [9] 
Age Men  Women  
15-24 0.78 0.78 
25-34 0.72 0.78 
35-49 0.86 0.88 
 
For the intervention arm where individuals tested for HIV using door-to-door HIVST, the 
proportion of 37% ART initiation was applied (218) (Table S9). 
 
Table S9 Proportion of men and women in HIV care (223) 
HIV Care Men  Women  
Initiation of ART care for intervention-door-to-door HIVST  0.37 0.37 
Annual lost to follow-up from HIV care (%) 0.17 0.17 
Annual lost to follow-up from HIV care and died (%) 0.029 0.029 





Viral Load Suppression among those on treatment 
Among those who reported being on ART, Table S10 shows the proportion of viral load 
suppression stratified by age and gender.    
 
Table S10 Proportion of men and women viral load suppression (VLS) among those 
on treatment [9] 
 
The model incorporated the performance of both OraQuick HIV self-test and rapid 
diagnostic tests (Table S11). 
 
Table S11 List of HIV diagnostic test kits quality assurance 
Type of HIV test Sensitivity (CI) Specificity (CI) Reference  
Performance of 
OraQuick* 
94.2% (90.4-96.8) 99.7% (99.3-99.9) (208) 
Uni Gold* 99.8% 99.9% (224) 
Bioline* 100% 99.1% (224) 
*WHO Prequalified, CI = confidence interval 
 
  
Age (years)  Men  
VLS (< 1,000 copies/ml) 
Women  
VLS (< 1,000 copies/ml) 
15-24 0.78 0.78 
25-34 0.91 0.88 
35-49 0.88 0.91 
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Clinical course of HIV infection  
In the model, for individuals who are HIV positive and remain unaware of their HIV positive 
status (refused to test) and for individuals with no viral load suppression, the disability 
weights were applied according to the clinical course of HIV infection (Figure S2). In the 20-
year time horizon, the following disability weights were applied: 
o Year 1-7: disability weight of 0.221   
o Year 8-12: disability weight of 0.547 
o Year 13-20: disability weight of 1 (individuals without treatment are expected to die 














Figure S 2 Clinical course of HIV infection (3) 
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Annual mortality proportions 
Annual all-cause mortality proportions were applied to individuals who would assume to die 
other than HIV/AIDS (Table S12).  
 
Table S12 Men and women annual all causes of mortality (Zambia DHS, 2015) 
Age (years) Men  Women  
15-19 0.02 0.02 
20-24 0.03 0.03 
25-29 0.03 0.04 
30-34 0.08 0.07 
35-39 0.09 0.09 
40-44 0.14 0.10 





Classification of disability weight for HIV health states  
The mean HIV disability weights were applied at the Markov health states using a beta 
distribution. The utility descriptions for the different health states are discussed in Table S13. 
The application of these classified disability weights aided to calculate the mean years of life 
lived with disability (YLD). It also helped identify age-specific YLD for individuals who died 
from HIV within the 20-year time horizon (either not knowing HIV positive status or failed 
viral load suppression) (Equation 1).  
 
























0.053 0.011 0.034 0.079 20.13 359.73 (76) 
HIV-positive, 
asymptomatic 
(who don’t know 
their HIV 
positive status) 





0.547 0.085 0.382 0.715 18.23 15.10 (76) 




Formulas for calculating DALYs 
 
DALYs are calculated by adding the adjusted number of years lived with disability (YLDs) 
and the number of years of life lost due to premature mortality (YLLs) (66).  
 
DALY [r, K, B] = YLL [r, K, B] + YLD [r, K, B]     equation (1) 
 
YLL [r, K, B] = Number of deaths X life expectancy at the age of death  equation (2) 
 
YLD [r, K, B] = Number of cases X duration till remission or death  
X disability weight         equation (3) 
 
The formulas here are taken from Fox-Rushby (74) 
 
!""#[%, ', (] = !"#!"(%&')# {,
)!$%&$"[)(%&')(+&,))-])		#
'(!$%)"['(!$%)"'+]} + (-)!)% (1 − ,
)%+)  
Where: 
r = discount rate expressed as a decimal 
K = age weighting modulation factor  
C = constant  
B = parameter from the age weighting function  
a = age of death  
L = standard expectation of life at age a (age of death) 
 
The formula for YLDs [r, K, B] differs from YLLs [r, K, B] by incorporating D (the disability 
weight) and different interpretation of a and L and it is described below: 
 
!"2#[%, ', (] = 0{!"#!"(%&')# {,
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)%+)}  
Where: 
r = discount rate expressed as a decimal 
K = age weighting modulation factor  
C = constant  
B= parameter from the age weighting function  
a = age of HIV diagnosed   




Life expectancy by age and gender - Zambia 
 
The life expectancies at the age of death for Zambia in Table S14 were provided by the 
Institute of Health Metrics and Evaluation (IHME) (225). 
 
Table S14 Life expectancy at the age of death by age and gender - Zambia 
Age (years) Men  Women  
15-19 50.59 55.66 
20-24 46.11 51.03 
25-29 41.74 46.48 
30-34 37.47 42.10 
35-39 33.37 37.87 
40-44 29.40 33.76 
45-49 25.59 29.77 
50-54 21.96 25.87 
55-59 18.59 22.14 
60-64 15.34 18.41 
65-69 12.45 14.97 
70-74 9.88 11.85 





Calculating the years of life lost (YLL) 
In order to count the number of individuals who died from HIV, two absorbing states of 
individuals who died from HIV were created: one for the intervention arm and the second 
for the standard of care arm. The only function of these two absorbing states was to 
transition individuals who died from HIV into these absorbing states. To understand the 
steps in the model better, let us follow a 15-year-old male who was not tested in the last 12 
months. For example, within the first year, this 15-year-old individual gets tested using HIV 
self-test and learns his HIV positive status. After a confirmatory diagnostic HIV test, he gets 
linked to ART. Within the 20-year time horizon (20 cycles, 1 cycle = 1 year), he might fail to 
adhere to ART, which could lead to no viral load suppression and death from HIV. At the 
time of his death, the model transitions this individual into the absorbing state of individuals 
who died from HIV at the intervention arm. This absorbing state counts the number of 
cycles this individual stayed in this absorbing state. Since the model runs using a 20-year time 
horizon, the number of cycles in this absorbing health state counting cannot be greater than 
20 cycles. Then the age when this 15-year-old male who tested HIV positive died can be 
calculated as follows:   
 
Age of HIV positive test = 15  
Number for cycles in absorbing state = 17 
Model’s time horizon = 20 years (or 20 cycles) 
Age of 15-year-old died from AIDS = 15+ (20-17) = 18 years 
Standard life expectancy at age of death in years = 50.59 (the life expectancy at age 18, using 
the data provided for Zambia by Institute of Health Metrics and Evaluation 2017) 
 
In this example, the calculation of the YLLs requires two steps: 
First, to calculate the life lost from age 18 onwards and secondly to discount this value to 
age 15. 
r = 0.03 
K = 1  
C = 0.1658 
B= 0.04  
a = 18  
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(Undiscounted) YLL [r, K, b] = 34.45 





Discounted YLL[r,K,b]  = undiscounted YLL X EXP(-r*s) 
Where: 
r = 0.03 
s = number of years to be discounted  
Discounted YLL[r,K,b]  = 34.45*EXP(-0.03*(18 -15)) 
   =31.49 
 
Calculating the years of life lost with disability (YLD) 
The model is parameterized with HIV disability weights per Salomon et al. (Table S13). The 
application of these classified disability weight aided to calculate age-specific YLD for 
individuals who died from HIV within the 20-year time horizon (Figure S4). Again, the 
calculation for YLD differs from YLL by incorporating D (the disability weight) and different 
interpretation of a (age of HIV diagnosed) and L (duration of disability). 
Following the above example, YLD [r, K, b] is calculated as follows: 
Where: 
r = 0.03 
K = 1  
C = 0.1658  
B= 0.04  
a = 15   
HIV diagnosis  
Age 15  
Death from HIV  
Age 18  
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L = 3    
D = 1.788 (from the individual model output) 
 
!"2#[%, ', (] = 0{!"#!"(%&')# 5,
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)%+)6 
           
  Equation 3 
YLD [r, K, B] =  




YLD [r, K, B] = 7.21 
 
Therefore, from the time of HIV diagnosis at age 15, the total numbers of discounted YLLs 
lose due to premature death equals 31.49. Adding this to the year of life lost with disability 
YLDs = 7.21, gives the total number of DALYs loss of 38.70.  
 
DALY [r, K, B] = YLLs + YLDs  
  = 31.49 + 7.21 













Figure S 4 YLD with and without age weighting (2)  
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Sensitivity analyses  
We explored different time horizons over which the intervention could be modelled by 
applying 5, 10, 15, 20-year, and lifetime horizons (Figure S5). For all age groups, the 
incremental cost for the different time horizons varied, while the number of DALYs averted 











$42.78 $35.26 $43.91 
























ICER using different time horizons (Men aged 15-24, 25-34 &35-49)





$23.31 $23.65 $27.59 $25.18 $27.96 
$26.98 
$25.88 























ICER using different time horizons (Women aged 15-24, 25-34 &35-49)
Aged 15-24 Aged 25-34 Aged 35-49





Probabilistic sensitivity analyses 
Figure S6 and S7 reflect the simulation plots on the cost-effectiveness plane for men and 








Figure S 7 Incremental cost-effectiveness scatterplots (Women) 
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CHAPTER 5 DISCUSSION AND CONCLUSIONS   
This thesis set out to investigate the costs and cost-effectiveness of different HIV testing 
services in sub-Saharan Africa, the costs of HIVST kit distribution, and the cost-effectiveness 
of HIV self-testing added on to the standard of care in Zambia. This chapter provides a 
critical assessment of the key findings of the thesis, discusses their strengths and limitations, 
and highlights future research and policy implications. This chapter aims to answer the one 
overall policy question stated in the conceptual framework (Chapter 1 Figure 1.5): does 
HIVST have a role or can HIVST be cost-effective when targeted at those who do not test? 
  
5.1.   Key findings  
This section summarizes the key results arising from the thesis research question outlined in 
Chapter 1. 
 
Research Q1: What is the cost of providing HIV testing in sub-Saharan Africa 
through different HIV testing models, and how does the scale of the service impact 
the costs?  
  
The first research question sought to examine the gaps in cost and cost-effectiveness studies 
of HIV testing services in sub-Saharan Africa using a systematic literature review (Paper 1). 
The review found that a large number of studies reported the cost of different HIV testing 
modalities, but few studies undertook a cost-effectiveness analysis. Although cost and cost-
effectiveness estimates varied widely, this review identified that in general, the costs of the 
different testing modalities were comparable to each other. 
  
The few cost-effectiveness studies identified and highlighted the importance of ensuring 
users do not pay fees, and of targeting pregnant women and their sexual partners potentially 
through couples testing, home-based testing, or HIVST. In addition, home-based, mobile, 
and HIVST are potentially cost-effective if providers are willing to pay the additional money 
needed to deliver these services and thereby realize the potential health benefits from their 
use. Policymakers and implementing partners would find the result of the systematic 
literature review helpful and could do more cost-effectiveness and budget analyses of the 
different combination of HIV testing modalities to inform HIV testing policy and budgets. 
 
Research Q2: How much does it cost to add HIV self-testing into male circumcision, 




The second research question was addressed in Paper 2, where costs of different HIVST 
distribution modalities were calculated. The VMMC model distributed 2,742 HIVST kits in 
Malawi, 11,330 HIVST kits in Zambia, and 2,870 HIVST kits in Zimbabwe. The average 
cost per HIVST kit distributed was US$9.65, US$13.01, and US$7.71 for Malawi, Zambia, 
and Zimbabwe, respectively. In Zambia, the OPD model distributed 12,885 HIVST kits that 
resulted in an average cost of US$15.81 per kit distributed. In Zimbabwe, the integrated HTS 
model distributed 14,886 HIVST kits and reported the average cost as US$9.85 per kit 
distributed.  
  
HIVST distribution costs varied substantially by model and location, and a model with higher 
numbers of HIVST kits distributed generally showed lower unit costs (i.e., economies of 
scale). HIVST kits distributed via the VMMC model were designed to create demand and 
increase uptake of VMMC services among HIV negative men for HIV prevention benefits. 
The OPD model was designed to increase more targeted provider-initiated testing to reach 
undiagnosed HIV positive people. The impact of this approach is significant when removing 
the start-up cost, and this substantially lowered the average cost of each HIVST distribution 
modality. This paper strengthens the evidence for integrating HIVST into existing HTS. 
 
Research Q3: What is the incremental cost-effectiveness of community-based (door-
to-door) self-test kit distribution compared with the standard of care HTS in Zambia 
(Paper 3)?  
  
The third research question was addressed in Paper 3, in which a microsimulation model 
showed the cost-effectiveness of HIVST distribution among men/women ages 15-24 years, 
25-34 years, and 35-49 years who did not test in the last 12 months.  
 
The ICERs for adolescent men and women ages 15-24 were $101.81 and $154.73 per DALY 
averted, respectively. The ICERs for men and women were $35.26 and $25.18 for ages 25-
34 and $32.10 and $23.03 for ages 35-49. Men and women in the 25-34 and 35-49 age groups 
could benefit greatly from HIV self-testing. Although the ICERs for adolescent men and 
women were highest, the ICERs per DALY averted were below the US$1,430 per DALY 
averted threshold. Thus, policymakers could use these age-stratified ICERs to prioritize for 




The microsimulation modeling paper outlined in greater detail how to simulate individuals 
using both HIV prevention and treatment cascades. The HIV prevention cascade specifically 
helped to present the provision of HIVST among HIV negative and HIV positive individuals 
who do not regularly test at a facility-based HTS. The treatment cascade helped visualize 
treatment flows of individuals after they tested HIV positive and enrolled in HIV care 
services. Bringing these two cascades together facilitated the building and parametrization of 
the model. Most importantly, it helped to identify the weakest decision point in the cascade 
that might affect the impact of the intervention. In a series of one-way sensitivity analyses, I 
tested the sensitivity of the model parameters and found that the calculated ICER results 
were sensitive to the variation in cost per HIVST kit distributed, lifetime ART cost, discount 
rate of effects, ART initiation, ART retention and viral load suppression, and the sensitivity 
of OraQuick among intended users. 
 
5.2.   Contribution to knowledge 
The contribution of this thesis can be summarized in terms of both empirical findings and 
methods. 
 
Contribution to empirical findings 
The first contribution of this thesis is the systematic literature review. This review will extend 
the scope of the existing literature by contributing the costs and cost-effectiveness of HIV 
testing services in sub-Saharan Africa. The key findings of the systematic literature review 
(Paper 1) showed that the costs of different HIV testing modalities are comparable and that 
more cost-effectiveness analyses are needed. More cost-effectiveness analyses are critical 
before substantial financial and human resources are spent in scaling-up the HTS. Large-
scale spending on HTS that may not be cost-effective and demonstrate impact (e.g., identify 
new HIV positive cases) and may result in misallocation of scarce resources. Notably, in 
recent years bilateral and multilateral donors significantly reduced funding for HIV response 
in low and middle-income countries (LMIC) (226). This has started to increase pressure on 
LMIC to finance their own HIV responses, which makes opportunity cost decisions and 
sustainability of HIV responses even more crucial (227). Thus, LMIC needs to find more 
efficient and cost-effective HTS approaches for individuals who need HIV testing.  
  
A second contribution involves the cost analyses, in which this thesis calculated the 
incremental unit cost for HIVST kits distribution within 13 VMMC services and at 21 health 
facilities from the providers’ perspective in Malawi, Zambia, and Zimbabwe (Paper 2). For 
these models, the unit cost per HIVST kit distributed are slightly higher than the standard 
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facility-based finger-prick testing services (US$2.60-22.42) (133), and HIVST delivery 
through community-based distribution agents (door-to-door distribution) (US$8.15-16.42) 
(49), that we had previously estimated using the same methods in the same sites. Despite the 
higher unit costs that were observed within the VMMC and OPD HIVST distribution 
models, it is important to evaluate these unit costs in relation to the target population of 
interest for HIV testing. The VMMC model not only targets men but also aims to increase 
the uptake of VMMC services by encouraging men to HIV test themselves prior to VMMC 
services. Additionally, the OPD model targets undiagnosed HIV positive individuals during 
their routine OPD visits and provides the opportunity to test themselves to maximize HIV 
diagnosis, ART initiation, and uptake of other HIV prevention services. Therefore, in both 
models, the higher unit costs achieved more than covering the cost of HIV testing and went 
beyond enhancing HIV prevention and ART initiations targets.  
  
The third important contribution of this thesis is the Markov microsimulation model that 
evaluated the incremental cost-effectiveness of an additional one-year home-based HIV self-
testing campaign (Paper 3). This was the first cost-effectiveness model to incorporate age 
and gender heterogeneity and present results by gender across three age groups in Zambia. 
Men and women 25-34 and 35-49 age groups could benefit greatly from HIV self-testing. In 
the model, the different proportions for HIV testing uptakes for HIVST had an impact on 
both HIV prevention and the HIV care cascade. 
 
In addition, the findings from Papers 1 and 2 strengthen the parameterization of the model 
and highlight which parameters to test for uncertainty using sensitivity analyses. For instance, 
the unit cost per HIVST kits distributed ($16.42) through a door-to-door distribution 
modality was applied in the model to estimate the incremental cost of HIVST provision. Our 
previously published work (50) showed the variation of unit cost at the site level based on 
the scale of HIVST kits distributed. The sensitivity analyses in Papers 2 and 3 showed the 
impact of lower than optimal uptake to HIVST on the unit cost and ICERs, respectively. 
  
Taken together, Papers 1 and 3 highlight the importance of using high-quality parameters to 
closely estimate the impact and the cost-effectiveness of an intervention. Most importantly, 
the high-quality parameters extend to the sensitivity analysis as well. Ideally, programmes for 
the introduction of new interventions should support both cost and cost-effectiveness 





Contribution to methods  
This thesis has also made several important contributions to methods. The systematic 
literature review on the cost and cost-effectiveness of HIV testing services in Chapter 2 
employed two recently published frameworks: the Global Health Cost Consortium (GHCC) 
reference case (116) and the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) (117) to assess the quality of the cost and cost-effectiveness studies respectively. 
The 17 GHCC principles that were applied to assess the costing studies stressed the gaps in 
designing costing studies and reporting the results in a standardized manner. Also, it 
highlighted the importance of following the 17 principles for future costing studies. This will 
facilitate budget allocation for HIV testing services and estimating future scale-up costs using 
programme costs. The 24-item CHEERS checklist could also be used as standard checklist 
practice to follow in reporting cost-effectiveness estimates. This could also identify technical 
challenges in predicting the resources needed to adopt the same interventions from one 
country to another. It is apparent that high-quality cost and CE studies are especially crucial 
for sub-Saharan Africa, where scarce resources must be allocated efficiently. Thus, these two 
frameworks for standard reporting of cost and cost-effectiveness results could improve the 
validity and comparability of studies across sub-Saharan Africa. 
 
The cost analyses in Chapter 3 employed cost allocation factors by cost input types. These 
allocation factors aim to guide the process of allocating aggregated financial costs to specific 
cost inputs to calculate total and unit cost of new interventions in greater detail and 
transparency. Thus, this study provides methodological guidance about which allocation 
factors to apply for a given cost input for expenditure-based cost analysis. I also hope these 
allocation factors will invite future cost studies to expand these allocation factors based on 
study setting and type of health intervention. 
  
The Markov microsimulation model in Chapter 4 is the first cost-effectiveness study 
simulating a heterosexual population representing Zambian adults aged 15 to 49, 
incorporating each decision  an individual makes in the process, beginning with uptake of 
HIV testing, confirmatory testing, linkage to ART, retention in care, and eventually leading 
to viral load suppression, which encompasses both HIV prevention and HIV care cascades. 
The HIV prevention cascade helps present the flow of people who are unaware of HIV 
negative status and people unaware of HIV infection (not in care) (169, 171, 209,168, 170, 
208). The HIV treatment cascade helps present how to move people along with treatment 
services after they enroll in HIV care services. This includes: 1) initiating ART, 2) alive and 
remaining in care for 90 or more days, and 3) alive and viral load suppressed (210-213, 209-
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212). The model is parameterized in a way that can easily be updated with the most recently 
published data to generate the most up-to-date cost-effective estimates. This can be done 
not only in the context of Zambia but also in other comparable countries such as Malawi 
and Zimbabwe, which are STAR countries where HIV self-testing was introduced using 
different HIV testing modalities and is currently in the process of being scaled-up to reach 
high-risk groups. 
 
5.3.   Limitations of thesis approach 
  
The strengths and limitations of specific methodological and analytical approaches are 
discussed in greater detail at the end of this chapter. This section focuses on overarching 
limitations. 
 
Comparability and transferability of cost and cost-effectiveness estimates  
Chapter 2 (Paper 1) presents the cost and cost-effectiveness of different HTS in sub-Saharan 
Africa. Although the review shows the variation in reported costs and cost-effectiveness 
estimates, the review acknowledges the diversity and complexity of healthcare systems in 
sub-Saharan Africa. Thus, the review presented the costs and the CE results following the 
study perspective. The six HIV testing modalities could not all be assessed in one country, 
which made it difficult to compare different testing modalities. The methods used to 
undertake the economic analysis were not always comprehensive or comparable, limiting 
transferability of findings. 
 
Unit of measurement cost per HIVST kit distributed  
The first limitation of the cost analysis (Paper 2) is reporting unit costs per kit distributed for 
the different distribution modalities but without observed data linking the unit costs to 
numbers of new HIV case identified and those linked to care. In Zambia, the STAR endline 
survey design did not incorporate the monitoring of the number of people tested, new HIV 
positive cases, or linkage to ART. As a result, I was unable to estimate the unit cost per 
person tested or per HIV positive individual tested or linked to care after self-testing or a 
negative person linked to prevention – notably to VMMC services. Second, STAR is the first 
implementation project that introduced HIVST in the Southern Africa region. Thus, the 
distribution numbers were relatively small for VMMC, OPD, and integrated models 
compared to community-based distribution, which accounted for 82.7% of HIVST kit 
distribution (46). If respective MOHs scale-up HIVST using the community-based 
 
 233 
distribution modalities, it is posible that unit costs may reduce due to the higher number of 
test kits distributed. 
 
Simplification of static Markov microsimulation model  
First, this study recognized that HIV is an infectious disease and models with individual 
interactions were necessary to capture the disease transmission rate. The static Markov 
microsimulation model did not allow individual interaction. For example, individuals in the 
model who were screened might be infected at a later time, and individuals who were enrolled 
in ART might have a lower possibility of infecting others (228), which in turn might decrease 
the cost-effectiveness of each alternative HTS. However, this study tried to minimize this 
limitation by incorporating stratification of HIV prevalence and testing behavior by gender 
and age, and transitioning individuals through the 10 different health states. 
  
Second, the model in this thesis was designed in order to explore the cost of one-year of 
HIVST provision and explore its impact over a 20-year time horizon for different age groups. 
Due to a lack of observed data, the model applied assumptions around important parameters 
such as the proportion of ART initiation after HIV-self test. The model applied the same 
proportion for ART initiation in the intervention and standard of care arm. One study 
published the effect of home initiation of HIV cases following HIVST (221), though no 
other study published the follow-up of home ART initiation to linkage in HIV care at the 
health facilities. Sensitivity analyses were conducted to mitigate the impact of the assumed 
parameters. 
 
Moreover, I acknowledge that costs were additive, and the proportions of ART initiation, 
ART retention, and viral load suppression were applied in a linear manner, where in reality 
these three cascades in HIV care represent complex behaviors. This study also identified data 
gaps for ART initiation, ART retention, and viral load suppression post-HIVST. Having 
these parameters would have improved the accuracy of the model prediction. 
 
5.4.   Strength of thesis approach  
 
Combination of cost and cost-effectiveness analysis  
 The key strength of this thesis is in generating empirical evidence of unit cost using cost 
analysis and cost-effectiveness estimates using the microsimulation model. The 
microsimulation model allowed this study to objectively track people in  10 health states due 
to the complexity of the model parameters. Particularly, variation in HIV testing uptake, 
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ART initiation, ART retention, and viral load suppression by sex and the three age groups 
offered a great understanding of complex nuance in order to estimate the impact of HIVST 
intervention. Paper 3 used our previously published cost data plus new data, and it was the 
first microsimulation model for HIVST for the Zambian population. 
 
Zambia as a research context  
Zambia was chosen as a study site for the STAR project and this study is embedded in 
STAR’s research. Zambia has a very high HIV prevalence, and there is political will from the 
Zambian MOH to include HIVST in its HIV testing strategic framework and to scale-up 
HIVST provision. With available funding and social acceptability of HIVST as an additional 
HTS, the results of this thesis have the potential to reach those who do not test regularly at 
the health facility. The available ICERs per DALY averted estimates in Paper 3 could inform 
funders to allocate HIV test resources accordingly. 
  
Generalizability to other settings 
The parameterization of the model applied weightings to quantitatively make the results 
generalizable to the Zambian population. However, the generalizability of these results 
outside of Zambia may not be possible. As noted in the modelling paper, the 
parameterization of the model was only done using data from studies done in Zambia. 
Moreover, the conceptualization of the model structure is grounded in the Zambian 
healthcare system following the HIV prevention and care cascade. Thus, the structure of the 
model can be adapted to other countries following the country’s HIV testing and treatment 
guidelines.   
 
A number of studies highlighted that the transfer of economic evaluation estimates to other 
settings should only be done following the proposed checklists (165-168, 164-167).  
 
5.5.   Implications for research  
This section lays out the broad research implication of this thesis, along with its 
generalizability to other settings.  
  
More routine cost-effectiveness analysis  
Results from this thesis suggest that future HIV programmes need to incorporate both HIV 
prevention and HIV care cascades in their programme design and conduct cost-effectiveness 
analyses. As UNAIDS 90-90-90 targets are approaching, HIV prevention programmes need 
to target individuals who do not test regularly. Adolescent men and women and men in other 
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age groups could benefit significantly from the provision of targeted HTS. Additionally, 
programmes that support HIV care cascade need to do more research to generate accurate 
data on ART initiation, ART adherence, and viral load suppression. Thus, cost-effectiveness 
analyses can combine these two cascades and generate complete empirical evidence to 
optimize HIV response. 
 
5.6.   Implications for policy  
 
Prioritizing adolescent men and women 
In high HIV burdened countries such as Zambia, the health systems are likely to have limited 
resources. Thus, it is critical to identify which population could benefit the most from 
prioritized HVST provision. Although this thesis demonstrated that HIVST is cost-effective 
for all age groups (i.e. below the $1,430 per DALY averted threshold) for scaling up of 
HIVST, it could prioritize men and women ages 25-34 and 35-49 years and adolescents 
second.  
 
This work will also inform national HIV testing services guidelines and policies in multiple 
ways. First, the findings from this study can inform the government of Zambia about 
strategies for the next National Strategic Framework on HIV testing services and integrate 
HIVST as one of the HIV testing options. Moreover, it provided evidence about cost-
effective modalities for scaling-up HIVST.     
  
The need for investment for ART initiation and adherence after HIVST 
A large number of studies evaluated adherence-enhanced interventions to improve 
adherence to ART (229). HIVST has the potential to reach undiagnosed HIV positive 
people. Given the adherence assumptions in Paper 3 of this thesis, I would recommend 
investment in ART initiation and ART adherence after the provision of HIVST to have a 
high probability of being cost-effective. Promoting HIVST alone will not generate a long-
term impact because it requires enhancing and maintaining complex ART initiation and 
adherence programmes. Policymakers and funders should work together to facilitate the HIV 
care system to make it more attractive and as integrated as possible to improve ART initiation 
and adherence after HIVST. 
 
5.7.   Conclusion 
HIVST is a promising intervention to reach people who do not test regularly at facility-based 
HTS. This thesis explored the cost and cost-effectiveness of HIVST. It found that the 
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provision of HIVST may be cost-effective among all age groups who did not test in the last 
12 months. Cost analysis also calculated the unit cost of delivering HIVST using the VMMC 
and OPD models to increase VMMC uptake and identify new HIV positive people, 
respectively. This thesis has shown the value of combining systematic literature review, cost 
analysis, and cost-effectiveness modeling to explore the full potential of HIVST. Further 
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APPENDIX I: CO-AUTHORED PAPER 1: COSTS OF FACILITY-
BASED HIV TESTING IN MALAWI, ZAMBIA, AND ZIMBABWE 
 
This first paper, Costs of facility-based HIV testing in Malawi, Zambia, and Zimbabwe, is a cross-
country collaboration paper published in PLOS ONE, which provided evidence on unit cost 
per person tested and positive case identified at the standard health facility (standard of care) 
in these three countries. The Zambian unit cost per person tested was used to parametrizes 
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APPENDIX II: CO-AUTHORED PAPER 2 – ECONOMIC COST 
ANALYSIS OF DOOR-TO-DOOR COMMUNITY-BASED 
DISTRIBUTION OF HIV SELF-TEST KITS IN MALAWI, ZAMBIA, 
AND ZIMBABWE 
 
This second paper, Economic cost analysis of door-to-door community-based distribution of HIV self-test 
kits in Malawi, Zambia, and Zimbabwe, is also a cross-country collaboration paper published in 
Journal of the International AIDS Society, which provided evidence on unit cost per HIVST kits 
distributed using door-to-door distribution modality. The Zambian unit cost for HIVST kit 
distribution was used to parametrize the model in Chapter 5. This paper is added in Appendix 
2 as published and JIAS permitted  this. 
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APPENDIX III: CO-AUTHORED PAPER 3: COSTS OF ACCESSING 
HIV TESTING SERVICES AMONG RURAL MALAWI 
COMMUNITIES  
 
This third paper, Costs of accessing HIV testing services among rural Malawi communities, is a co-
authored paper published in AIDS Care journal, which helped to expand the understanding 
of cost beyond unit cost of HTS and explored the costs among HIV testing clients. This 
paper is added in Appendix 1 as published, and AIDS Care permitted  this. 
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